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Introduction
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma 
and is histologically characterized by a diffuse proliferation of large neoplastic B cells with a 
nuclear size equal to or exceeding normal nuclei. The disease has an incidence of 7–8 cases 
per 100,000 people per year in the USA and the UK, and although the disease can arise at 
any age, DLBCL is mostly found in elderly patients with an average age of 70 years old [1]. 
Because of its aggressive nature, the first symptoms of DLBCL are often the discovery of a 
fast-growing mass combined with fever, weight loss and night sweats, which are classified 
as B-symptoms. DLBCL arises as the result of a malignant transformation of B-cells, or as the 
result of a transformation of other types of lymphoma or leukemia, such as follicular lymphoma 
(FL) or chronic lymphocytic leukemia (CLL). Based on pathological classification or side of 
presentation, DLBCL is divided in several subtypes which include amongst others primary 
DLBCL of the central nervous system (CNS), T-cell/histiocyte-rich large B-cell lymphoma and 
intravascular large B-cell lymphoma. The most common subtype is the DLBCL not otherwise 
specified (NOS) group, including cases that do not fit into any specific disease subgroup.
Genetic background and subclassification
Although DLBCL is a very heterogeneous disease, it can be subdivided into three different 
subcategories based on gene-expression profiles, which reflect the cell of origin (COO) of 
the maturation stage of the precursor B cell. These subtypes are classified as the germinal 
center B-cell (GCB) subtype, activated B-cell (ABC) or non-GCB subtype and the third 
unclassified subtype, which each have a unique gene-expression profile and differ in 
prognosis for survival [2]. The more common GCB subtype is known for its expression of 
cell surface enzyme CD10 and transcription factors LMO2 and BCL-6 [3,4]. Approximately 
30% of GCB-DLBCLs have a (14;18) translocation, resulting in the translocation of the 
anti-apoptotic BCL-2 gene locus to the immunoglobulin heavy chain gene (IGH) enhancer 
locus, inducing BCL-2 overexpression and inhibition of apoptosis [5]. Similarly, the (8;14) 
translocation of the MYC gene locus to the IGH enhancer induces overexpression of the 
oncogene MYC resulting in an enhanced cellular proliferation rate. The MYC translocation 
can be found together with a BCL-2 translocation in about 10% of DLBCL cases, which are 
referred to as high grade B-cell lymphoma with rearrangement or “double-hit” cases [6]. Other 
characteristics of GCB-DLCBL include mutations of the histone methyltransferase EZH2 gene 
and loss of tumor suppressor gene PTEN, resulting in increased transcriptional repression of 
tumor suppressors and decreased inhibition of the Akt/PKB pro-survival signaling pathway, 
respectively [7]. The gene expression profile of the GCB subtype shows great overlap with 
normal germinal center B-cells, suggesting that the GCB subtype arises at an early stage in 
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B-cell development in the germinal center [8]. Besides the GCB subtype, gene expression 
profiling also recognizes the more aggressive non-GCB subtype or activated B-cell (ABC) 
subtype. These tumors arise from the activated plasmablast B-cell stage, which is the 
maturation stage of B-cells just prior to the germinal center exit [8]. Thus, non-GCB cells 
are in a more “activated” state and often show constitutive activation of the NF-κB signaling 
pathway, promoting cell survival, proliferation, and inhibition of apoptosis [9]. This NF-κB 
activation can be the result of mutations in the adaptor protein MYD88, CD79A or CD79B, 
or via activation of the CBM signaling complex (formed by CARD11, BCL10, and MALT1), 
constitutive active B-cell receptor (BCR) signaling, or activation of downstream kinases such 
as SYK, PI3K and BTK [10]. Because of this highly active state, non-GCB DLBCL patients 
often have a worse prognosis compared to GCB DLBCL patients, with 3-year overall survival 
rate of 56% versus 84% (p>0.001) [2]. Last but not least, a small group of DLBCL patients 
remains unclassified, which are believed to represent lymphomas arising from different 
stages of B cell differentiation/maturation. 
DNA damage and DLBCL
An important feature shared by both GCB and non-GCB DLBCL are the high levels of 
genomic instability, which results in constitutive high expression and activation of the DNA 
damage response (DDR) pathway in DLBCL compared to other cancers [11]. The DNA 
damage response pathway is multi layered pathway which can be subdivided into three 
basic steps of 1) detection of DNA damage by “sensor” proteins (e.g. RPA, yH2AX or the 
MRN complex) and “mediator” proteins (e.g. BRCA1/2), which is followed by 2) activation of 
downstream “transducer” proteins (e.g. ATM or ATR), and leads to activation of 3) “effector” 
proteins that are involved in DNA repair, cell cycle regulation and apoptosis (Figure 1).   
  Depending on the type of DNA damage and/or the timing it occurred, DNA damage 
can be detected and repaired by several different players of the DNA damage response 
pathways. In general, acquisition of single stranded DNA damage allows for relative error-
free repair, as the remaining DNA strand can serve as an accurate template. In this situation, 
several repair options are available, which include base excision repair (BER), nucleotide 
excision repair (NER) or mismatch repair (MMR). Initial steps in the detection and repair 
of single stranded breaks (SSB) and/or replication stress require recognition by replication 
protein A (RPA) and activation of kinases ataxia telangiectasia and rad3-related protein 
(ATR) and checkpoint kinase 1 (CHK1), forming the ATR-CHK1 axis [12]. The most common 
inducer of single stranded breaks is oxidative stress or reactive oxygen species (ROS). In 
addition, they can also be induced by X-ray radiation or alkylating agents [13]. 
 In the situation of double stranded DNA damage, the mechanisms of repair are 
dependent on the presence or absence of a DNA template: if cells have completed 
DNA replication in S-phase, a template is available to allow the error-free homologous 
recombination (HR), which is similar to the chromosomal crossover during meiosis. In 
absence of a template, damage can be repaired using either non-homologous end joining 
(NHEJ) or microhomology-mediated end joining (MMEJ). Initial steps in the repair of double 
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stranded breaks (DSB) require the recognition of double stranded breaks (DSB) by the 
kinase ataxia telangiectasia mutated (ATM) and the MRE11:RAD50:NBS1 (MRN) sensor 
complex [14], resulting in phosphorylation of DNA damage-associated yH2AX histone mark 
and activation of checkpoint kinase 2 (CHK2), together forming the ATM-CHK2 pathway [12]. 
 Double stranded DNA breaks (DSB) are mostly induced by ionizing radiation and 
chemotherapeutic drugs, such as DNA-alkylating agents (cyclophosphamide), DNA cross-
linking agents (cisplatin) and radiomimetic compounds (bleomycin or phleomycin) (15). 
Together these different pathways are able to recognize and repair DNA damage and 
prevent abnormal cellular functioning. 
 Simultaneously with the initiation of the DNA damage repair pathway, the ATM and 
ATR transducers also activate pathways to regulate cell cycle progression (Figure 2). 
Activation of cell cycle checkpoint proteins is necessary to allow time for repair and prevent 
progression into mitosis and cell division, which would lead to permanently damaged DNA 
into the next generation of cells. The most important cell cycle regulator in this pathway is 
WEE1, which is part of the WEE family of kinases that function as regulators for cell cycle 
progression. Members of this family include WEE1 (WEE1A), MYT1 (PKMYT1) [16] and the 
oocyte-specific WEE2 (WEE1B) which regulates meiosis [17]. The main function of WEE1 
concerns phosphorylation of cyclin dependent kinase 1 (CDK1/CDC2) on tyrosine 15, thereby 
inhibiting CDK1 activity and preventing regular transition from G2 phase into the M phase 
until cells are ready for mitosis [18]. At the same time, WEE1 has shown to control CDK2 
activity during DNA replication in S-phase, thereby preventing excessive firing of replication 
origins, preventing DNA replication stress and promoting homologous recombination [19-
Figure 1. Simplified schematic overview of the multiple pathways activated by DNA damage. Induction of DNA 
damage result in activation of sensors and mediators of either double stranded (i.e. MRN complex, yH2AX) or single 
stranded DNA breaks (i.e. RPA), which activate downstream transducers ATM and/or ATR. These transducers are 
responsible for the initiation of pathways for repair, cell cycle checkpoints and if necessary, apoptosis.
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21]. Opposite of the WEE kinases are the phosphatases of the cell division cycle 25 (CDC25) 
family, which include CDC25A, CDC25B and CDC25C, and are responsible for the removal 
of the inhibitory phosphate residues from the CDK active site [22]. 
 In the case of DNA damage inflicted during or at the end of the G2 phase, cells will 
activate the G2-checkpoint which checks for cell size and DNA integrity [23]. As a result, 
activation of the ATR-CHK1-pathway will result in activation of WEE1 by CHK1 in order to 
prevent unwanted cell cycle progression and allow time either repair the inflicted damage or 
induce apoptosis [24]. In addition, activation of ATM/ATR results in inactivation of CDC25C 
to prevent removal of the inhibitory phosphate added by WEE1 [25,26]. This makes WEE1 an 
essential link between cell cycle and DNA damage pathways, by preventing unscheduled 
cell cycle progression and allowing time for critical DNA damage repair. In this rather complex 
and extensive network of cell cycle and DNA damage related proteins, many factors have 
shown to be either mutated or aberrantly expressed in DLBCL (Figure 3). Clinical analysis 
of DDR proteins in DLBCL through immunohistochemistry found positive staining for yH2AX, 
CHK1/2 and CDC25C in half of the DLBCL cases, which was significantly higher compared 
to the percentages of positive cases observed in indolent B-cell lymphomas such marginal 
zone lymphoma (MZL) and chronic lymphocytic leukemia (CLL) [11]. Moreover, mutation 
studies in DLBCL samples revealed recurrent mutations in DNA damage repair genes, 
including mismatch repair genes (EXO1, MSH2, and MSH6) and NHEJ genes (DCLRE1C/
ARTEMIS, PRKDC/DNA-PKcs, XRCC5/KU80 and XRCC6/KU70) [27,28]. In addition, Bret et 
al. showed that the expression pattern of 176 genes involved in FANC, NER, HR, BER, NHEJ 
and MMR pathways was associated with survival in DLBCL patients [29]. 
Figure 2. Overview of the cross-talk between the DNA damage response and the cell cycle regulator WEE1. 
Depicted are the ATM-CHK2 and ATR-CHK1 pathways which are involved in repair of double stranded (DS) and single 
stranded (SS) DNA breaks, respectively. Inactivation of the CDC25 family members and/or activation of WEE1 by CHK1 
prevents G2/M progression upon DNA damage, couples the DNA damage response to cell cycle, thereby allowing DNA 
repair.
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DNA damage and the germinal center reaction
As previously mentioned, DLBCL show a significantly higher incidence of genetic instability 
as compared to many other cancers (Figure 2). As a result of this genetic instability, DLBCL 
are characterized by high percentages of translocations and mutations, which leads 
to the activation of DNA damage pathways. The genomic instability is the result of high 
activity of activation-induced cytidine deaminase (AID). AID is an enzyme required for 
somatic hypermutation (SHM) and class-switch recombination (CSR) which facilitate the 
rearrangement of the immunoglobulin genes to generate antigen-specific, high-affinity, class-
switched B-cells [30]. However, aberrant and off-target activity of AID and other enzymes 
involved in these processes, are major drivers of DLBCL [31]. Immunohistochemical staining 
of AID in DLBCL samples demonstrated high expression in ~40% of DLBCL patients and its 
expression was associated with poor survival [32]. In addition, it was shown that AID gene 
expression was detected in both GCB- and non-GCB DLBCL and was decreased in DLBCL 
that evolved from follicular lymphoma (FL) [33]. Moreover, AID expression was not associated 
with the degree of intra-clonal heterogeneity. In mice experiments, AID deficiency prevented 
formation of BCL-6-dependent GC B-cell derived NHL, but it had no impact on MYC-driven 
Figure 3. Schematic representation of the affected DNA damage response proteins in DLBCL. Depicted are 
the sensors, mediators, transducers and effectors involved in the DNA damage response, which show aberrant gene 
expression, protein expression or high incidence of mutations in DLBCL. Depicted in red are the cell cycle checkpoints 
that determine whether cells can progress into the next phase of the cell cycle.
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pre-GC lymphomas [34]. In contrast, Compagno et al. showed a direct link between AID 
activity and genomic instability, in which activation of AID through PI3 kinase blockade 
resulted in increased genome-wide off-target chromosomal translocations and increased 
incidence of plasma cell tumors in mice [35]. Taken together, these data demonstrate a 
pivotal role of AID in the transformation of normal GC B-cells into a tumorigenic state, in 
which AID remains to be activated in cells which may otherwise have lost expression of AID 
and other germinal center-related genes. 
Treatment
Despite an increase in the knowledge for DLBCL genetic subtypes, activated pathways and 
differential clinical features, treatment of DLBCL has remained unchanged in the last decade. 
For a long period of time, treatment for DLBCL has consisted of the chemotherapeutic 
combination of cyclophosphamide, doxorubicin, vincristine and prednisolone to create 
CHOP. With the discovery of the favorable results of the anti-CD20 antibody rituximab on 
survival of lymphoma patients, the combined R-CHOP treatment was approved and has been 
used as standard treatment for DLBCL since 1997 [36]. CD20 is an activated-glycosylated 
phosphoprotein expressed at the membrane of all B-cells, and is thought to play a role 
in B-cell activation, differentiation, and cell-cycle progression [37]. Addition of anti-CD20 
antibody rituximab to the CHOP regiment has increased the overall 5-year survival from 
40% to 60% in DLBCL patients [38]. Despite this improvement, a large portion of patients 
still respond poorly, with ~20% of DLBCL patients having refractory disease and 30% with 
relapse disease. For these patients, limited treatment options are available, which include 
salvage chemotherapy or autologous stem cell transplantation [39]. Overall, treatment for 
DLBCL remains inadequate and burdensome, and therefore novel therapies are required, 
preferentially therapies that focus on the specific biology of DLBCL or focus on specific 
therapy-induced intra-cellular changes. 
Scope of this thesis
Based on the current response rate of DLBCL patients to standard R-CHOP treatment it 
is clear that novel targets are needed to improve therapy outcome for these patients. With 
the knowledge that DNA damage response and cell cycle pathways play important roles in 
either the initiation or progression of DLBCL, it is attractive to explore feasibility of targeting 
these pathways. We therefore aimed to explore the DNA damage response pathway, in both 
its intrinsic biology and as a target for therapy. In order to answer these questions, we first 
investigated whether DNA damage response and cell cycle proteins were associated with 
CD20 expression in DLBCL, and whether these could be efficiently targeted for therapy 
(Chapter 2). This association with CD20 was chosen because CD20 is not only an important 
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target for therapy with the mono-clonal antibody rituximab, but also because CD20 is closely 
involved in signaling through the B-cell receptor (BCR), which is often a driver pathway in 
DLBCL. Based on these findings, we selected cell cycle regulator WEE1 to further study in 
depth as a target for combination therapy. Since our aim is to improve therapy response and 
reduce treatment burden, we investigated the potential of WEE1 inhibition in combination 
with first line radiation and chemotherapy (Chapter 3) and in combination with second line 
cytarabine and cisplatin treatment (Chapter 4). In addition, we tested whether WEE1 inhibition 
would synergize with novel therapeutic compounds that target the cell cycle trough inhibition 
of cyclin-dependent kinases (CDKs), which are currently tested in clinical trials (Chapter 5). 
 Finally, in order to define the role of the anti-apoptotic pathways that allow tumor survival 
and resistance in DLBCL (such as BCL-2), we explored the effects of WEE1 inhibition (Chapter 
6) and CHOP chemotherapy (Chapter 7) on the anti-apoptotic dependency, allowing us 
to determine the potential efficacy of anti-apoptotic inhibitors in DLBCL treatment. In the 
final Chapter 8, we summarize and discuss our findings and provide future perspectives for 
WEE1 in treatment of patients with DLBCL and other cancers.
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Abstract
Forty percent of patients with diffuse large B-cell lymphoma (DLBCL) show resistant disease 
to standard chemotherapy (CHOP) in combination with the anti-CD20 monoclonal antibody 
rituximab (R). Although many new anti-cancer drugs were developed in the last years, it is 
unclear which of these drugs can be safely combined to improve standard therapy without 
antagonizing anti-CD20 efficacy. In this study, we aimed to identify rituximab compatible 
drug-target combinations for DLBCL. For this, we collected gene expression profiles of 
1,804 DLBCL patient samples. Subsequently, we performed a guilt-by-association analysis 
with MS4A1 (CD20) and prioritized the 500 top-ranked CD20-associated gene probes for 
drug-target interactions. This analysis showed the well-known genes involved in DLBCL 
pathobiology, but also revealed several genes that are relatively unknown in DLBCL, such 
as WEE1 and PARP1. To demonstrate potential clinical relevance of these targets, we 
confirmed high protein expression of WEE1 and PARP1 in patient samples. Using clinically 
approved WEE1 and PARP1 inhibiting drugs in combination with rituximab, we demonstrated 
significantly improved DLBCL cell killing, also in rituximab-insensitive cell lines. In conclusion, 
as exemplified by WEE1 and PARP1, our CD20-based genome-wide analysis can be used 
as an approach to identify biological relevant drug-targets that are rituximab compatible and 
may be implemented in phase 1/2 clinical trials to improve DLBCL treatment.
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Introduction
Diffuse Large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma 
(NHL). Standard immunochemotherapy consisting of cyclophosphamide, doxorubicin, 
vincristine, and prednisolone combined with the anti-CD20 monoclonal antibody rituximab 
(R-CHOP) results in a cure rate of 60% [1]. However, 40% of patients have refractory or 
relapsing disease and their prognosis is poor [2]. Unfortunately, since the introduction of 
rituximab two decades ago, all efforts to intensify chemotherapy or develop next generations 
anti-CD20 antibodies failed to improve their survival [3–5]. For these patients, there is an 
unmet need to improve standard treatment for DLBCL.
 The B-cell receptor (BCR) complex, with the CD20 protein—a product of the MS4A1 
gene —as a part of the BCR signalosome [6], is recognized as an important pathway that 
drives tumor growth and survival of various B-cell NHLs [7,8]. It has been demonstrated that 
DLBCL shows the highest basal phosphorylation levels of the BCR complex compared to 
other B-cell malignancies [9], and that the ongoing antigenic engagement of self-antigens 
on the BCR is required for tumor survival in activated B-cell (ABC) subtype DLBCL [10]. 
Emerging data from clinical trials indicate that blocking kinases downstream of the BCR has 
substantial anti-lymphoma activity. For example, inhibition of BTK, PI3K and SYK through 
ibrutinib [11,12], idelalisib [13], and fostamatinib [14,15], respectively, has been shown to 
be effective in follicular lymphoma, mantle cell lymphoma (MCL), and chronic lymphocytic 
leukemia (CLL). The efficacy of rituximab depends on CD20 clustering within the BCR, 
whereby rituximab also activates complement in a BCR-dependent manner [16]. In addition, 
CD20 ligation with monoclonal antibodies on NHL cell lines downregulates important 
components of the BCR signaling pathway [17,18]. Indeed, kinase inhibitors downstream 
of the BCR have been shown to interfere with the activity of rituximab [19–22]. Therefore, it 
is preferred to identify new drug targets for DLBCL outside the context of the CD20/BCR-
signalosome.
 In the present study, we aimed to identify therapeutic targets for combination therapy 
in DLBCL, which would be likely to improve treatment outcome without antagonizing the 
efficacy of rituximab. We therefore collected a large compendium of DLBCL gene expression 
profiles (GEPs) from the public domain and performed a guilt-by-association analysis with 
MS4A1. Subsequently, after the identification of the well-known but also several unknown 
DLBCL genes in association with CD20, we prioritized the top-ranked genes for drug-target 
interaction. Then, as an example, we confirmed high protein expression of two new target 
genes, WEE1 and PARP1, in DLBCL patient samples. As a next step we combined clinically 
available inhibiting drugs for these targets with rituximab, which resulted in improved DLBCL 
cell killing.
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Materials and methods
Data acquisition and sample processing and quality control
Publicly available raw microarray expression data of DLBCL samples were extracted from 
the Gene Expression Omnibus (GEO) [23]. The analysis was confined to the Affymetrix HG- 
U133A (GPL96) and Affymetrix HG-U133 Plus 2.0 (GPL570) platforms. Non-corrupted raw 
data CEL files were downloaded from GEO for the selected samples. To identify samples 
that have been uploaded to GEO multiple times we generated a MD5 (message-digest 
algorithm 5) hash for each individual CEL file. Before these MD5 hashes were generated 
we converted all CEL files to the GCOS XDA binary file format (version 4), which was done 
using the Affymetrix Power Tools (version 1.15.2) apt-cel-convert tool. A MD5 hash acts like 
a unique fingerprint for each individual file and duplicate CEL files will have an identical 
MD5 hash. After removal of duplicate CEL files, pre-processing and aggregation of CEL files 
was performed with RMAExpress (version 1.1.0) by applying the robust multi-array average 
(RMA) algorithm, using the latest Affymetrix GeneChip Array CDF layout files REF. Principal 
Component Analysis (PCA) on the sample correlation matrix was used for quality control. The 
first principal component (PCqc) of such an expression microarray correlation matrix nearly 
always describes a constant pattern that dominates the data, explaining around 80–90% of 
the total variance, which is independent of the biological nature of the sample being profiled. 
The correlation of each microarray expression profile with this PCqc can be used to detect 
outliers, as arrays of lesser quality will have a lower correlation with the PCqc. We removed 
samples that had a correlation R < 0.8. To minimize false positive or negative associations 
due to batch effects (different platforms and experiments) we calculated association statistics 
within meta-analysis batches. The combination of platform identifier (GPL number, i.e. GEO 
platform accession number) and experiment identifier (GSE number, i.e. GEO experiment 
accession number) were defined a meta-analysis batch. Meta-analysis statistic and p-values 
were calculated according to the generic inverse method with fixed effect model. To 
assess the degree of multiple testing, we performed this meta-analysis within a multivariate 
permutation test with 1000 permutation, a false discovery rate of 1% and a confidence level 
of 99%. For a detailed description we refer to our previous publication [24].
CD20 (MS4A1) guilt-by-association analysis
Probes representing MS4A1 were collapsed according to the mean. Next, we used mRNA 
signals to determine the association of each gene with the expression pattern of MS4A1. 
The association was determined by the Pearson correlation coefficient. Gene set enrichment 
analyses (GSEA) were performed on the 500 top-ranked MS4A1-associated probes (390 
unique genes). The 390 MS4A1 co-expressed genes were uploaded to Enrichr [25], and 
several gene set databases were consulted (KEGG, Wiki pathways, Biocarta, NCI Nature, 
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Panther and GO biological process). To annotate a single gene to only one biological 
pathway, we manually marked single genes to 9 different biological pathways (BCR signaling, 
cytoskeleton regulation, DNA repair and cell cycle, histone modification, immune regulation, 
metabolism, protein processing, RNA processing, signaling protein (not further specified)).
Target prioritization
The 390 MS4A1-associated genes were analyzed in the drug-gene interaction database 
(DGidb) [26]. Next, by means of manual curation utilizing Pubmed, clinicaltrials.gov, and 
the websites of the American Society of Hematology, European Hematology Association, 
American Society of Clinical Oncology, and the European Society of Medical Oncology, 
we excluded the identified genes for which anti-neoplastic drugs had been previously 
investigated in clinical trials with DLBCL patients or already approved for clinical use in 
DLBCL.
Cell lines and culture conditions
DLBCL cell lines OCI-ly3, U-2932, SUDHL4 and SC-1 (all obtained from Deutsche Sammlung 
from Microorganism und Zellculturen, Braunschweig, Germany), SUDHL2 (obtained from 
American Type Culture collection, Manassus, Virginia, US) and Epstein-Barr virus transformed 
lymphoblastoid cells (LCL (LCL-1, LCL-2), immortalized from healthy volunteers, anonymized, 
obtained from A. van den Berg, University Medical Center Groningen [27]) were cultured in 
RPMI1640 (Lonza BioWhittaker, Walkersville, MD, USA) with 10% Fetal Bovine Serum (FBS; 
HyClone Thermo Scientific, Waltham, MA, USA), and DLBCL cell lines SUDHL5, SUDHL6 
and SUDHL10 in RPMI1640 with 20% FBS. All cell lines were cultured at 37˚C with 5% CO2 
in a humidified atmosphere and in 1% Penicillin-Streptomycin (Lonza Bio-Whittaker) and 1% 
Glutamine (Lonza BioWhittaker). The identity of our cell lines was checked periodically by 
STR profiling.
Western blot, patient material and immunohistochemistry
Cells were washed with PBS and lysed in RIPA buffer (50mM Tris/ 150mM NaCl/ 2.5mM 
Na2EDTA/ 1% Triton X-100, 0.5%mM sodium deoxycholate/0.1% SDS in dH20) with 1mM 
phenylmethanesulphonyl fluoride for 30–45 minutes on ice. Protein concentration was 
determined using the Pierce™ BCA Protein Assay Kit (#23227; Thermo Scientific, Waltham 
MA, USA). Samples were loaded at 40μg per lane and electrophoresis and blotting was 
performed according to standard protocols. Staining with primary antibodies for anti-WEE1 
(1:200, sc-5285 (B11), Santa Cruz Biotechnology, Dallas TX, USA), anti-phospho-CDC2 
(Tyr15) (10A11) (1:1000, #4539, Cell Signaling Technology, Danvers, MA, USA), anti-
phospho-Histone H2AX (Ser139) (1:1000, clone JBW301, Merck Milipore, Temecula, CA, 
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USA) and PARP1 (1:1000, #9542, Cell Signaling Technology, Danvers, MA, USA) was done 
overnight and staining for GAPDH (1:20,000; sc-47724 (0411), Santa Cruz Biotechnology, 
Dallas TX, USA) was done for one 1 hour at 4˚C.
 Randomly selected primary formalin fixed paraffin (FFPE) tissue from our anonymous 
tissue repository (Pathology, University Medical Center Groningen) was used of 16 primary 
DLBCL cases. The study protocol was consistent with international ethical and professional 
guidelines (the Declaration of Helsinki and the International Conference on Harmonization 
Guidelines for Good Clinical Practice). The use of anonymous rest material is regulated 
under the code for good clinical practice in the Netherlands. Informed consent was waived 
in accordance with Dutch regulations.
 Immunohistochemistry (IHC) was performed on FFPE tissue according to standard 
protocols with appropriate positive and negative controls (based on manufacturer’s 
instructions). FFPE tissue of 16 randomly selected DLBCL patients was used. We used the 
following antibodies: anti-WEE1 (1:200, antigen retrieval with 10mM TRIS/ 1mM EDTA pH9 
for 15 min at 120˚C, one hour incubation at room temperature, Santa Cruz Biotechnology, 
Dallas TX, USA) and anti-PARP-1 (1:1000, antigen retrieval with 0.1M TRIS-HCL pH9 for 15 
min at 120˚C, incubation O/N at 4˚C, Biorbyt, Cambridge, UK).
CD20 flowcytometry
A total of 0.1x106 cells were incubated with anti-CD20 (Clone B-Ly1 (R7013), Dako, Glostrup 
Municipality, Denmark) for 30 minutes on ice in the dark. After washing with 1% BSA in PBS 
cells were resuspended in 2% paraformaldehyde (Sigma) and analyzed for CD20 expression 
(mean fluorescence intensity (MFI)) with flow cytometry. To study the effect of PARP1 and 
WEE1 inhibition on CD20 expression levels, we determined CD20 expression levels with 
flow cytometry after AZD1775 (WEE1 inhibition) and olaparib (PARP1 inhibition) treatment 
after 48 hours. For WEE1 inhibition, 0.2 μM AZD1775 for SUDHL6, SUDHL10 and SC-1 was 
used, and 1 μM AZD1775 for U2932. For olaparib 20 μM was used for SUDHL6, 50 μM for 
SUDHL10 and SC-1, and 100 μM for U9232.
Flow cytometry-based cytotoxicity assays
A total of 0.1x106 cells were pre-incubated with the inhibitor AZD1775 (WEE1 inhibitor, 
Selleckchem, Houston, TX, USA) for 48 hours at 37˚C. After this pre-incubation 0 or 10 μg/
mL rituximab with 5% plasma (pooled plasma from 5 donors; Sanquin, the Netherlands) 
was added for 1 hour at 37˚C. Next, cells were washed with 1% BSA in PBS and propidium 
iodide (Sigma, St. Louis MO, United States) was added for assessment of cell viability via 
flow cytometry (FACSCalibur, BD Biosciences, Franklin Lakes NJ, United States). Data 
were analyzed with Winlist 3D (Verity Software house, Topsham ME, USA). Cell lines 
were determined rituximab-sensitive when > 90% still have propidium iodide uptake upon 
rituximab treatment.
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AZD1775 and olaparib dose optimization
The optimal concentration window for AZD1775 and olaparib was determined in rituximab 
sensitive and insensitive cell lines with flowcytometry assays as described above. AZD1775 
was titrated in a range from 0.001 μM to 10 μM and olaparib in a range from 1 μM to 10.000 
μM.
Statistical methods
All statistical analysis with respect to survival analysis and in vitro assays were undertaken 




Gene expression profiles of 1,804 DLBCL patients were collected from 20 studies 
(Supplemental table 1). For all patients metadata were also included (Figure 1). The majority 
of the DLBCL expression profiles originated from biopsies of lymph nodes (99%). For 93% 
of the cases a GEP-based cell-of-origin (COO) was provided, with 35% of the patients 
being classified as ABC DLBCL, 49% as Germinal Center B-cell (GCB) DLBCL, and 15% 
as unclassified DLBCL. Treatment data were available for 52% of the patients of which the 
majority (67%) received R-CHOP, and 33% received CHOP or an Acute Lymphoblastic 
Leukemia-like regimen. DLBCL patient characteristics are shown in Table 1. 
MS4A1 guilt-by-association
To identify genes with similar expression patterns as MS4A1 we performed a guilt-by-
association analysis. We identified 5,355 probes representing 3,893 unique genes that were 
significantly associated with MS4A1 (FDR 1%, CI 99%) (Figure 2A and Supplemental table 
2). As expected, expression of several genes involved in BCR signaling such as CD79a, 
CD79b and CD22 was highly associated with MS4A1. For several of these genes, clinically-
approved drugs are available and used to treat other types of cancer (Figure 2A). Fig 2A 
also shows targets that are under clinical evaluation for DLBCL, but for which expression is 
not associated with MS4A1, such as PIK3CA, BCL-2 or AKT1. Gene set enrichment analyses 
(GSEA) of the 500 top-ranked MS4A1-associated probes—representing 390 protein-coding 
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genes—demonstrated a significant overrepresentation of the BCR signaling pathway 
according to multiple GSEAs with different gene set databases (e.g. KEGG p=7.7x109, 
Wiki pathways p=1.8x1018, Biocarta p=1.7x106, Supplemental table 2A–2F). To summarize 
the results of the GSEAs with different gene set databases, we annotated the 390 MS4A1 
co-expressed gene set to 9 different biological pathways. Besides the well-known BCR 
signaling genes and immune regulation genes, other pathways included DNA repair and cell 
cycle, cytoskeleton regulation, metabolism and histone modification (Supplemental table 4). 
Correlation of the individual MS4A1-associated genes categorized by biological pathway 
is shown in Figure 2B. These 390 MS4A1 co-expressed genes include multiple potential 
targets for DLBCL treatment.
Target prioritization of MS4A1-associated genes
Next, the 390 MS4A1-associated gene set was prioritized for drug-gene interactions, to 
identify targets for which clinically-grade drugs are already available. At least 50 genes had 
one reported drug-target interaction (Supplemental table 5). Various genes belonging to the 
BCR signaling pathway were identified, such as like BTK, CD19, LYN, and SYK, which can 
be targeted with ibrutinib, SAR3419, ponatinib, and fostamatinib, respectively. 
Figure 1. Work flow of the study. 
(A+B) 1804 Gene expression 
profiles (GEP) of patients with 
Diffuse Large B-cell Lymphoma 
from 20 studies were collected 
from the gene expression 
omnibus (GEO). (C) CD20 (gene: 
MS4A1), as a central protein in 
B-cell receptor (BCR) signaling 
and key target for the treatment 
of DLBCL, was chosen to perform 
a guilt-by-association analysis. 
Genes outside the context of BCR 
signaling (indicated by the grey 
dots) were chosen for drug-gene 
prioritization. (D) The Drug Gene 
Interaction database (DGIdb), 
Pubmed and clinicaltrials.gov 
were used to identify drug-gene 
targets that were not clinically 
studied in DLBCL before. (E) Two 
drug-gene targets were chosen 
for proof-of-concept in vitro 
studies.
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Table 1. Patient characteristics of the 20 collected DLBCL studies.
Clinical data Number (and %) of available data
Characteristics of 
available clinical data

























Additional radiotherapy 158 (8.8%) 37 (23.4%)
Outcome 1016 (56.3%)
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Table 1 continued. 




Activated B-cell 592 (35.2%)
Germinal Center B-cell 830 (49.3%)
Unclassified 260 (15.5%)
MYC rearrangment 283 (15.7%)
MYC-neg 157 (55.5%)
IG-MYC 103 (36.4%)
Non-IG MYC 23 (8.1%)
Non-IG translocation BCL-2 286 (15.9%)
BCL-2 44 (15.4%)
Non-IG BCL-2 expression 245 (13.6%)
BCL-2 (pos) 166 (67.8%)
Non-IG translocation BCl-6 283 (15.7%)
BCL-6 41 (14.5%)
Non-IG BCL-6 expression 231 (12.8%)
BCL-6 (pos) 191 (82.7%)
 In addition, we identified targets that interact with anti-neoplastic drugs that are currently 
used in treatment of DLBCL (e.g. DHFR interaction with methotrexate). We also observed 
targets that are involved in cellular energy metabolism interacting with non-cancer drugs (e.g. 
PRKAB1 with metformin, and PPP1CA with vitamin E). In addition, HDAC1 (panobinostat, 
belinostat, vorinostat, romidepsin), PSMD3 and PSMD6 (both carfilzomib) were identified as 
potential drugs for DLBCL treatment. These drugs are currently under clinical investigation 
in DLBCL. In Table 2, we summarize the identified drug-target combinations that, to our 
knowledge, have not been clinically studied in DLBCL patients, and do not interfere with 
the BCR signalosome. These drugs could potentially be introduced in clinical studies to 
improve DLBCL patient survival. The potential targets include DNA repair genes and cell 
cycle, such as PARP1, WEE1, CDK1, which can be targeted by olaparib, AZD1775 and 
dinaciclib respectively. Other genes are ESR2, (targeted by tamoxifen), PRKD3 (targeted by 
momelotinib), and BIRC3 (targeted by AT406). As proof-of-concept of our drug-discovery 
strategy, we selected WEE1 and PARP1, involved in cell cycle and DNA repair for further 
preclinical investigations.
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Figure 2. MS4A1 guilt-by-association analysis. (A) Pearson’s correlation plot of MS4A1 Guilt-by-Association of gene 
expression profiles of 1,804 DLBCL patient samples. In green, genes significantly positively associated with MS4A1, and 
in red, genes negatively associated with MS4A1. Several known and unknown genes in DLBCL are annotated in white 
(MS4A1-associated genes) and clear circles (drugable targets involved in clinical trials for diffuse large B-cell Lymphoma, 
but not highly associated with MS4A1). (B) The 500 top-ranked MS4A1 probes (representing 390 genes) were classified 
into 9 biological subgroups. This plot depicts genes within the subgroups associated to MS4A1 (Pearson correlation). 
The big dots represent genes for which clinical inhibitors are available.
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Table 2. Drug-gene target prioritization.
Gene Location Protein Protein Function Inhibitor Clinical Use 
Inhibitor
BIRC3 11q22 baculoviral IAP 
repeat containing 3
inhibits apoptosis 
by binding to tumor 
necrosis factor receptor-
associated factors
AT-406 Ovarium cancern/ 
Acute myeloid 
Leukemia
PARP1 1q41-q42 poly (ADP-ribose) 
polymerase 1
repair of single-stranded 
DNA breaks
olaparib Mammae and 
prostate cancer










organization of the 
interphoto-receptor 
matrix and may promote 
the growth
PX-866 Non-small-cell lung 
cancer
WEE1 11p15.4 WEE1 G2 
checkpoint kinase
tyrosine kinase, 
catalyzes the inhibitory 
tyrosine phosphorylation 




ESR2 14q23.3 estrogen receptor 2 
(ER beta)
protein forms homo- or 
hetero-dimers that 
interact with specific 
DNA sequences to 
activate
tamoxifen mammacarcinoma
CKD1 10q21.2 Cyclin-dependent 
kinase 1
Ser/Thr protein kinase 
family and catalytic 
subunit protein kinase 
complex known as 
M-phase promoting 
factor
Dinaciclib Chronic Lymfocytic 
Leukemia and 
multiple myeloma






complex that catalyzes 
the overall conversion of 





MAP3K1 5q11.2 mitogen-activated 
protein kinase 




kinase and is part of 
transduction cascades, 
including the ERK and 
JNK kinase




Relevance of WEE1 and PARP1 mRNA expression in DLBCL treatment
For both WEE1 and PARP1, mRNA expression was significantly higher within the GCB DLBCL 
subtype compared to ABC and unclassified subtypes (Kruskal-Wallis p<0.001, Figure 3A 
and 3B). Survival and treatment data were available for 872 patients (R-CHOP and CHOP). 
Improved overall survival was observed in patients treated with R-CHOP compared to CHOP 
in DLBCL patients in all COO subgroups (Supplemental figure 1). The addition of rituximab 
to CHOP was markedly more beneficial in GCB-DLBCL patients with high WEE1 expression 
than in patients with low WEE1 expression (Hazard Ratio (HR) of 2.8, CI 1.5–5.1, p=0.001 vs 
HR 2.0. CI 1.0–3.8, p=0.016) (Figure 3C). For ABC-DLBCL patients with low or high WEE1 
expression we observed no differences in the addition of rituximab to CHOP chemotherapy, 
respectively (HR of 2.2, CI 1.3–3.6, p=0.0008 vs HR 2.0. CI 1.2–3.3, p=0.001) (Figure 3D).
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 In GCB-DLBCL there were no differences in survival HRs for the addition of rituximab 
to CHOP in patients with high or low PARP1 expression (high PARP1: HR 2.3, CI 1.4–4.8, 
p=0.003 vs low PARP1 HR 2.6, CI 1.4–4.8, p=0.0005, Figure 3E). However, addition of 
rituximab to CHOP was markedly more beneficial with respect to survival in ABC-DLBCL 
patients with high PARP1 expression than in patients with low PARP expression (HR 2.8, 
CI 1.6–4.7. p=0.001 vs HR 1.6 CI 0.9–2.5 p=0.04) (Figure 3F). These data show that the 
additional effect of rituximab to CHOP may also be associated with the expression level of 
WEE1 and PARP1.
WEE1 and PARP1 protein expression and targeting of WEE1 and PARP1 kills 
DLBCL cell lines
Immunoblotting revealed WEE1 and PARP1 expression in all eight DLBCL cell lines, and not 
in control LCL cells (Figure 4A). In FFPE tissue samples both WEE1 and PARP1 showed a 
Figure 3. Expression levels of WEE1 and PARP1 in different DLBCL subgroups and in relation to anti-CD20 
therapy with or without standard chemotherapy. (A) WEE1 and (B) PARP1 mRNA expression levels in Germinal 
Center B-cell (GCB, black), Activated B-cell (ABC, dark grey), and unclassified (light grey) Diffuse Large B- cell 
Lymphoma (DLBCL) samples. Overall survival for patients with DLBCL-GCB (C) and DLBCL-ABC (D) with low and high 
WEE1 expression treated with CHOP or R-CHOP, and overall survival for DLBCL-GCB (E) and DLBCL-ABC (F) patients 
with low and high PARP1 expression treated with CHOP or R-CHOP. Shown in the tables provided are the hazard ratios 
of adding anti-CD20 therapy with rituximab to standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP)). Log-rank testing was used to test whether the curves are statistically different and to calculate the 
hazard ratio’s.
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nuclear staining pattern in tumor cells. WEE1 was expressed in 14 out of 16 cases (78%) and 
PARP1 in 15 out of 16 cases (94%), for both WEE1 and PARP1 the percentage of positive 
cells and protein intensity levels differed between patient samples (Figure 4B). This indicates 
that WEE1 and PARP1 are expressed at the protein level in DLBCL, both in DLBCL cell lines 
and primary cases.
 Next, we tested the effect of WEE1 and PARP1 inhibitors on DLBCL cell lines as single 
agent and in combination with rituximab. Single agent rituximab killing assays demonstrated 
that 4 of the 8 DLBCL cell lines were sensitive to rituximab treatment, corresponding to 
CD20 expression levels (Supplemental figure 2A and Supplemental figure 2B). We selected 
2 rituximab-sensitive (RS) (SUDHL6 and SUDHL10) and 2 rituximab-insensitive (RI) cell 
Figure 4. Protein expression of WEE1 and PARP1 in DLBCL and in in vitro killing assays. (A) Western blot 
results for Wee1, PARP1 in eight DLBCL cell lines. Two LCL cell lines are shown as normal B-cell controls. (B) 
Immunohistochemistry of Wee1 (left column) and PARP1 (right column) on DLBCL patient samples. Both Wee1 and 
PARP1 showed a nuclear staining pattern. (C) Cytotoxicity assays of the WEE1 inhibitor AZD1775 with or without 
rituximab in two rituximab sensitive and two resistant cell lines: SUDHL6 (rituximab sensitive, RS), SUDHL10 (RS), 
U2932 (rituximab insensitive, RI) and SC-1 (RI). Shown is the normalized live population (propidium iodide negative 
population) of three independent experiments. Student T-test was used to demonstrate significance (*) p<0.05/ (**) 
p<0,005. (D) Resazurin metabolic activity assay with the PARP1 inhibitor olaparib with or without rituximab in the above-
mentioned cell lines. Shown is the normalized metabolic activity of three independent analyses. Student T-test was used 
to compare samples without inhibitor treatment. Significant (*) p<0.05 / (**) p<0,005 / (***) p<0.001.
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lines (U2932 and SC-1) for further preclinical investigation. As a single agent, increasing 
concentrations of the WEE1 inhibitor AZD1775 strongly reduced cell viability in RS and RI cell 
lines after 48 hours (Figure 4C), without influencing CD20 expression levels (Supplemental 
figure 2C). Combining AZD1775 with rituximab showed a significant additional decline 
of cell survival in all tested cell lines (Figure 4C). In the DLBCL cell line SUDHL6 (RS), 
adding rituximab to a concentration of 2 μM AZD1775 decreased cell viability from 18% 
to 5% (p=0.0311) compared to AZD1775 alone, for SUDHL10 (RS), adding rituximab to a 
concentration of 0.2 μM AZD1775 decreased cell viability from 105% to 18% (p=0.0015) 
compared to AZD1775 alone, for the U2932 cell line (RI), cell viability decreased from 62% 
to 37% at 5 μM (p=0.00154) compared to AZD1775 alone, and for SC-1 (RI), a concentration 
of 2 μM AZD1775 plus rituximab decreased cell viability from 36% to 18% (p=0.0039). 
Similar results were obtained when WEE1 inhibition with rituximab was tested in the resazurin 
metabolic activity assay (Supplemental figure 2D). PARP1 inhibition by clinically obtained 
olaparib dose levels had limited single agent activity (Figure 4C). However, in cell viability 
assays combining 10 μM olaparib with rituximab in SUDHL6 (RS) resulted in an additional 
decline in cell viability (75% to 44% (p<0.001)), for the SUDHL10 cell line (RS), a concentration 
of 1 μM olaparib with rituximab decreased cell viability from 105% to 63% (p<0.001), for the 
U2932 cell line (RI), cell viability decreased from 60% to 53% at 5 μM (p=0.003), and for the 
SC-1 cell line (RI), a concentration of 10 μM olaparib plus rituximab decreased cell viability 
from 33% to 26% (p=0.03) (Figure 4C). In conclusion, the combination of WEE1 or PARP1 
inhibition with rituximab resulted in enhanced cytotoxicity and reduced cell viability in 3 out of 
4 tested almost all DLBCL cell lines. The added effect of the WEE1 or PARP1 inhibitors with 
rituximab was independent of rituximab sensitivity.
Discussion
In this study, we performed a large meta-analysis on the transcriptomic data of 1,804 
DLBCL patient samples to identify drug-target combinations for improvement of standard 
DLBCL immunochemotherapy (R-CHOP). We therefore took CD20, which is part of the 
BCR signalosome and a key target in DLBCL treatment, as the central protein to perform a 
guilt-by-association analysis. By employing CD20 for guilt-by-association we aimed to find 
targets with similar expression patterns to CD20. We focused on the associated genes as 
therapeutic targets for DLBCL. Co-expression does not necessarily indicate a direct relation 
or interaction with CD20, but was used for selection of promising targets. Guilt-by-association 
analysis has been used in cancer research to identify biomarkers. However, as a therapeutic 
purpose, guilt-by-association has been used only to identify targets in defined pathways, 
such as cancer metabolism [28]. In the present study, we used this method for the first 
time to identify targets in relation to a single gene—CD20 –which is a central molecule for 
current treatment regimens of DLBCL patients. This guilt-by-association approach may also 
be applied more generally in future studies to improve drug combinations for other types of 
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cancer and any starting gene with a central role in standard therapies.
 We selected the top 500 associated probes, corresponding to 390 protein-encoding 
MS4A1-associated genes. All well-known genes to be actively involved and expressed in 
DLBCL were present, including for instance BTK as a target for ibrutinib in current DLBCL 
clinical trials. In addition, we identified many genes for which the pathogenetic relevance 
in the context of DLBCL is still unknown (Table 2). From this list, candidate drug-targets 
were selected when not involved in BCR signaling or currently already under clinical study 
in DLBCL. Moreover, only clinical-grade inhibiting drugs from the treatment of other (solid) 
malignancies were selected to accelerate their application in clinical trials. The choice for 
clinically approved drugs also circumvents the problem of a worldwide lack of a proper 
mouse model to study the effect of rituximab in vivo. The human Fc region of the chimeric IgG1 
antibody rituximab lacks the ability to activate the murine complement (CDC) and effector 
cells (ADCC) [29,30], thereby limiting the study of relevant rituximab-drug combinations in a 
murine or xenogeneic setting.
 Our selection revealed multiple targets which were more strongly associated with 
CD20 than other well-known targets in DLBCL. We therefore consider them to be of high 
potential for direct combination with current DLBCL treatment. Examples are CDK1 (cell 
cycle; targeted by dinaciclib, PRKD3 (signaling protein; targeted by momelotinib), WEE1 
(replication checkpoint kinase; targeted by AZD1775) and PARP1 (DNA repair; targeted by 
olaparib).
 For primary investigation we chose WEE1 and PARP1. Although neither of these genes 
have been investigated in DLBCL in combination with rituximab, both WEE1 and PARP1 
have clinically approved inhibiting drugs and have been studied extensively in vivo. Both 
are currently used in clinical trials for several (solid) cancers, including cervical cancer, 
ovarian cancer, breast cancer, lung cancer, adenocarcinoma and gliomas (ClinicalTrials.
gov). Another important reason for our interest in these two genes was based on DLBCL 
pathophysiology. DLBCL originates from normal B-cells due to aberrant effects of somatic 
hypermutation and class-switch recombination machinery during the germinal center 
reaction, which results in chromosomal breaks leading to oncogenic transformation of B 
cells [31,32]. There is a crucial role for DNA damage response (DDR) and repair proteins 
during the germinal center reaction [33] and high expression of DNA damage response 
proteins have been demonstrated in DLBCL patient cases [34]. Since DLBCL is a tumor with 
high levels of DNA damage, targeting proteins involved in DDR and damage repair, such as 
WEE1 and PARP1, is a rational choice for therapy in DLBCL.
 WEE1 is a replication checkpoint kinase that prevents the onset of mitosis in cells that 
have incompletely replicated or have damaged genomes. In case of DNA damage, WEE1 
indirectly arrests the cells at the G2/M checkpoint, allowing time for repair or resulting in cell 
death [35]. Targeting WEE1 with AZD1775 in patients with a diversity of chemorefractory 
solid tumors demonstrated single agent activity [36]. Targeting WEE1 with AZD1775 in 
combination with the CHK1 inhibitor PF-00477736 resulted in cell killing and destabilization 
of the oncogenic transcription factor MYC in DLBCL and was strongly synergistic in mantle 
cell lymphoma [37,38]. Moreover, great potential has been shown for WEE1 inhibition in 
combination with cell cycle arresting chemotherapeutics such as doxorubicin and cytarabine 
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[39]. Our results show that WEE1 is highly expressed in DLBCL patient specimen. In addition, 
we demonstrated that the combination of the WEE1 inhibitor AZD1775 and rituximab resulted 
in additive cytotoxicity for all tested DLBCL cell lines, also in the rituximab-insensitive cell 
lines.
 PARP1 is well-known for its role in repairing DNA single strand breaks, and is thought 
to accumulate at sites of damage, inducing chromatin remodeling and attracting DNA repair 
factors [40]. PARP inhibitors have been mainly used in a setting of defective double strand 
break repair (DSBR), as PARP inhibition leads to double stranded breaks, which causes 
synthetic lethality in a DSBR defective background. To this extent, PARP1 inhibition has 
proven to be successful when used in DDR deficient tumors such as BRCA1- or BRCA2-
deficient breast cancer, ATM-deficient colorectal cancer [41], ATM-deficient lung cancer 
[42], TP53/ATM-deficient MCL [43], IGH/MYC-induced BRCA2 deficient Burkitt lymphoma 
[44] and PTEN/ TP53-deficient prostate cancer [45]. In DLBCL, TP53 mutations are found 
in 21–24% of cases and are inversely correlated with survival [46,47]. Moreover, PARP1 is 
known for its role in NF-kB activation [48] contributing to inflammation and carcinogenesis. 
Therefore, targeting PARP1 in a setting of high genomic instability, as seen in DLBCL, and 
high NF-kB activation, as seen in the ABC type DLBCL [49], is an understandable choice. Our 
results demonstrate that PARP1 is highly expressed in DLBCL patient samples. Interestingly, 
this finding is supported by the recently published PARP1-targeted PET imaging approach 
which can differentiate malignant from inflamed lymph nodes in DLBCL [50]. The combination 
of the PARP inhibitor olaparib and rituximab enhanced cytotoxicity in all 4 DLBCL cell lines 
tested, which all carried mutations in the TP53 gene. Consequently, combining PARP1 
inhibitors with current therapy could improve survival of patients with mutant TP53. Recently, 
the potential synergistic effects of combining WEE1 and PARP1 inhibition in acute leukemia 
revealed also a potential synergistic effect, creating a double-hit model by increasing DNA 
damage and preventing DNA damage repair [51].
 A potential bias of our approach might have been the selection of only high-quality 
mRNA samples. For this reason, we performed survival analyses for the different COO 
DLBCL groups and for CHOP versus R-CHOP treated DLBCL patients. These results were 
similar to survival data as reported in the literature. The addition of rituximab to CHOP 
chemotherapy seems more beneficial in GCB-DLBCL with high WEE1 expression compared 
to low WEE1 expression. This might be explained by the correlation of WEE1 with CD20 
expression level as observed in our guilt-by-association analysis, as patients with low CD20 
expression also have inferior survival [30,52]. For PARP1, our data showed that patients with 
a relatively high PARP1 expression in ABC-DLBCL benefitted the most from the addition of 
rituximab to CHOP chemotherapy. This suggests an additional effect of PARP1 response in 
the ABC subtype patients to rituximab. We hypothesize that this might be explained by the 
continuous activation and essential role of NF-κB in ABC-subtype DLBCL. Rituximab directly 
inhibits subunits of the NF-κB pathway [53] and might therefore lead to accumulation of more 
damage in ABC-type DLBCL that depends on high PARP1 expression for repair and NF-κB 
activation.
 In conclusion, a genome wide analysis of MS4A1 (CD20) guilt-by-association and drug-
target prioritization has been able to identify potentially relevant drug-targets to combine with 
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and improve DLBCL treatment. For the identified genes WEE1 and PARP1 clinically approved 
inhibitory drugs showed improved DLBCL cell killing when combined with rituximab. Our 
approach may be used as a fast-track approach to direct the use of clinically approved 
agents in future phase I/II trials to improve standard DLBCL treatment.
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Supplemental Table 3A. Table enrichment analysis: KEGG database. 




1 B cell receptor signaling pathway_Homo sapiens_
hsa04662
7,70E-09 1,69E-06 -2,00 40,35
2 Fc gamma R-mediated phagocytosis_Homo 
sapiens_hsa04666
2,71E-05 2,97E-06 -1,83 23,32
3 Ribosome_Homo sapiens_hsa03010 6,71E-05 4,90E-06 -1,70 20,76
4 RNA transport_Homo sapiens_hsa03013 1,30E-06 7,14E-05 -1,79 17,13
5 NF-kappa B signaling pathway_Homo sapiens_
hsa04064
1,78E-06 7,78E-05 -1,65 15,64
6 Epstein-Barr virus infection_Homo sapiens_
hsa05169
4,03E-05 1,10E-03 -1,78 12,09
7 Mismatch repair_Homo sapiens_hsa03430 3,80E-06 1,39E-04 -1,24 11,00
8 Transcriptional misregulation in cancer_Homo 
sapiens_hsa05202
4,95E-05 1,21E-03 -1,56 10,49
9 Shigellosis_Homo sapiens_hsa05131 3,46E-05 1,08E-03 -1,53 10,42
10 mRNA surveillance pathway_Homo sapiens_
hsa03015
6,58E-05 1,39E-03 -1,48 9,71
11 Pathogenic Escherichia coli infection_Homo 
sapiens_hsa05130
8,63E-05 1,58E-03 -1,40 9,05
12 Regulation of actin cytoskeleton_Homo sapiens_
hsa04810
2,81E-04 4,39E-03 -1,60 8,68
13 Cell cycle_Homo sapiens_hsa04110 1,48E-04 2,49E-03 -1,43 8,57
14 Fc epsilon RI signaling pathway_Homo sapiens_
hsa04664
3,33E-04 4,56E-03 -1,56 8,41
15 Primary immunodeficiency_Homo sapiens_
hsa05340
6,97E-05 1,39E-03 -1,20 7,92
16 Platelet activation_Homo sapiens_hsa04611 6,07E-04 7,39E-03 -1,47 7,20
17 Ubiquitin mediated proteolysis_Homo sapiens_
hsa04120
3,33E-04 4,56E-03 -1,29 6,94
18 Pyrimidine metabolism_Homo sapiens_hsa00240 9,80E-04 1,13E-02 -1,30 5,82
19 Oocyte meiosis_Homo sapiens_hsa04114 2,69E-03 2,94E-02 -1,38 4,87
20 Endocytosis_Homo sapiens_hsa04144 4,68E-03 4,88E-02 -1,47 4,44
21 Viral carcinogenesis_Homo sapiens_hsa05203 6,67E-03 6,01E-02 -1,40 3,93
22 Base excision repair_Homo sapiens_hsa03410 3,97E-04 5,11E-03 -0,67 3,51
23 Pathways in cancer_Homo sapiens_hsa05200 1,07E-02 8,06E-02 -1,36 3,43
24 Purine metabolism_Homo sapiens_hsa00230 7,32E-03 6,17E-02 -1,18 3,30
25 Tuberculosis_Homo sapiens_hsa05152 7,86E-03 6,37E-02 -1,17 3,22
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Supplemental Table 3B. Table enrichment analysis: Wiki pathways. 




1 B Cell Receptor Signaling Pathway_Homo sapiens_
WP23
1,81E-18 4,85E-16 -2,07 87,26
2 Cytoplasmic Ribosomal Proteins_Homo sapiens_
WP477
1,53E-07 1,61E-05 -1,98 35,57
3 Retinoblastoma (RB) in Cancer_Homo sapiens_
WP2446
1,80E-07 1,61E-05 -1,90 34,05
4 Cytoplasmic Ribosomal Proteins_Mus musculus_
WP163
7,40E-07 4,96E-05 -1,94 32,64
5 Translation Factors_Homo sapiens_WP107 5,03E-04 2,70E-05 -1,93 20,29
6 mRNA processing_Mus musculus_WP310 9,59E-04 4,28E-05 -2,01 20,21
7 Translation Factors_Mus musculus_WP307 2,46E-06 9,42E-05 -1,75 16,23
8 G1 to S cell cycle control_Homo sapiens_WP45 6,11E-06 2,05E-04 -1,84 15,63
9 G1 to S cell cycle control_Mus musculus_WP413 1,91E-05 5,68E-04 -1,77 13,26
10 XPodNet - protein-protein interactions in the 
podocyte expanded by STRING_Mus musculus_
WP2309
1,04E-04 2,08E-03 -1,93 11,94
11 Interferon type I signaling pathways_Homo 
sapiens_WP585
7,66E-05 2,05E-03 -1,81 11,20
12 IL-3 Signaling Pathway_Mus musculus_WP373 1,08E-04 2,08E-03 -1,77 10,92
13 TNF-alpha NF-kB Signaling Pathway_Mus 
musculus_WP246
1,94E-04 3,46E-03 -1,90 10,78
14 IL-6 signaling Pathway_Mus musculus_WP387 1,08E-04 2,08E-03 -1,73 10,66
15 Pathogenic Escherichia coli infection_Homo 
sapiens_WP2272
8,63E-05 2,08E-03 -1,64 10,13
16 EGF/EGFR Signaling Pathway_Homo sapiens_
WP437
3,36E-04 5,62E-03 -1,69 8,77
17 TNF alpha Signaling Pathway_Homo sapiens_
WP231
4,06E-04 6,40E-03 -1,52 7,69
18 Integrated Breast Cancer Pathway_Homo sapiens_
WP1984
8,78E-04 1,07E-02 -1,61 7,29
19 mRNA Processing_Homo sapiens_WP411 8,11E-04 1,07E-02 -1,46 6,63
20 Cell Cycle_Homo sapiens_WP179 8,64E-04 1,07E-02 -1,37 6,24
21 EGFR1 Signaling Pathway_Mus musculus_WP572 1,84E-03 1,97E-02 -1,56 6,11
22 TCR Signaling Pathway_Homo sapiens_WP69 1,79E-03 1,97E-02 -1,41 5,53
23 IL-5 Signaling Pathway_Homo sapiens_WP127 9,85E-04 1,15E-02 -1,21 5,42
24 IL-5 Signaling Pathway_Mus musculus_WP151 1,99E-03 2,04E-02 -1,34 5,20
25 Regulation of Actin Cytoskeleton_Homo sapiens_
WP51
2,58E-03 2,29E-02 -1,37 5,19
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Supplemental Table 3C. Table enrichment analysis: Biocarta. 




1 BCR Signaling Pathway_Homo sapiens_h_
bcrPathway
1,67E-06 1,22E-04 -1,90 17,11
2 How does salmonella hijack a cell_Homo 
sapiens_h_salmonellaPathway
1,10E-06 1,22E-04 -1,03 9,32
3 Role of MAL in Rho-Mediated Activation of SRF_
Homo sapiens_h_malPathway
2,43E-05 7,09E-04 -1,23 8,91
4 Y branching of actin filaments_Homo sapiens_h_
actinYPathway
9,57E-06 3,49E-04 -1,09 8,69
5 Fc Epsilon Receptor I Signaling in Mast Cells_
Homo sapiens_h_fcer1Pathway
2,12E-04 4,41E-03 -1,42 7,72
6 Human Cytomegalovirus and Map Kinase 
Pathways_Homo sapiens_h_hcmvPathway
2,07E-04 4,41E-03 -1,41 7,66
7 Role of PI3K subunit p85 in regulation of Actin 
Organization and Cell Migration_Homo sapiens_h_
cdc42racPathway
9,57E-06 3,49E-04 -0,94 7,50
8 Cell Cycle: G1/S Check Point _Homo sapiens_h_
g1Pathway
1,46E-03 2,66E-02 -1,01 3,68
9 p38 MAPK Signaling Pathway _Homo sapiens_h_
p38mapkPathway
2,52E-03 3,68E-02 -1,08 3,58
10 MAPKinase Signaling Pathway_Homo sapiens_h_
mapkPathway
4,45E-03 5,90E-02 -0,97 2,74
11 Role of Erk5 in Neuronal Survival_Homo sapiens_h_
erk5Pathway
1,34E-02 1,03E-01 -0,73 1,65
12 Regulation of eIF4e and p70 S6 Kinase_Homo 
sapiens_h_eif4Pathway
1,07E-02 9,92E-02 -0,67 1,55
13 Skeletal muscle hypertrophy is regulated via AKT/
mTOR pathway_Homo sapiens_h_igf1mtorpathway
1,20E-02 9,92E-02 -0,54 1,25
14 Keratinocyte Differentiation_Homo sapiens_h_
keratinocytePathway
1,90E-02 1,25E-01 -0,56 1,16
15 FAS signaling pathway ( CD95 )_Homo sapiens_h_
fasPathway
6,37E-03 7,64E-02 -0,45 1,16
16 RB Tumor Suppressor/Checkpoint Signaling in 
response to DNA damage_Homo sapiens_h_
rbPathway
1,77E-03 2,87E-02 -0,32 1,14
17 Angiotensin II mediated activation of JNK Pathway 
via Pyk2 dependent signaling_Homo sapiens_h_
At1rPathway
2,74E-02 1,37E-01 -0,46 0,91
18 Phosphoinositides and their downstream targets,_
Homo sapiens_h_ptdinsPathway
7,33E-03 7,64E-02 -0,26 0,66
19 HIV-1 Nef: negative effector of Fas and TNF_Homo 
sapiens_h_HivnefPathway
1,90E-02 1,25E-01 -0,26 0,54
20 Erk and PI-3 Kinase Are Necessary for Collagen 
Binding in Corneal Epithelia_Homo sapiens_h_
ecmPathway
2,15E-02 1,26E-01 -0,23 0,47
21 WNT Signaling Pathway_Homo sapiens_h_
wntPathway
1,97E-02 1,25E-01 -0,09 0,18
22 Ceramide Signaling Pathway_Homo sapiens_h_
ceramidePathway
2,54E-02 1,37E-01 -0,07 0,14
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Supplemental Table 3D. Table enrichment analysis: NCI Nature. 




1 BCR signaling pathway_Homo sapiens_acbf44e2-
618c-11e5-8ac5-06603eb7f303
3,04E-12 4,96E-10 -1,84 52,00
2 ErbB1 downstream signaling_Homo 
sapiens_30d60550-6192-11e5-8ac5-06603eb7f303
1,78E-07 1,45E-05 -1,77 31,86
3 PDGFR-beta signaling pathway_Homo sapiens_
c901a3e4-6194-11e5-8ac5-06603eb7f303
2,67E-05 1,45E-06 -1,96 26,31
4 RAC1 signaling pathway_Homo sapiens_faffa4fc-
6194-11e5-8ac5-06603eb7f303
8,58E-06 3,50E-04 -1,65 13,15
5 CDC42 signaling events_Homo sapiens_50b98ae0-
6190-11e5-8ac5-06603eb7f303
5,95E-05 1,94E-03 -1,65 10,30
6 E2F transcription factor network_Homo sapiens_
bb4d0fd3-6191-11e5-8ac5-06603eb7f303
7,30E-05 1,98E-03 -1,54 9,60
7 Class I PI3K signaling events_Homo 
sapiens_12b82bb7-6191-11e5-8ac5-06603eb7f303
3,08E-04 7,16E-03 -1,36 6,74
8 Fc-epsilon receptor I signaling in mast cells_Homo 
sapiens_86cd7795-6192-11e5-8ac5-06603eb7f303
8,63E-04 1,28E-02 -1,28 5,60
9 IL8- and CXCR2-mediated signaling events_Homo 
sapiens_fe78e284-6193-11e5-8ac5-06603eb7f303
4,58E-04 9,33E-03 -1,16 5,40
10 GMCSF-mediated signaling events_Homo 
sapiens_095aa3ef-6193-11e5-8ac5-06603eb7f303
6,01E-04 1,09E-02 -1,15 5,19
11 FAS (CD95) signaling pathway_Homo 
sapiens_79cc9c14-6192-11e5-8ac5-06603eb7f303
7,76E-04 1,26E-02 -1,14 5,00
12 C-MYB transcription factor network_Homo 
sapiens_61020228-618e-11e5-8ac5-06603eb7f303
1,04E-03 1,41E-02 -1,12 4,77
13 Ceramide signaling pathway_Homo sapiens_
d3747df2-6190-11e5-8ac5-06603eb7f303
1,53E-03 1,91E-02 -0,91 3,61
14 Integrin-linked kinase signaling_Homo 
sapiens_21738158-6194-11e5-8ac5-06603eb7f303
1,69E-03 1,97E-02 -0,87 3,40
15 TNF receptor signaling pathway_Homo 
sapiens_316be05e-6196-11e5-8ac5-06603eb7f303
1,87E-03 1,98E-02 -0,80 3,13
16 p73 transcription factor network_Homo sapiens_
a88c505e-6194-11e5-8ac5-06603eb7f303
3,97E-03 3,41E-02 -0,84 2,84
17 Thromboxane A2 receptor signaling_Homo 
sapiens_27d5800d-6196-11e5-8ac5-06603eb7f303
4,45E-03 3,63E-02 -0,83 2,76
18 Regulation of retinoblastoma protein_Homo 
sapiens_407a3468-6195-11e5-8ac5-06603eb7f303
7,84E-03 5,14E-02 -0,65 1,94
19 Regulation of Telomerase_Homo 
sapiens_4dfe97ca-6195-11e5-8ac5-06603eb7f303
9,48E-03 5,94E-02 -0,56 1,59
20 Alpha-synuclein signaling_Homo 
sapiens_588134bc-6187-11e5-8ac5-06603eb7f303
3,20E-03 2,90E-02 -0,42 1,48
21 Signaling events mediated by Hepatocyte Growth 
Factor Receptor (c-Met)_Homo sapiens_ac39d2b9-
6195-11e5-8ac5-06603eb7f303
1,66E-02 9,02E-02 -0,59 1,41
22 Retinoic acid receptors-mediated signaling_Homo 
sapiens_5797691b-6195-11e5-8ac5-06603eb7f303
1,94E-03 1,98E-02 -0,33 1,30
23 Internalization of ErbB1_Homo sapiens_3aa9aafa-
6194-11e5-8ac5-06603eb7f303
7,22E-03 5,12E-02 -0,43 1,27
24 amb2 Integrin signaling_Homo sapiens_5d4f90b6-
6188-11e5-8ac5-06603eb7f303
7,22E-03 5,12E-02 -0,26 0,77
25 Noncanonical Wnt signaling pathway_Homo 
sapiens_7ff5fe76-6194-11e5-8ac5-06603eb7f303
3,20E-03 2,90E-02 -0,20 0,69
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Supplemental Table 3E. Table enrichment analysis: Panther. 




1 B cell activation_Homo sapiens_P00010 4,79E-08 3,78E-06 -1,69 32,75
2 Inflammation mediated by chemokine and cytokine 
signaling pathway_Homo sapiens_P00031
3,66E-03 5,16E-02 -1,53 4,52
3 Apoptosis signaling pathway_Homo sapiens_
P00006
3,63E-03 5,16E-02 -1,49 4,43
4 Cytoskeletal regulation by Rho GTPase_Homo 
sapiens_P00016
2,30E-03 5,16E-02 -1,36 4,02
5 VEGF signaling pathway_Homo sapiens_P00056 3,80E-03 5,16E-02 -1,34 3,97
6 CCKR signaling map ST_Homo sapiens_P06959 4,85E-03 5,16E-02 -1,23 3,65
7 EGF receptor signaling pathway_Homo sapiens_
P00018
5,23E-03 5,16E-02 -1,08 3,20
8 Parkinson disease_Homo sapiens_P00049 4,78E-03 5,16E-02 -1,02 3,03
9 T cell activation_Homo sapiens_P00053 1,34E-02 8,84E-02 -0,51 1,23
10 PDGF signaling pathway_Homo sapiens_P00047 2,15E-02 1,31E-01 -0,50 1,03
11 Ubiquitin proteasome pathway_Homo sapiens_
P00060
9,32E-03 7,36E-02 -0,34 0,90
12 FGF signaling pathway_Homo sapiens_P00021 4,29E-02 1,95E-01 -0,05 0,08
13 Ras Pathway_Homo sapiens_P04393 4,43E-02 1,95E-01 0,09 -0,14
14 Angiotensin II-stimulated signaling through G 
proteins and beta-arrestin_Homo sapiens_P05911
2,74E-02 1,55E-01 0,13 -0,23
15 Cadherin signaling pathway_Homo sapiens_
P00012
9,47E-01 9,47E-01 5,59 -0,31
16 Huntington disease_Homo sapiens_P00029 9,24E-02 3,06E-01 0,37 -0,44
17 Alzheimer disease-presenilin pathway_Homo 
sapiens_P00004
8,56E-01 8,66E-01 6,36 -0,91
18 Angiogenesis_Homo sapiens_P00005 1,41E-01 3,83E-01 1,02 -0,98
19 Heterotrimeric G-protein signaling pathway-Gq 
alpha and Go alpha mediated pathway_Homo 
sapiens_P00027
1,49E-01 3,92E-01 1,10 -1,03
20 Interleukin signaling pathway_Homo sapiens_
P00036
8,14E-01 8,35E-01 5,72 -1,03
21 p53 pathway by glucose deprivation_Homo 
sapiens_P04397
7,33E-03 6,43E-02 0,39 -1,07
22 p53 pathway_Homo sapiens_P00059 1,58E-01 3,94E-01 1,52 -1,42
23 Nicotinic acetylcholine receptor signaling pathway_
Homo sapiens_P00044
7,35E-01 7,64E-01 5,97 -1,61
24 Adrenaline and noradrenaline biosynthesis_Homo 
sapiens_P00001
8,33E-02 3,06E-01 1,56 -1,85
25 Alpha adrenergic receptor signaling pathway_
Homo sapiens_P00002
7,20E-02 3,00E-01 1,54 -1,86
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Supplemental Table 3F. Table enrichment analysis: GO biological process. 




1 B cell activation (GO:0042113) 8,73E-19 2,40E-15 -2,18 88,40
2 gene expression (GO:0010467) 1,09E-12 1,50E-09 -2,34 63,63
3 immune response-activating signal transduction 
(GO:0002757)
1,42E-07 2,29E-05 -3,55 62,46
4 lymphocyte activation (GO:0046649) 6,53E-12 4,48E-09 -2,32 60,66
5 B cell receptor signaling pathway (GO:0050853) 1,71E-11 9,36E-09 -2,36 59,95
6 immune response-activating cell surface receptor 
signaling pathway (GO:0002429)
1,01E-06 1,21E-04 -3,68 58,66
7 translational initiation (GO:0006413) 2,74E-12 2,50E-09 -2,18 58,28
8 leukocyte activation (GO:0045321) 6,42E-11 2,94E-08 -2,37 57,40
9 activation of immune response (GO:0002253) 4,52E-07 6,20E-05 -3,40 56,49
10 immune response-regulating cell surface receptor 
signaling pathway (GO:0002768)
3,09E-06 3,39E-04 -3,51 52,25
11 nuclear-transcribed mRNA catabolic process, 
nonsense-mediated decay (GO:0000184)
9,68E-11 3,80E-08 -2,13 51,03
12 nuclear-transcribed mRNA catabolic process 
(GO:0000956)
8,79E-09 2,68E-06 -2,20 43,36
13 translation (GO:0006412) 6,56E-08 1,20E-05 -2,33 42,49
14 translational elongation (GO:0006414) 6,88E-09 2,36E-06 -2,11 41,98
15 mRNA catabolic process (GO:0006402) 2,55E-08 6,37E-06 -2,22 41,94
16 macromolecular complex disassembly 
(GO:0032984)
3,59E-08 8,20E-06 -2,19 40,77
17 translational termination (GO:0006415) 1,33E-08 3,66E-06 -2,09 40,54
18 protein complex disassembly (GO:0043241) 8,59E-08 1,48E-05 -2,17 39,15
19 cellular protein complex disassembly 
(GO:0043624)
5,89E-08 1,20E-05 -2,12 38,68
20 viral transcription (GO:0019083) 6,47E-08 1,20E-05 -2,07 37,74
21 RNA catabolic process (GO:0006401) 3,31E-07 5,05E-05 -2,23 37,39
22 antigen receptor-mediated signaling pathway 
(GO:0050851)
3,88E-07 5,61E-05 -2,21 36,97
23 protein localization to organelle (GO:0033365) 9,13E-07 1,14E-04 -2,31 36,95
24 Fc receptor signaling pathway (GO:0038093) 1,52E-06 8,56E-05 -3,63 34,02
25 establishment of protein localization to endoplasmic 
reticulum (GO:0072599)
7,16E-07 9,37E-05 -2,06 33,28
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Supplemental Table 4. CD20 guilt-by-association subgroup analysis. The first 500 MS4A1-associated gene probes 
with corresponding gene name were grouped according to biological pathway. 
Gene Name Chromosome Pearson P  Biological 
pathway
SWAP70 SWAP switching B-cell complex 
70kDa subunit
chr11p15 0,55 4,15E-148 BCR signaling
PAX5 paired box 5 chr9p13 0,54 7,15E-139 BCR signaling
BCL11A B-cell CLL/lymphoma 11A (zinc 
finger protein)
chr2p16.1 0,53 2,12E-131 BCR signaling
CD79A CD79a molecule, 
immunoglobulin-associated 
alpha
chr19q13.2 0,48 1,08E-107 BCR signaling
SKAP2 src kinase associated 
phosphoprotein 2
chr7p15.2 0,47 6,21E-100 BCR signaling




0,45 7,86E-89 BCR signaling
CD22 CD22 molecule chr19q13.1 0,44 1,43E-86 BCR signaling
PLEKHF2 pleckstrin homology domain 
containing, family F (with FYVE 
domain) member 2
chr8q22.1 0,43 5,33E-80 BCR signaling
RRAS2 related RAS viral (r-ras) 
oncogene homolog 2
chr11p15.2 0,42 2,95E-77 BCR signaling
LPXN leupaxin chr11q12.1 0,41 1,60E-75 BCR signaling
LRMP lymphoid-restricted membrane 
protein
chr12p12.1 0,40 3,07E-71 BCR signaling
Supplemental Table 5. Prioritized drug-gene targets. List of drug-gene interactions for the first 500 MS4A1-associated 
gene probes, with corresponding pubmed IDs.
Search 
Term
Gene Drug PubMed IDs
ACTR2 ACTR2 - ARP2 actin-related protein 2 
homolog (yeast)
CK-636 10592235
ACTR3 ACTR3 - ARP3 actin-related protein 3 
homolog (yeast)
CK-636 10592235
ALOX5AP ALOX5AP - arachidonate 
5-lipoxygenase-activating protein
VELIFLAPON, AM103
ARPC2 ARPC2 - actin related protein 2/3 
complex, subunit 2, 34kDa
CK-636 10592235
ARPC3 ARPC3 - actin related protein 2/3 
complex, subunit 3, 21kDa
CK-636 10592235
ARPC4 ARPC4 - actin related protein 2/3 
complex, subunit 4, 20kDa
CK-636 10592235
ARPC5 ARPC5 - actin related protein 2/3 




BIRC3 BIRC3 - baculoviral IAP repeat 
containing 3
CK-636
BLK BLK - B lymphoid tyrosine kinase ENMD-2076
BTK BTK - Bruton agammaglobulinemia 
tyrosine kinase
IBRUTINIB, AVL-292 24869598
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Supplemental Table 5 continued.
Search 
Term
Gene Drug PubMed IDs
CD19 CD19 - CD19 molecule SAR3419
BTK BTK - Bruton agammaglobulinemia 
tyrosine kinase
IBRUTINIB, AVL-292 24869598
CD19 CD19 - CD19 molecule SAR3419
CDK1 CDK1 - cyclin-dependent kinase 1 DINACICLIB
CNR2 CNR2 - cannabinoid receptor 2 
(macrophage)
NABILONE, DRONABINOL
CREB1 CREB1 - cAMP responsive element 
binding protein 1
NALOXONE 12969258, 14653953, 
12956944, 15953421, 
16417577
DCK DCK - deoxycytidine kinase FLUDARABINE, DEOXYCITIDINE
DHFR DHFR - dihydrofolate reductase METHOTREXATE, 
PRALATREXATE




FDFT1 FDFT1 - farnesyl-diphosphate 
farnesyltransferase 1
NB-598 , BPH-830
FNTA FNTA - farnesyltransferase, CAAX 
box, alpha
TIPIFARNIB, AZD3409
GATM GATM - glycine amidinotransferase 
(L-arginine:glycine 
amidinotransferase)
DELTA-AMINO VALERIC ACID 17486546, 16970975
GMDS GMDS - GDP-mannose 
4,6-dehydratase
DB02547 17016423, 17139284, 
10592235
GPR18 GPR18 - G protein-coupled receptor 
18
CANNABIDIOL
HDAC1 HDAC1 - histone deacetylase 1 PANOBINOSTAT, VALPROIC 
ACID, VORINOSTAT, 
ROMIDEPSIN
HTR3A HTR3A - 5-hydroxytryptamine 
(serotonin) receptor 3A, ionotropic
GRANISETRON, MIRTAZAPINE
ITPR1 ITPR1 - inositol 1,4,5-trisphosphate 
receptor, type 1
CAFFEINE 1844813
LYN LYN - v-yes-1 Yamaguchi sarcoma 
viral related oncogene homolog
BOSUTINIB, PONATINIB
MAP3K7 MAP3K7 - mitogen-activated protein 
kinase kinase kinase 7
RGB-286638
MAPK1 MAPK1 - mitogen-activated protein 
kinase 1
ERLOTINIB 26181029





METAP2 METAP2 - methionyl aminopeptidase 
2
BELORANIB
NPM1 NPM1 - nucleophosmin (nucleolar 
phosphoprotein B23, numatrin)
NSC348884 21719597
PAPOLA PAPOLA - poly(A) polymerase alpha 3-SULFINOALANINE 17016423, 17139284, 
10592235
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Supplemental Table 5 continued.
Search 
Term
Gene Drug PubMed IDs
PARP1 PARP1 - poly (ADP-ribose) 
polymerase 1
OLAPARIB, VELIPARIB
PDK3 PDK3 - pyruvate dehydrogenase 
kinase, isozyme 3
CPI-613
PLCG2 PLCG2 - phospholipase C, gamma 2 
(phosphatidylinositol-specific)
IBRUTINIB 24869598
PPP1CA PPP1CA - protein phosphatase 1, 
catalytic subunit, alpha isozyme
SCY-635 Vitamin E
PRKAB1 PRKAB1 - protein kinase, AMP-
activated, beta 1 non-catalytic subunit
METFORMIN
PRKD3 PRKD3 - protein kinase D3 QUERCETIN
PSMD6 PSMD6 - proteasome (prosome, 
macropain) 26S subunit, non-ATPase, 
6
CARFILZOMIB
PSME3 PSME3 - proteasome (prosome, 
macropain) activator subunit 3 (PA28 
gamma; Ki)
BORTEZOMIB
QPCT QPCT - glutaminyl-peptide 
cyclotransferase
N-ACETYLHISTAMINE
RAB8B RAB8B - RAB8B, member RAS 
oncogene family
DB02082 17016423, 17139284, 
10592235
ROCK1 ROCK1 - Rho-associated, coiled-coil 
containing protein kinase 1
HYDROXYFASUDIL 11752352, 10592235
RPL19 RPL19 - ribosomal protein L19 PUROMYCIN 10592235
RRM1 RRM1 - ribonucleotide reductase M1 CLADRIBINE, HYDROXYUREA 16316309, 9923554, 
19576186, 19715446, 
17852710
SDHC SDHC - succinate dehydrogenase 
complex, subunit C, integral 
membrane protein, 15kDa
SUCCINIC ACID 15986240, 17636259, 
16405730, 16288654, 
16232921
SYK SYK - spleen tyrosine kinase PACLITAXEL, FOSTAMATINIB 26096845
UGCG UGCG - UDP-glucose ceramide 
glucosyltransferase
MIGLUSTAT
WEE1 WEE1 - WEE1 homolog (S. pombe) MK-1775
XRCC4 XRCC4 - X-ray repair complementing 
defective repair in Chinese hamster 
cells 4
DOCETAXEL
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Supplemental Figure 1. Overall survival for patients with diffuse large B-cell lymphoma (DLBCL). (A), Germinal 
Center B-Cell (GCB) DLBCL (B), Activated B-cell (ABC) DLBCL (C), and unclassified DLBCL (D) treated with CHOP or 
R-CHOP. Log-rank testing was used to test whether the curves are statistically different (* p-value < 0.0001, ** p-value 
0.003). Abbreviation: R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.
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Supplemental Figure 2. In vitro activity of rituximab, AZD1775 and olaparib. (A) CD20 expression level of 8 different 
Diffuse Large B-cell Lymphoma (DLBCL) cell lines. The cell-of-origin is indicated of each individual cell line. (B) The in 
vitro susceptibility of the DLBCL cell line to rituximab in the presence of human complement. (C) Western blot results 
of WEE1, PARP1 and yH2AX protein expression of SUDHL16 and SUDHL10 treated for 24 hours with 1 μM AZD1775 
or 250 μM Olaparib. (D) Resazurin metabolic activity assay of the WEE1 inhibitor AZD1775 with or without rituximab in 
two rituximab sensitive and two resistant cell lines: SUDHL6, SUDHL10, U2932, and SC-1. Shown is the normalized 
metabolic activity of three independent analyses. Data was analyzed with student T-test as compared to sample without 
inhibitor treatment. Significant (*) p≤0.01/ (**) p≤0,001/ (***) p≤0.0001.
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Abstract
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, characterized by 
high levels of genomic instability and the activation of DNA damage repair pathways. We 
previously found high expression of the cell cycle regulator WEE1 in DLBCL cell lines. Here, 
we investigated the combination of the WEE1 inhibitor, AZD1775, with cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP) and radiation therapy (RT), with the aim of 
improving first-line treatment. 
 Cell viability experiments were performed to determine synergistic combinations. Levels 
of DNA damage were established using flow cytometry for yH2AX and protein analysis for 
DNA damage response proteins CHK1 and CHK2. Flow cytometry analysis for cell cycle and 
pH3 were performed to determine cell cycle distribution and premature mitotic entry. 
 Treatment with either RT or CHOP led to enhanced sensitivity to AZD1775 in several 
DLBCL cell lines. Treatment of cells with AZD1775 induced unscheduled mitotic progression, 
resulting in abnormal cell cycle distribution in combination with RT or CHOP treatment. In 
addition, a significant increase in DNA damage was observed compared to CHOP or RT 
alone. Of the single CHOP components, doxorubicin showed the strongest effect together 
with AZD1775, reducing viability and increasing DNA damage. 
 In conclusion, the combination of RT or CHOP with AZD1775 enhances sensitivity to 
WEE1 inhibition through unscheduled G2/M progression, leading to increased DNA damage. 
Based on these results, WEE1 inhibition has great potential together with other G2/M arresting 
and/or DNA damaging (chemo)therapeutic compounds and should be further explored in 
clinical trials.
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Introduction
For several decades the first-line treatment for diffuse large B cell lymphoma (DLBCL) has 
consisted of the chemotherapy combination of cyclophosphamide, vincristine, doxorubicin 
and prednisone (CHOP) together with the anti-CD20 antibody rituximab (R), with or without 
radiation therapy (RT) [1]. Although around 60% of DLBCL patients are cured using R-CHOP, 
30-40% will experience disease relapse and 10% of patients develop primary refractory 
disease [2], which has a very poor prognosis. Intensification of chemotherapy has not 
improved survival and has only led to greater toxicity [3]. Furthermore, second generation 
anti-CD20 antibodies such as ofatumumab, veltuzumab or the third generation anti-CD20 
antibody obinutuzumab have all failed to out-perform rituximab in DLBCL [4,5]. Novel 
therapies that combine R-CHOP with bortezomib [6], lenalidomide [7] or ibrutinib [8] have 
not yet produced the expected improved responses in DLBCL patients. Clearly, there is still 
an unmet need for improvements to first-line therapies for a significant number of DLBCL 
patients. New first-line combinations for DLBCL should be based on the targeting of unique 
and specific DLBCL proteins and should act synergistically with R-CHOP.
 We recently identified WEE1 as a promising target in DLBCL and demonstrated its 
efficacy as a druggable target in combination with rituximab [9]. WEE1 is a cell cycle regulator 
that inhibits G2/M transition by blocking CDC2/CDK1 activity through phosphorylation at 
Tyr15. In the event of DNA damage, WEE1 is activated by CHK1 to allow DNA damage 
repair before the cell transitions into mitosis [10]. Many tumour cells rely on this cell cycle 
checkpoint for repair because they have lost the ability to repair DNA damage at the G1/S 
phase as a result of TP53 abnormalities (deletions or mutations) or mutations in other cell 
cycle controlling genes, often resulting in diminished activity of the CDK inhibitor p21 
[11]. In DLBCL, aberrant and off-target activity of activation-induced cytidine deaminase 
(AID) induces oncogenic mutations and chromosomal translocations [12], causing genetic 
instability [13] and activation of DNA damage repair pathways [14]. In this setting, targeting 
WEE1 could prevent proper initiation of the G2/M checkpoint, leading to accumulation of 
DNA damage and mitotic catastrophe. Inhibition of WEE1 using AZD1775 has been shown 
to be effective in many different tumour types, especially in tumours with compromised DNA 
damage response pathways such as TP53-deficient ovarian adenocarcinoma tumour cells 
[15]. Since WEE1 inhibition prevents adequate DNA damage repair, targeting WEE1 in cells 
with an already compromised DNA damage repair pathway and/or inducing additional DNA 
damage through genotoxic compounds would seem a rational application for WEE1 inhibition 
in DLBCL treatment. 
 Here, we investigated the effect of the WEE1 inhibitor AZD1775 combined with standard 
RT or CHOP therapy. We observed a synergistic effect of AZD1775 with both RT and CHOP, 
as treatment of DLBCL cells with RT or CHOP led to increased expression of the DNA 
damage response proteins CHK1 and CHK2, increased levels of the DNA damage marker 
γH2AX and increased levels of premature mitotic entry. Together, these findings indicate that 
blocking WEE1, in combination with RT or CHOP, limits the time necessary for DNA repair 
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due to unscheduled mitosis, increases DNA damage and ultimately results in enhanced cell 
death. These data indicate the potential of WEE1 inhibition in combination with first-line RT 
and CHOP therapy for DLBCL patients and highlight the clinical potential of AZD1775 in 
DLBCL treatment.
Materials and methods
Cell lines and culture conditions
The DLBCL cell lines U-2932, SUDHL-2, SUDHL-4 and SC-1 were cultured in suspension in 
Roswell Park Memorial Institute medium 1640 (RPMI 1640; Lonza BioWhittaker, Walkersville, 
MD, USA) with 10% fetal bovine serum (FBS; HyClone Thermo Scientific, Waltham, MA, 
USA), 1% penicillin-streptomycin (PS; Lonza BioWhittaker) and 1% glutamine (Lonza 
BioWhittaker). The DLBCL cell lines OCILY3, SUDHL-5, SUDHL-6 and SUDHL-10 were 
cultured in suspension in RPMI 1640 with 20% FBS, 1% PS and 1% glutamine. All cell lines 
were cultured at 37°C with 5% CO2 in a humidified atmosphere. The identity of our cell lines 
was regularly checked using STR typing and their TP53 gene status was determined by 
sequencing exons 1-10. 
Compounds and radiation
The WEE1 inhibitor AZD1775 was acquired from Selleckchem (No. S1525, Houston, TX, 
USA). RT was performed at a dosage from 2 to 20 Gy using a 137Cesium source-662 keV 
photons (IBL 637, Cis Bio International, Gif-sur-Yvette, France) and metabolic activity of cells 
was measured after 72 hours. CHOP included cyclophosphamide (University Medical Center 
Groningen (UMCG) pharmacy), doxorubicin (No. S1208, Selleckchem), vincristine (UMCG 
pharmacy) and prednisolone (No. S1737, Selleckchem), in a composition set at the clinical 
ratio of 83/5.5/0.16/11.1, respectively [16]. 
Metabolic activity
Metabolic activity of cells was measured after 72 hours treatment of 0.4 x 106 cells/ml. Cells 
were incubated with 10 µl resazurin (5% final concentration, AlamarBlue, Thermo Fisher 
Scientific, Waltham, MA USA) for nine hours prior to read-out (Varioskan, excitation 560nm, 
emission 590nm). Experiments were performed 5 times. 
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Flow cytometry – cell cycle, γH2AX and pH3 with DNA content
For cell cycle analysis, 0.2 x 106 cells/ml were treated for the indicated time points, washed 
with 1% BSA/PBS and resuspended in solution containing 0.1% sodium citrate (A0158348, 
Merck, Kenilworth, New Jersey, United States), 0.01% propidium iodide (P4170, Sigma-
Aldrich, St. Louis, Missouri, United States), 0.002% RNase A (R4875, Sigma-Aldrich) and 
0.3% Triton X100 (T9284, Sigma-Aldrich). Samples were processed on a BD FACSCalibur 2 
and analysed with ModFit LT (Verity Software House). Experiments were performed 3 times.
 For γH2AX analysis, 0.2 x 106 cells/ml were treated for the indicated time points and 
then stained with mouse anti-γH2AX-AlexaFluor-647 (clone 2F3, #613408, BioLegend) 
and propidium iodide solution (P4170, Sigma) according to the protocol provided with the 
eBioscience™ Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher, #00-5523-00). 
Samples were processed on a MACSQuant and the data were analyzed using Kaluza 1.5 
analysis software (Beckman). Experiments were performed 3 times.
 For pH3 analysis, 0.2 x 106 cells/ml were treated for the indicated time points and 
stained with mouse-anti-pH3-AlexaFluor-647 (clone 11D8, #650806, Biolegend) and 
propidium iodide solution (P4170, Sigma) according to the protocol provided with the 
eBioscience™ Foxp3 / Transcription Factor Staining Buffer Set (ThermoFisher, #00-5523-
00). Samples were processed on a MACSQuant and data were analyzed using Kaluza 1.5 
analysis software (Beckman). Premature mitotic cells were identified as pH3 positive cells 
measured in S-phase instead of in G2/M phase. Experiments were performed 3 times.
Western blot
Cells were washed with PBS and lysed in RIPA buffer (50mM Tris, 150mM NaCl, 2.5mM 
Na2EDTA, 1% Triton X-100, 0.5%mM sodium deoxycholate, 0.1% SDS in dH20) with 1mM 
phenylmethanesulphonyl fluoride for 30-45 minutes on ice. Protein concentration was 
determined using the Pierce™ BCA Protein Assay Kit (#23227; Thermo Scientific, Waltham 
MA, USA). Samples were loaded at 40µg per lane and electrophoresis and blotting was 
performed according to standard protocols. Staining with primary antibodies for anti-WEE1 
(1:200, sc-5285 (B11), Santa Cruz Biotechnology, Dallas TX, USA), anti-phospho-CDC2 
(Tyr15) (10A11) (1:1000, #4539, Cell Signaling Technology, Danvers, MA, USA), anti-
phospho-Histone H2AX (Ser139) (1:1000, clone JBW301, Merck Millipore, Temecula, CA, 
USA) and GAPDH (1:10,000; NovusBio) was done overnight at 4°C. 
Statistical analysis
Data were analysed using Graphpad PRISM (version 5.0) software and tested for significant 
differences using a paired T-test. Bubble graphs were plotted, with the position of each 
bubble on the y-axis representing an IC50 value and the size representing the calculated 
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factor differences versus the control. The size of each bubble is an arbitrary unit, determined 
by the factor and fold change between the combination IC50 (AZD+treatment) versus AZD 
alone (=1). This is calculated with the formula: 1 (factor of AZD alone) * IC50 AZD+treatment÷ 
IC50 AZD alone. If the IC50 value could not be calculated the value is marked with “not 
available” (n.a.). Synergism of combination therapies was calculated using the method of 
Combination Subthresholding, which calculates as the difference between the expected 
effect (E) of the combination therapy compared to the observed effect (O) of the combination 
therapy and tested for significant differences using a paired T-test. Corresponding significant 
p-values were colour coded to represent additive combinations in white (E=O), synergistic 
combinations in green (E<O) and antagonistic combinations in red (E>O). * indicates p≤0.05, 
** indicates p≤0.01 and *** indicates p≤0.001.
Results 
Radiation and CHOP therapy enhance sensitivity to AZD1775 in DLBCL cell lines
Radiation therapy (RT) and CHOP chemotherapy are part of the standard treatment for 
DLBCL and both induce high levels of DNA damage thereby causing cell death. Efficient 
DNA damage repair and survival and/or resistance require both activation of the DNA 
damage response and cell cycle arrest. We hypothesized that WEE1 inhibition together with 
RT and CHOP prevents cell cycle arrest and allows DNA damage to accumulate against a 
background of repair inhibition, resulting in enhanced cell killing. Titration of AZD1775 in eight 
DLCBL cell lines revealed a wide range of sensitivities to AZD1775, with a minimum IC50 
value of 357 nM for OCI-LY3 to a maximum IC50 value of 1835 nM for SUDHL-4, values that 
are comparable to or less than the clinical Cmax serum concentration for AZD1775 of 1650 
nmol/L in solid tumours [17] (Supplemental figure 1A). The combination of AZD1775 with RT 
showed a dose-dependent decrease in the IC50 values of all cell lines, thereby enhancing 
sensitivity to AZD1775. The combination of RT and AZD1775 was synergistic in six out of 
eight cell lines (Figure 1A and Supplemental figure 2A). Combination of AZD1775 with 4 Gy 
radiation resulted in a 5.5-fold increased sensitivity to AZD1775 (IC50 decrease from 357 nM 
to 65 nM) in OCI-LY3. The combination of AZD1775 together with CHOP chemotherapy gave 
similar results, with a dose-dependent decrease in the IC50 values of all cell lines, resulting 
in synergism in seven out of eight cell lines (Figure 1B and Supplemental figure 2B). An 
up to 6-fold enhanced sensitivity to AZD1775 was observed in SUDHL-10 (IC50 decrease 
from 608 nM to 100 nM) (Figure 1B). Analysis of the TP53 status of our cell lines revealed 
no correlation between TP53 mutation status and IC50 values for AZD1775 (p=0.2500) 
(Supplemental figure 1B), CHOP (p=0.5446) (Supplemental figure 1C) or RT (p=0.1876) 
(Supplemental figure 1D) nor the response to combination therapy. In conclusion, these 
results demonstrate the great potential of the WEE1 inhibitor AZD1775 in combination with 
CHOP and RT as a first-line standard therapy in DLBCL. 
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Figure 1. AZD1775 combination therapy with either radiation therapy (RT) or CHOP in DLBCL cell lines. (A) IC50 
values are plotted for DLBCL cell lines treated with AZD1775 alone (blue), together with either 2 Gy (red) or 4 Gy (green) 
ionizing radiation. (B) IC50 values are plotted for DLBCL cell lines treated with AZD1775 alone (blue), together with 0.01 
µg/mL CHOP (red), with 0.1 µg/mL CHOP (green) or with 1 µg/mL CHOP (purple). IC50 values were determined from 
metabolic activity data measured after 72 hours of treatment using resazurin. Data were normalized to the control and 
plotted as the mean IC50 of n=3. The size of each bubble is an arbitrary unit, determined by the factor and fold change
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AZD1775 with RT or CHOP therapy activates the DNA damage response
Next, we investigated whether the synergistic effect of WEE1 inhibition together with DNA 
damaging agents (RT or CHOP) was a result of increased DNA damage in the representative 
cell lines SUDHL-5, SUDHL-6 and SUDHL-10. 
between the combination IC50 (AZD+treatment) versus AZD alone (=1), calculated with the formula: 1 (factor 
of AZD alone) * IC50 AZD+treatment÷ IC50 AZD alone. If the IC50 value could not be calculated the value 
is marked with “not available” (n.a.). Synergy of each combination was calculated as the difference between 
the expected effect (E) compared to the observed effect (O) of the combination therapy, with a corresponding 
(significant) p-value, analyzed for significance using a one-sample T-test. Colours represent additive in white 
(E=O), synergy in green (E<O) and antagonism in red (E>O).
Figure 2. DNA damage analysis of AZD1775 combined with RT or CHOP. (A) Analysis of γH2AX positive cells in the 
cell lines SUDHL-5, SUDHL-6 and SUDHL-10 treated for 24 hours with 100 nM and 500 nM AZD1776 combined with 2 
Gy or 4 Gy radiation therapy (RT). (B) Analysis of γH2AX positive cells in SUDHL-5, SUDHL-6 and SUDHL-10 treated for 
24 hours with 100 nM and 500 nM AZD1776 combined with 0.1 or 1 µg/mL CHOP. Data are plotted as the mean ± S.D. 
of n=3. Samples of untreated control cells were compared to treated cells, unless otherwise marked with capped lines. 
Statistical analysis was performed using a one-sample paired T-test (*p≤0.05) (**p≤0.01) (***p≤0.001).
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 Flow cytometry analysis of the DNA damage marker γH2AX showed a moderate 
increase in γH2AX positive cells (3-13%) after treatment with AZD1775 (Figure 2A-B). 
Similarly, radiation alone at the suboptimal dose of 2 and 4 Gy induced little DNA damage 
(5-11% γH2AX positive cells) (Figure 2A). However, the combination of RT with AZD1775 led 
to a dose-dependent increase of γH2AX positive cells. In SUDHL-6, 4 Gy radiation produced 
10% γH2AX positive cells, increasing to 34% when combined with 500 nM AZD1775 (p=0.02) 
(Figure 2A). Treatment with CHOP (Figure 2B) at a suboptimal dose of 0.1 µg/mL induced 
minimal DNA damage (5-7% γH2AX positive cells) in all cell lines, whereas 1 µg/mL induced 
significant levels of DNA damage (39-54% γH2AX positive cells) in DLBCL cell lines. The 
addition of 500 nM AZD1775 to 0.1 µg/mL CHOP significantly increased γH2AX positive 
cells (from 7% to 40%; p=0.0107) in both SUDHL-5 and SUDHL-6 (5% to 16%; p=0.0261). At 
the CHOP dosage of 1 µg/mL, addition of AZD1775 did not further increase γH2AX positive 
cells, indicating that cells had reached their maximum potential for DNA damage. A dose-
dependent increase in γH2AX positive cells was observed for the combination of CHOP with 
AZD1775 in SUDHL-10, which was most prominent in the range 500 nM AZD1775 to 1 µg/mL 
CHOP, producing a significant increase in γH2AX positive cells (from 1% to 40%; p=0.0003). 
These findings demonstrate that the combination of a suboptimal dose of AZD1775 together 
with a suboptimal dose of either RT or CHOP leads to a strongly increased level of DNA 
damage.
 Following up these results, we next performed protein analysis of the DDR kinases, 
checkpoint kinase 1 (CHK1) and checkpoint kinase 2 (CHK2), which are activated in 
response to single-stranded DNA breaks and double-stranded DNA breaks, respectively 
[18].
 Treatment of the cell lines SUDHL-5 (Figure 3A), SUDHL-6 (Figure 3B) and SUDHL-10 
(Figure 3C) with AZD1775 or RT alone for 3 hours increased phospho-CHK1 levels (Ser345). 
These effects were more prominent when RT was combined with AZD1775. While no induction 
of phospho-CHK1 was observed in response to CHOP monotherapy, an increase was 
Figure 3. Protein analysis of the DNA damage response after treatment with AZD1775 in combination with RT or 
CHOP. Western blot analysis of WEE1, pCDC2 (Tyr15), pCHK1 (Ser345), CHK1, pCHK2 (Thr68), CHK2, pH3 (Ser10), 
H3 and GAPDH protein levels in the (A) SUDHL-5, (B) SUDHL-6 and (C) SUDHL-10 cell lines treated with 500 nM 
AZD1775, 4 Gy RT and 1 µg/mL CHOP for 3 hours. Inhibition of CDC2 is facilitated by phosphorylation on Tyr15 by WEE1, 
and therefore a marker for WEE1 activity. Induction of DNA damage results in downstream activation/phosphorylation 
of Ser345 on CHK1 (single-stranded DNA breaks) and/or Thr68 on CHK2 (double-stranded DNA breaks). Increased 
expression of phosphorylated Ser10 on histone H3 was measured as a marker for G2/M cell cycle arrest. GAPDH was 
measured as a loading control.
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observed combination with AZD1775. In SUDHL-5, protein levels of phospho-CHK2 (Thr68) 
were increased (Figure 3A) upon treatment with RT and CHOP monotherapy, however no 
further increase was observed by addition of AZD1775. In the cell lines SUDHL-6 (Figure 3B) 
treatment with RT strongly induced phospho-CHK2, whereas little effect was observed by 
CHOP chemotherapy. Addition of AZD1775 had little additional effect. 
 In cell line SUDHL-10 (Figure 3C), only a mild phospho-CHK2 induction was observed 
upon RT or CHOP treatment, whereas addition of AZD1775 to RT strongly enhanced 
phospho-CHK2 expression. 
 In all three cell lines mentioned above, treatment with AZD1775 led to a significant 
reduction in phospho-CDC2 (Tyr15) levels, the downstream target of WEE1, indicating 
that WEE1 kinase activity was reduced but without an effect on WEE1 protein levels. In 
conclusion, these data show activation of both CHK1 and CHK2 DDR pathways, indicating 
that the combination of AZD1775 with RT or CHOP induces harmful DNA damage. Combined 
protein and γH2AX results show that while monotherapy with AZD1775, radiation or CHOP 
can activate the DDR (phospho-CHK1 and phospho-CHK2) in response to treatment, the 
combination of RT or CHOP with AZD1775 is much more effective in inducing high levels of 
DNA damage.
AZD1775 abrogates mitotic arrest and induces premature mitotic entry
We next studied the effect of AZD1775, RT or CHOP monotherapy and combination therapy 
on cell cycle distribution and premature mitotic entry, measured as phospho-H3 (Ser10) 
positive cells in S-phase (Figure 4). Cell cycle analysis in the cell lines SUDHL-5, SUDHL-6 
and SUDHL-10 showed that monotherapy with radiation induced a significant dose-
dependent increase in the percentage of G2/M phase cells, which was most prominent in 
SUDHL-10 (with an increase from 21% to 80%; p=0.0047) after 4 Gy radiation (Figure 4A). 
The addition of AZD1775 induced a dose-dependent reduction in the percentage of G2/M 
phase cells (decreased from 80% to 46%; p=0.0025), an effect also observed in SUDHL-5 
and SUDHL-6 (Figure 4A). These cell cycle data were linked to the data on phospho-H3 
positive cells, which normally occurs during mitosis, but can be observed during S-phase 
in the situation or premature mitotic entry. Analysis of phospho-H3 positive cells in S-phase 
(a marker for premature mitosis) revealed that AZD1775 treatment significantly increased 
premature mitosis in SUDHL-5 (p=0.0132) and SUHDL-10 (p=0.0008) and a trend for 
SUDHL-6 (p=0.0842) compared to control cells, while no effect was observed for RT 
monotherapy (Figure 4B). Moreover, levels of premature mitotic entry were increased in 
the cell lines SUDHL-5 and SUDHL-6 when AZD1775 was combined with RT, although the 
changes were not statistically significant. 
 Together, these data indicate that addition of AZD1775 to RT reduces the G2/M arrest 
induced by RT, by allowing these cells to re-enter the cell cycle, but at the same time are 
likely over-stimulating cell cycle progression by facilitating premature mitotic entry. Cell cycle 
analysis of CHOP monotherapy showed little effect for CHOP at 0.1 µg/mL, whereas CHOP 
treatment at 1 µg/mL significantly increased the percentage of G2/M phase cells in SUDHL-5 
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(p=0.0040), SUDHL-6 (p=0.0349) and SUDHL-10 (p=0.0237) (Figure 4C). However, no 
rescue of the CHOP-induced G2/M arrest was observed when CHOP was combined with 
AZD1775, like was previously observed for the combination of AZD1775 with RT (Figure 4A). 
 Analysis of premature positive phospho-H3 cells revealed a dose-dependent increase 
in premature mitotic entry when cells were treated with AZD1775 or when AZD1775 was 
combined with CHOP, while no effect was observed for CHOP alone (Figure 4D). In SUDHL-5, 
a strong decrease was observed in phospho-H3 cells treated with 1 µg/mL CHOP, which 
was caused by a strong induction of DNA damage (Figure 2B) and cell death (Figure 1). 
Taken together, these data indicate that RT likely induces G2/M phase arrest to allow DNA 
repair, which is abrogated by addition of AZD1775, resulting in premature mitotic entry and 
increased DNA damage. A different effect can be observed for the combination of AZD1775 
with CHOP, in which the combination of CHOP with AZD1775 does not rescue the CHOP-
induced G2/M phase arrest. This difference is likely caused by the multiple detrimental effect 
of the CHOP compounds attacking the tubulin network and/or the DNA structure, resulting 
in structural damage and irreversible cell cycle arrest, accompanied by high levels of DNA 
damage. 
Figure 4. Cell cycle and pH3 analysis of AZD1775 combined with RT or CHOP. (A) Percentage of G2/M phase 
cells treated for 24 hours with 100 nM and 500 nM AZD1776 combined with 2 Gy or 4 Gy radiation therapy (RT) in 
the cell lines SUDHL-5, SUDHL-6 and SUDHL-10. (B) Percentage of phospho-H3 (Ser10) positive cells in S-phase 
treated for 24 hours with 100 nM and 500 nM AZD1776 combined with 2 Gy or 4 Gy radiation therapy (RT) in SUDHL-5, 
SUDHL-6 and SUDHL-10. (C) Percentage of G2/M phase cells treated for 24 hours with 100 nM and 500 nM AZD1776 
combined with 0.1 µg/mL or 1 µg/mL CHOP in SUDHL-5, SUDHL-6 and SUDHL-10. (D) Percentage of phospho-H3 
(Ser10) positive cells treated for 24 hours with 100 nM and 500 nM AZD1776 combined with 0.1 µg/mL or 1 µg/mL CHOP 
in SUDHL-5, SUDHL-6 and SUDHL-10. Data are plotted as the mean ± S.D. of n=3. Samples of untreated control cells 
were compared to treated cells, unless otherwise marked with capped lines. Statistical analysis was performed using a 
one-sample paired T-test (*p≤0.05) (**p≤0.01) (***p≤0.001).
72 | Chapter 3
Radiation, cyclophosphamide and doxorubicin enhance WEE1 protein expression 
To further investigate the effect of RT or CHOP treatment, with or without AZD1775, on WEE1 
kinase activity, we performed protein analysis in the cell line SUDHL-10 treated with the 
respective CHOP compounds for 24 hours (Figure 5A-B). Protein analysis showed that RT 
led to an increased phospho-CDC2 level, indicating increased WEE1 activity, which was 
subsequently reduced to control levels on addition of AZD1775 (Figure 5A). This suggests 
that upregulated WEE1 activity acts to control RT-induced DNA damage, as observed by 
the increased γH2AX levels measured by flow cytometry (Figure 2A) and DDR activation by 
western blot (Figure 3A). No changes in phospho-CDC2 levels were observed upon CHOP 
monotherapy treatment (Figure 5BA). We next investigated the effect of individual CHOP 
components on WEE1 protein activity, treating cells with each distinct component at the 
concentration used in 1 µg/mL CHOP or at a concentration that was 10/100/1000-fold higher. 
 The individual compounds present in 1 µg/mL CHOP were 0.1 µM doxorubicin, 1.8 nM 
vincristine and 3.17 µM cyclophosphamide, all of which are below clinical Cmax dosages 
[19]. Cyclophosphamide monotherapy at low non-toxic dosages increased WEE1, phospho-
CDC2 and γH2AX protein levels in a dose-dependent manner, while toxic treatment at 30 mM 
reduced both WEE1 and pCDC2 protein levels (Figure 5C). Similarly, doxorubicin monotherapy 
induced a strong dose-dependent increase of phospho-CDC2 and γH2AX levels compared 
to control cells, which was absent in cells treated with a toxic concentration of 10 µM (Figure 
5C). Unlike cyclophosphamide and doxorubicin, vincristine monotherapy actually reduced 
both phospho-CDC2 and WEE1 protein levels at the low 1.8 nM dose, while upregulating 
γH2AX protein levels (Figure 5C). These data show that although cyclophosphamide and 
doxorubicin are able to increase WEE1 activity, these changes are likely suppressed by 
the presence of vincristine in CHOP, thereby counteracting the upregulation of the WEE1 
protein. 
Figure 5. WEE1 protein activity analysis after treatment with radiation, 
CHOP or doxorubicin, vincristine and cyclophosphamide monotherapy. 
(A) Western blot analysis of WEE1, pCDC2 (Tyr15), γH2AX (Ser139; double-
stranded DNA breaks) and GAPDH protein levels in SUDHL-10 treated with 
0.5 µM AZD1775 in combination with 4 Gy RT or 1 µg/mL CHOP for 24 hours. 
(B) Western blot analysis of WEE1, pCDC2 (Tyr15) and γH2AX in SUDHL-10 
treated with an increasing concentration of doxorubicin and vincristine for 
24 hours. (C) Western blot analysis of WEE1, pCDC2 (Tyr15) and γH2AX in 
SUDHL-10 treated with an increasing concentration of cyclophosphamide for 
24 hours. SUDHL-10 cells were treated with a 10-fold increasing concentration 
of each compound, the lowest concentration of which (0.1 µM doxorubicin, 
1.8 nM vincristine and 3.17 µM cyclophosphamide) was used in the 1 µg/mL 
CHOP treatment.
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Doxorubicin and vincristine enhance AZD1775-induced cell killing
Pursuing the finding that certain CHOP components can upregulate WEE1 protein expression, 
we next determined whether single CHOP components (cyclophosphamide, doxorubicin or 
vincristine) complement AZD1775 treatment in the SUDHL-10 cell line. Cyclophosphamide 
treatment alone or in combination with AZD1775 had no effect on metabolic activity, indicating 
that the concentrations used were too low to affect viability (Figure 6A). Doxorubicin treatment 
combined with 500 nM AZD1775 significantly reduced metabolic activity (from 88% to 32%; 
p=0.0023), indicating that upregulation of WEE1 protein by doxorubicin enhanced sensitivity 
to AZD1775 (Figure 6C). Single agent treatment with vincristine decreased metabolic activity 
by 91% compared to control, with no additional effect of AZD1775 (Figure 6B). Analysis 
of the cell cycle showed that both doxorubicin and vincristine monotherapy increased 
the percentage of G2/M phase cells, while no effect was observed for cyclophosphamide 
(Figure 6D). Similar to previous results, addition of AZD1775 decreased G2/M percentages, 
indicating premature mitotic entry.
 Analysis of γH2AX showed that doxorubicin monotherapy induced minimal γH2AX 
positive cells, but addition of AZD1775 significantly increased γH2AX from 2% to 13% 
(p=0.0083) (Figure 6E). Vincristine was particularly effective in inducing DNA damage, 
especially in combination with AZD1775 (γH2AX increased from 31% to 43%). Remarkably, 
Figure 6. Combination therapy of AZD1775 and single CHOP compounds. (A) Metabolic activity determined by 
resazurin analysis of SUDHL-10 treated for 72 hours with cyclophosphamide and AZD1775. (B) Metabolic activity by 
resazurin analysis of SUDHL-10 treated for 72 hours with doxorubicin and AZD1775. (C) Metabolic activity by resazurin 
analysis of SUDHL-10 treated for 72 hours with vincristine and AZD1775. D) G2/M phase flow cytometry analysis 
of SUDHL-10 treated with AZD1775 and cyclophosphamide, doxorubicin or vincristine for 24 hours. E) γH2AX flow 
cytometry analysis of SUDHL-10 treated with AZD1775 and cyclophosphamide, doxorubicin or vincristine for 24 hours. 
Data were normalized to the control and plotted as the mean ± S.D. of n=3. Samples of untreated control cells were 
compared to treated cells, unless otherwise marked with capped lines. Statistical analysis was performed with a one-
sample paired T-test (*p≤0.05) (**p≤0.01) (***p≤0.001) (n=3). 
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the DNA damaging effect of vincristine was lost in CHOP chemotherapy, since CHOP 
only induced 5% γH2AX positive cells compared to 31% γH2AX positive cells induced by 
vincristine. Nevertheless, the combination of AZD1775 with CHOP resulted in a significant 
increase in γH2AX levels (5% to 38% with p=0.0092), similar to the levels achieved by 
vincristine alone (31%) or vincristine combined with AZD1775 (43%). Taken together, these 
results demonstrate the potential of chemotherapeutic agents such as cyclophosphamide 
and doxorubicin as inducers of WEE1 protein expression, potentially making them suitable 
for use in combination with AZD1775 in other cancers besides DLBCL.
Discussion
We presented highly robust data showing that the combination of the WEE1 inhibitor AZD1775 
with RT or CHOP chemotherapy results in increased levels of DNA damage, activation of 
the DDR pathways and induction of premature mitotic entry, leading to synergistic lethality 
of DLBCL cells. Moreover, protein analysis revealed that RT, cyclophosphamide and 
doxorubicin all effectively increased WEE1 protein expression, indicating that these agents 
might be suitable for use in combination treatments with AZD1775. 
 The WEE1 tyrosine kinase plays an essential role in maintaining genomic stability by 
allowing DNA damage repair at the G2/M transition. Activation of WEE1 by CHK1 is a key 
mechanism preventing cell cycle progression during DNA damage repair [10]. As DLBCL is 
a cancer with high levels of genomic instability [13] and DNA damage [14], DLBCL cells rely 
heavily on checkpoint activation and DNA damage repair, which are effectively prevented 
by blocking WEE1. Furthermore, inhibition of CDC2/CDK1 by WEE1 during S-phase allows 
DNA replication and stabilization of replication forks, which become hazardous in the event 
of WEE1 inhibition [20]. In tumours cells lacking a mechanism for repair in G1/S phase 
as a result of TP53 mutation, cell cycle arrest and repair at the G2/M phase checkpoint is 
especially important [21] These factors all contribute to making WEE1 an attractive target 
for inhibitor therapy in either TP53-deficient tumours or together with genotoxic therapy to 
either enhance DNA damage induction or block DNA damage repair. However, we found 
that TP53 mutation status did not determine sensitivity to the WEE1 inhibitor AZD1775 in our 
DLCBL cell lines, a finding that contradicts current literature in non-small cell lung cancer 
[17] and ovarian adenocarcinoma tumour cells [15]. However, other studies in AML have 
shown that TP53 does not determine therapy outcome with AZD1775 [22,23], indicating 
possible differences between solid tumours and hematologic malignancies. 
 High levels of synergism and DNA damage were observed across multiple cell lines, 
likely due to the high levels of genomic instability and DNA damage outweighing the presence 
of TP53 in DLBCL. 
 Chemotherapy in combination with AZD1775 has been shown to be synergistic together 
with compounds such as doxorubicin in colon cancer cell lines [24] and B-cell lymphoma cell 
lines [25], with cytarabine in B-cell lymphoma cell lines and xenograft mouse models [25], 
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vincristine in B-cell and T-cell leukaemia cell lines and patient cells [26], cyclophosphamide-
like compounds in lymphoblastoid cell lines and rhabdomyosarcoma cell lines [27,28] and 
with paclitaxel in breast cancer [29]. Similarly, combined WEE1 inhibition and radiation 
therapy has proven successful in gliomas and osteosarcoma [30,31]. Recently, Wang et 
al. showed that the efficacy of doxorubicin with AZD1775 was dependent on the moment of 
cell cycle arrest induced by doxorubicin, with combination therapy proving highly effective 
in G2/M phase-arrested lymphoma cell lines but not in G1/S-phase-arrested cells [24,26]. 
At the same time, doxorubicin was also shown to influence WEE1 and pCDC2 levels based 
on TP53 status in a time-dependent manner in melanoma cell lines. In TP53 wild type cells, 
doxorubicin induced a steady increase over the first 1-9 hours after treatment, but both 
WEE1 and pCDC2 levels declined at 24 hours. By contrast, pCDC2 levels steadily increased 
in TP53 mutant cells after treatment, even at 24 hours [32]. A comparable synergy with 
AZD1775 was shown for ionizing radiation, which causes predominantly single stranded DNA 
breaks [33], leading to ATR activation and downstream phosphorylation and activation of 
CHK1 [34,35]. Since CHK1 is one of the most important positive regulators of WEE1 [10], any 
activation of the ATR-CHK1 axis will likely result in increased activation of WEE1 and will likely 
benefit from AZD1775 combination treatment. We found enhanced toxicity for combinations 
of AZD1775 with RT, CHOP and single agent doxorubicin, which all resulted in G2/M arrest, 
increased WEE1 protein levels and high levels of DNA damage. Based on current evidence, 
synergy with AZD1775 seems likely when a treatment induces either 1) G2/M arrest, 2) WEE1 
upregulation, 3) activation of the DDR, or 4) all of the above. An exception to this rule was 
vincristine combined with AZD1775, as vincristine led to decreased protein levels of WEE1 
and pCDC2. Visconti et al. showed that at the spindle assembly checkpoint (SAC) during 
mitosis, WEE1 promotes survival when cells are under pressure from anti-microtubule cancer 
drugs or malformed spindles, and that this checkpoint is only restored through genetic or 
chemical inhibition of WEE1. In line with their hypothesis, Visconti et al. found synergism for 
the combination of vincristine and AZD1775, but no downregulation of WEE1 protein was 
observed upon treatment with 25 nM vincristine [27]. Although vincristine reduced WEE1 
protein levels in our DLBCL cell line, these effects are likely counteracted by induction of 
WEE1 by doxorubicin and cyclophosphamide, therefore maintaining high levels of toxicity 
and synergism with AZD1775 in the CHOP combination. 
 In conclusion, we demonstrated that AZD1775 combined with RT and CHOP effectively 
inhibits WEE1 and is synergistic in multiple cell lines. Based on protein, cell cycle and DNA 
damage analysis, we predict that AZD1775 will be a highly effective treatment in combination 
with other (chemo)therapeutic compounds that induce either WEE1 upregulation, G2/M 
arrest or activation of the DDR. These data underline the considerable potential of WEE1 
inhibition in the clinical setting and help pave the way for the application of AZD1775 and 
chemotherapeutic combination therapies in other cancer types.
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Supporting information
Supplemental Figure 1. TP53 mutation status of DLBCL cell lines. (A) Overview of cell or origin (COO), TP53 
mutation status and IC50 for AZD1775, CHOP and RT in eight DLBCL cell lines. Comparison of IC50 of TP53 wild type 
(WT) or mutated (MUT) DLBCL cell lines for (B) AZD1775, (C) CHOP and (D) radiation therapy.
Supplemental Figure 2. Combination therapy of AZD1775 with radiation therapy radiation (RT) and CHOP. (A) 
Raw data for eight DLBCL cell lines treated for 72 hours with 100 nM or 500 nM AZD775 combined with 2 Gy or 4 Gy 
radiation. (B) Raw data for eight DLBCL cell lines treated for 72 hours with 100 nM or 500 nM AZD775 combined with 
0.01 µg/mL, 0.1 µg/mL or 1 µg/mL CHOP. Data were normalized to the control and plotted as the mean ± S.D. of n=3. 
Statistical analysis was performed using a one-sample paired T-test (*p≤0.05) (**p≤0.01) (***p≤0.001) (n=3).
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Abstract
First line treatment for diffuse large B cell lymphoma (DLBCL) consist of cyclophosphamide, 
vincristine and doxorubicin together with the immunosuppressive agent prednisone and 
the anti-CD20 antibody rituximab (R-CHOP) and cures roughly 60% of DLBCL patients. In 
relapsed or refractory patients, treatment consists of chemotherapeutic combinations, often 
including anti-metabolite cytarabine or the platinum-based alkylating agent cisplatin. We 
recently identified cell cycle regulator WEE1 as a strong candidate for targeted-treatment in 
DLBCL, and demonstrated favorable combinations with first line therapies rituximab, CHOP 
and radiation. 
 In the current study, we investigated the synergistic effect of the WEE1 inhibitor AZD1775 
when combined with chemotherapeutic compounds cytarabine and cisplatin in DLBCL cell 
lines. Based on cell viability data, cell cycle analysis and DNA damage analysis we confirmed 
strong synergism for AZD1775 and cytarabine, which enhanced DNA damage levels and 
cell death. In contrast, AZD1775 combined with cisplatin induced very little additional cell 
death in DLBCL cell lines, which was corroborated by a lack of additional DNA damage. 
Further analysis revealed a decrease of WEE1 protein and mRNA levels upon cisplatin 
monotherapy treatment, explaining the lack of synergism, while no effect was observed after 
cytarabine or AZD1775 treatment. Moreover, chromatin immunoprecipitation (ChIP) showed 
a decrease in active transcription marks H2K4Me3 and H3K27Ac, indicating reduced WEE1 
gene transcription as a results of cisplatin treatment. 
 These results demonstrate that although DNA damaging agents might seem a rational 
choice for AZD1775 combination therapy, not all genotoxic agents do synergize with WEE1 
inhibition and it is important to first evaluate its synergistic or any potential antagonistic 
effects.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma 
(NHL) subtype for which standard therapy of rituximab with cyclophosphamide, vincristine, 
doxorubicin and prednisone (R-CHOP) cures approximately 60% of patients. For patients 
with relapse or refractory disease, different treatment options are available, which often 
include cytarabine [1] and/or cisplatin [2]. However, 40% of patients that undergo second 
line therapy still develop refractory disease. To improve survival especially for this group, 
additional targets are needed to improve the treatment outcome. 
 We recently identified the cell cycle regulator WEE1 as a promising novel target in 
DLBCL cell lines either as a single agent or in combination with rituximab [3]. Targeting of 
WEE1 with the inhibitor AZD1775 was shown to induce both premature mitotic entry [4,5] 
and DNA damage [6], making it a promising candidate to test alongside genotoxic drugs. 
Indeed, combination of AZD1775 and cytarabine was shown to be synergistic in TP53-
deficient and wild type AML cell lines [7] and in B-cell lymphoma cells lines [8]. Moreover, 
an RNAi screen in AML cell lines identified WEE1 inhibition as the most potent sensitizer with 
cytarabine, outperforming both ATR and CHK1 [9]. Similar results have been achieved for the 
combination of cisplatin with WEE1 inhibitors in medulloblastoma cell lines [10]. Furthermore, 
WEE1 inhibition was able to overcome cisplatin resistance in triple negative breast cancer 
cell lines [11] and head and neck cancer cell lines [12]. 
  In the current study, we investigated the synergistic effect of AZD1775 combined with 
second line chemotherapeutic compounds cytarabine and cisplatin in DLBCL cell lines. 
Based on cell viability, cell cycle and DNA damage analysis we showed that WEE1 inhibition 
is synergistic with cytarabine but not cisplatin chemotherapy. The lack of synergism for 
cisplatin was caused by the cisplatin-induced reduction of WEE1 protein expression as 
a result of reduced WEE1 transcription. These data show that not all genotoxic agents 
synergize with WEE1 inhibition. This implicates that although DNA damaging agents like 
cytarabine or cisplatin might seem like obvious choices for AZD1775 combination therapy, 
careful evaluation of such combination therapies must be performed before implementation 
into the clinic.
Materials and methods
Cell lines and culture conditions
DLBCL cell lines U-2932, SUDHL-2 and SC-1 were cultured in suspension in Roswell Park 
Memorial Institute medium 1640 (RPMI 1640; Lonza BioWhittaker, Walkersville, MD, USA) 
with 10% Fetal Bovine Serum (FBS; HyClone Thermo Scientific, Waltham, MA, USA), 1% 
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Penicillin-Streptomycin (PS; Lonza BioWhittaker) and 1% Glutamine (Lonza BioWhittaker). 
DLBCL cell line SUDHL-10 were cultured in suspension in RPMI 1640 with 20% FBS, 1% 
PS and 1% Glutamine. All cell lines were cultured at 37°C with 5% CO2 in a humidified 
atmosphere. The identity of our cell lines was checked at a regular base.
Compounds
WEE1 inhibitor AZD1775 was acquired from Selleckchem (No.S1525, Houston, TX, USA). 
Incubations with AZD1775 were done at sub-lethal concentrations of 100 nM and 500 nM. 
Cytarabine (Ara-C) was acquired from Selleckchem (No.S1648) and incubated for 96 hours. 
Cisplatin was acquired from UMCG pharmacy (Accord Healthcare Limited) and incubated 
for 72 hours. 
Flow cytometry – cell cycle and γH2AX 
For cell cycle analysis, 0.2 x 106 cells/ml were treated for the appropriate time points, washed 
with 1% BSA/PBS and resuspended in propidium iodide solution containing 0.1% sodium 
citrate (A0158348, Merck, Kenilworth, New Jersey, United States), 0.01% propidium iodide 
(P4170, Sigma-Aldrich, St. Louis, Missouri, United States), 0.002% RNase A (R4875, Sigma-
Aldrich) and 0.3% Triton X100 (T9284, Sigma-Aldrich). Samples were processed on BD 
FACSCalibur 2 and analysed with ModFit LT (Verity Software House). Experiments were 
performed 3 times.
 For γH2AX analysis, cells at 0.2 x 106 cells/ml were treated for the appropriate time 
points, and stained with mouse-anti-γH2AX-AlexaFluor-647 (2F3: BioLegend) and propidium 
iodide solution (P4170, Sigma) according to the protocol provided with the eBioscience™ 
Foxp3 / Transcription Factor Staining Buffer Set (ThermoFisher, #00-5523-00). Samples were 
processed on on MACSQuant and data was analysed with Kaluza 1.5 analysis software 
(Beckman). Experiments were performed 3 times.
Western blot
Cells were washed with PBS and lysed in RIPA buffer (50mM Tris / 150mM NaCl / 2.5mM 
Na2EDTA / 1% Triton X-100, 0.5%mM sodium deoxycholate/0.1% SDS in dH20) with 1mM 
phenylmethanesulphonyl fluoride for 30-45 minutes on ice. Protein concentration was 
determined using the Pierce™ BCA Protein Assay Kit (#23227; Thermo Scientific, Waltham 
MA, USA). Samples were loaded at 40µg per lane and electrophoresis and blotting was 
performed according to standard protocols. Staining with primary antibodies for anti-WEE1 
(1:200, sc-5285 (B11), Santa Cruz Biotechnology, Dallas TX, USA), anti-phospho-CDC2 
(Tyr15) (10A11) (1:1000, #4539, Cell Signaling Technology, Danvers, MA, USA), anti-
phospho-Histone H2AX (Ser139) (1:1000, clone JBW301, Merck Milipore, Temecula, CA, 
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USA) and GAPDH (1:10,000; NovusBio) was done overnight and staining at 4°C. 
RT-qPCR
cDNA was synthesized using random primers, dNTP mix and the Superscript II Reverse 
Transcriptase Kit (Life Technologies Europe BV, Bleiswijk, the Netherlands) according to the 
manufuctors standard protocol. A total input of 500 ng RNA was used per sample is a reaction 
volume of 20 µL. SYBRgreen mix (Applied Biosystems) was used to detect transcript levels in 
a qPCR reaction volume of 10 µL containing 1 ng cDNA on a Lightcycler 480 (Roche, Penzberg, 
Germany). WEE1 primer forward sequence: 5’-GATGTGCGACAGACTCCTCAAG-3’; reverse 
sequence 5’- CTGGCTTCCATGTCTTCACCAC-3’. WEE1 TaqMan gene expression assay 
HS01119384_G1 (Thermofisher, Waltham MA, USA). 
Chromatin immunoprecipitation (ChIP) 
For ChIP analysis, cells were collected and cross-linked using 1% formaldehyde (Sigma-
Aldrich) and sonicated using a Diagenode Bioruptor. Sheared chromatin fragments were 
incubated with specific antibodies against histone marks H3K4me3 (Diagenode C15410003-
50; RRID:AB_2616052), H3K27ac (Diagenode C15410196; RRID:AB_2637079), H3K27me3 
(Diagenode C15410195; RRID:AB_2753161) and H2AK119ub (D27C4, Cell Signaling 
Technology). After immunoprecipitation, cross-linking was reversed and the DNA used for 
quantitative PCR and sequencing analysis. As a control, a portion of the chromatin was 
processed without the immunoprecipitation step. Each sample was treated with the Kapa 
Hyper Prep Kit to create an Illumina library and subjected to sequencing on the Illumina 
HiSeq 2000 machine.
Statistical analysis
Data was analyzed using Graphpad PRISM (version 5.0) software and tested for significant 
differences with a paired T-test. * indicates p≤0.05, ** indicates p≤0.01 and *** indicates 
p≤0.001. Synergism was determined by comparing the observed effect of a treatment 
compared to the expected effect of a treatment as based on the single treatment outcome. 
Differences between expected and observed effects were tested with a paired T-test. * 
indicates p≤0.05, ** indicates p≤0.01 and *** indicates p≤0.001.
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Results 
AZD1775 synergizes with cytarabine therapy in DLBCL cell lines
To establish whether WEE1 inhibition would synergize with cytarabine, we tested the 
combination treatment at suboptimal concentrations for each compound (Supplemental 
table 1) in four DLBCL cell lines and observed that the combination significantly reduced cell 
viability in all cell lines (Figure 1A and Supplemental figure 1A). Cell viability decreased from 
61% to 28% (p=0.0205) in SUDHL-10, from 78% to 37% (p=0.0164) in SC-1, from 74% to 39% 
(p=0.0200) in U-2932 and from 61% to 28% (p=0.0205) in SUDHL-2. This combination was 
synergistic in SUDHL-10 (Δ46% p=0.0007), additive in SC-1 (Δ14% p=0.1008), synergistic 
in U-2332 (Δ40% p=0.0397) and additive in SUDHL-2 (Δ3% p=0.7365) (Supplemental table 
2). No correlation was found between TP53 mutation status of our cell lines and the levels of 
synergism for the cytarabine and AZD1775 combination treatment. 
Figure 1. Combination therapy of cytarabine or cisplatin with AZD1775. (A) Cell viability data of SUDHL-10 and 
SC-1 treated for 96 hours with cytarabine and AZD1775. Data was normalized to the control and plotted as the mean ± 
S.D. of n=3. (B) Cell cycle analysis of changes in S-phase in SUDHL-10 and SC-1 treated with cytarabine and AZD1775 
for 24 hours (n=3). (C) γH2AX analysis of SUDHL-10 and SC-1 treated with cytarabine and AZD1775 for 24 hours (n=3). 
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 Analysis of the cell cycle distribution in cell lines SUDHL-10 and SC-1 showed a small 
dose-dependent increase of the percentage of S-phase cells in SUDHL-10 cells treated 
with cytarabine, which was further increased by addition of AZD1775 (Figure 1B and 
Supplemental figure 2A). No changes were observed in cell line SC-1. Analysis of DNA 
damage marker γH2AX showed weak induction of DNA damage by AZD1775 or cytarabine 
alone, but a strong increase in the combination therapy (Figure 1C and Supplemental figure 
2B). In SUDHL-10, DNA damage levels increased from 2% to 36% (p=0.0023) and in SC-1 
from 20% to 72% (p=0.0007). These results strongly support the potential benefit for a 
combination therapy of AZD1775 with cytarabine, which acts synergistically to reduce cell 
viability and increase DNA damage levels.
AZD1775 does not synergize with cisplatin therapy in DLBCL cell lines
Next, we tested the combination of alkylating agent cisplatin with AZD1775. In contrast to 
cytarabine, addition of AZD1775 did not outperform the single cisplatin treatment (Figure 1D 
and Supplemental figure 1B). For SUDHL-10, cell viability levels decreased from 50% to 42% 
(p=0.4443), but this reduction was not significant. For SC-1 cell viability increased from 47% 
to 61% (p=0.0782), whereas no effect on cell viability was observed in U-2932 cells. In the 
highly cisplatin-sensitive cell line SUDHL-2, a significantly decreased viability was observed 
going from 88% to 25% (p=0.0085) (Supplemental figure 1B). Overall, addition of AZD1775 
with cisplatin treatment showed no significant synergism, but only additive or antagonistic 
effects (Supplemental table 2). No correlation was found between TP53 mutation status or 
the level of antagonism/synergism for the cisplatin and AZD1775 combination treatment.
 Analysis of the cell cycle distribution showed a significantly increased percentage of 
S-phase cells in SUDHL-10 but not in cell line SC-1 upon cisplatin treatment (Figure 1E and 
Supplemental figure 3A). Addition of AZD1775 reduced S-phase levels from 62% to 46% 
(p=0.0652) in SUDHL-10, whereas in SC-1 addition of AZD1775 enhanced S-phase cells 
at 10 µM Cisplatin and had no effect at 50 µM on the cell cycle distribution. Analysis of 
DNA damage levels showed significantly increased γH2AX levels in SUDHL-10 (from 11% 
to 43%; p=0.0351) (Figure 1F and Supplemental figure 3B), which however did not result in 
any significant additional cell death (Figure 1D). In SC-1, addition of AZD1775 DNA damage 
levels increased from 30% to 68% (p=0.0017) when combined with 10 µM cisplatin and 
from 66% to 68% (p=0.0870) when combined with 50 µM cisplatin, indicating that cisplatin 
treatment alone already induced the maximum levels of DNA damage. These results are 
consistent with the cell viability data for SC-1, which showed a small additive effect for 
AZD1775 addition at a lower cisplatin concentration of 10 µM, which turns into antagonism 
at a higher cisplatin concentration of 50 µM. Taken together, these results suggest that 
(D) Cell viability data of SUDHL-10 and SC-1 treated for 72 hours with cisplatin and AZD1775. Data was normalized to 
the control and plotted as the mean ± S.D. of n=3. (E) Cell cycle analysis of changes in S-phase in SUDHL-10 and SC-1 
treated with cisplatin and AZD1775 for 24 hours (n=3). (F) γH2AX analysis of SUDHL-10 and SC-1 treated with cisplatin 
and AZD1775 for 24 hours (n=3). Statistical analysis was performed with paired T-test. * indicates p≤0.05, ** indicates 
p≤0.01 and *** indicates p≤0.001.
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cisplatin-sensitive cells which are treated with a lower cisplatin dosage might still benefit 
from additional AZD1775 treatment, whereas cisplatin-insensitive cells which will require a 
higher cisplatin dosage will most likely not benefit from additional AZD1775 treatment. 
Cisplatin treatment decreases WEE1 protein and mRNA levels
To elucidate why cytarabine but not cisplatin synergizes with AZD1775, we performed 
western blot analyses for WEE1, its downstream target phosphorylated CDC2 and the DNA 
damage marker γH2AX in SUDHL-10 and SC-1 (Figure 2A). In addition, we performed a 
WEE1 RT-qPCR analysis (Figure 2B). 
 Both cell lines showed a decrease in pCDC2 protein levels as a result of AZD1775 
treatment, indicating reduced WEE1 activity, whilst no or only mild reduction of WEE1 protein 
levels were observed. At the same time, yH2AX levels were increased, indicating WEE1 
inhibition induced DNA damage. Cytarabine treatment induced WEE1 and pCDC2 protein 
expression in SUDHL-10, but not in SC-1, suggesting cell cycle arrest was activated to cope 
with the DNA damage induction, as confirmed by the increase in yH2AX protein levels. 
The combination of cytarabine and AZD1775 increased yH2AX levels further, indicating 
combination treatment was more effective compared monotherapies of cytarabine or 
AZD1775. For cisplatin, monotherapy caused increased protein expression of pCDC2 and 
yH2AX in SUDHL-10, indicating cell cycle arrest and DNA damage. In contrast, cisplatin 
monotherapy in SC-1 caused significant reduction of WEE1 and pCDC2 protein levels, 
despite induction of DNA damage marker yH2AX. These effects were further enhanced 
in the combination therapy, leaving WEE1 and pCDC2 protein levels nearly undetectable. 
This phenomenon was not observed in cell line SUDHL-10, which was treated with a lower 
Figure 2. WEE1 protein and gene expression analysis after cytarabine or cisplatin and AZD1775 therapy. (A) 
Representative western blot WEE1, pCDC2 and γH2AX protein levels in SUDHL-10 and SC-1 treated with cytarabine, 
cisplatin and AZD1775 or combined for 24 hours. All samples were run on the same gel. (B) mRNA expression of WEE1 
in SUDHL-10 and SC-1 treated with cytarabine, cisplatin and AZD1775 or combined for 24 hours.
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cisplatin concentration, indicating this could be either a dose-dependent of cell line specific 
observation. At the RNA level, WEE1 expression was not affected by treatment with AZD1775, 
cytarabine, cisplatin or the combinations in SUDHL-10. In SC-1, WEE1 transcript levels were 
strongly induced by treatment with AZD1775 monotherapy and mildly reduced by cisplatin 
monotherapy or in combination with AZD1775 in SC-1 (Figure 2B). The slightly reduced 
WEE1 transcript levels are consistent with the reduced WEE1 protein levels. These results 
give a possible indication for the lack of synergism for cisplatin and AZD1775, as WEE1 
protein expression are strongly reduced in response to cisplatin treatment.
 Based on previous results which showed strong cisplatin-induced reduction of WEE1 
protein expression, we next tested at which cisplatin concentration we could start to observe 
WEE1 protein reduction. As a control, we also tested a dilution range of cytarabine treatment. 
(Figure 3A-B and Supplemental figure 6). Western blot analysis cisplatin-treated SUDHL-10 
cells showed a dose-dependent increase in pCDC2 and γH2AX protein levels, with only 
minor changes in WEE1 protein levels (Figure 3A). This suggests that cisplatin increases 
WEE1 activity in a dose-dependent manner, which is likely part of a DNA damage response 
(DDR) pathway activation in response to the induction of DNA damage. In SC-1 a marked 
reduction of both WEE1 and pCDC2 protein levels were observed, starting at a dosage of 
50 µM cisplatin. At the same concentration, marked increase in protein levels of γH2AX were 
observed (Figure 3A). These data indicate that although cisplatin is able to induce significant 
levels of DNA damage in SC-1, these changes are accompanied by a reduction in WEE1 
activity, making combination therapies with WEE1 inhibitors ineffective. These results are in 
line with WEE1 gene expression analysis, which showed a reduction in WEE1 mRNA levels 
in cell line SC-1, but not in SUDHL-10 (Figure 3B). 
 Since SUDHL-10 showed higher sensitivity to cisplatin, combination treatment was 
performed at a much lower dosage of cisplatin, at which no adverse effects on WEE1 
protein or mRNA expression are observed. As expected, treatment with cytarabine showed 
Figure 3. WEE1 protein and gene expression dosage effect of cisplatin treatment. (A) Representative western blot 
of WEE1, pCDC2 and γH2AX protein levels in SUDHL-10 and SC-1 treated with increasing concentration of cisplatin 
for 24 hours. (B) mRNA expression of WEE1 in SUDHL-10 and SC-1 treated with increasing concentration cisplatin for 
24 hours.
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no changes in WEE1 and pCDC2 protein levels, but a steady dose-dependent increase 
of γH2AX protein levels, indicating cytarabine induces DNA damage in a dose-dependent 
manner without influencing WEE1 activity (Supplemental figure 4A). Similarly, qPCR analysis 
revealed no or only minor alterations in at the WEE1 transcript level after cytarabine treatment 
(Supplemental figure 4B). Taken together, these results indicate that in cisplatin-sensitive 
cells, cisplatin could work synergistic alongside AZD1775, however the combination could 
be antagonistic in cisplatin-insensitive cells due to a reduction in WEE1 expression.
Cisplatin treatment decreases WEE1 gene transcription
Based on the above described results showing that treatment with cisplatin results in 
regulate decrease of WEE1 at the protein and mRNA expression levels, we next analyzed 
treatment induced changes in histone marks by performing chromatin immunoprecipitation 
(ChIP) for active histone marks H2K4 trimethylation (H2K4Me3) and H3K27 mono-acetylation 
(H3K27Ac) and repressive histone marks H2AK119 mono-ubiquitination (H2AK119Ub) and 
H3K27 trimethylation (H3K27Me3) (Figure 4). 
 Analysis of ChIP data for cytarabine treated cells showed treatment had no effect on 
Figure 4. Chromatin immunoprecipitation of WEE1 in cell line SC-1. Cell line SC-1 was treated with 100 nM 
cytarabine or 100 µM cisplatin after which chromatin immunoprecipitation was performed of the WEE1 gene for active 
marks H2K4 trimethylation (H2K4Me3) and H3K27 mono-acetylation (H3K27Ac) and repressive marks H2AK119 mono-
ubiquitination (H2AK119Ub) and H3K27 trimethylation (H3K27Me3). Results are plotted as relative enrichment of 10% 
input and plotted as the mean ± S.D. of n=3. X-axis represent the position relative to the WEE1 gene with zero being the 
transcription start site (TSS).
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both active and repressive histone marks of the WEE1 gene, which is in line with the evidence 
that cytarabine treatment does not influence WEE1 protein or mRNA levels. In contrast, a 
strong decrease in active histone marks at the transcription start site of the WEE1 gene was 
observed upon treatment with cisplatin as compared to untreated cells, with a decrease 
of 30% for the H2K4Me3 histone mark and with 2% for the H3K27Ac histone mark. This 
suggests that there is less active transcription taking place of the WEE1 gene as a result of 
cisplatin treatment, consistent with the decrease in both WEE1 protein and mRNA levels. No 
changes were observed in presence of the repressive H2AK119Ub and H3K27Me3 histone 
marks, indicating there is no active repression of WEE1 gene transcription as a result of 
cisplatin treatment. These results show that the reduced WEE1 protein expression induced 
by cisplatin is the results of a decrease in active WEE1 gene transcription, and not the result 
of active gene repression. Taken together, these data show that cisplatin treatment will not 
only induce DNA damage as a result of DNA intercalation, but might thereby also alter WEE1 
gene transcription as a secondary effect, which could have an adverse outcome in WEE1 
inhibitor-based combination therapies. 
Discussion
In the current study, we examined the potential combination of second line chemotherapeutic 
agents cytarabine and cisplatin with WEE1 inhibitor AZD1775 in DLBCL. For the anti-
metabolite cytarabine, we found synergistic results when combined with AZD1775, which 
was caused by a significant increase in DNA damage levels in the combination therapy. 
The DNA damaging effect of cytarabine is acquired through its incorporation into the DNA 
as the active triphosphate form, preventing general DNA replication and repair, but also 
inhibiting DNA and RNA polymerases [13]. Like most genotoxic agents, cytarabine treatment 
leads to CHK1 activation [14], which is required for WEE1 activation upon DNA damage 
[15], making it both in theory and in practice a suitable agent for combination with WEE1 
inhibition. Wang et al. previously observed similar synergistic results for WEE1 inhibition in 
B-cell lymphoma cell lines arrested in the G2/M phase by cytarabine treatment, but not in 
cell lines arrested in the G1/S phase, which they hypothesized was the determining factor for 
synergism between WEE1 inhibition and cytarabine [8]. In our data, we observed little effect 
of cytarabine on the cell cycle, which could be explained by the use of a lower cytarabine 
dosage compared to Wang SD. However, despite the lack of a strong cell cycle arrest we 
still observed synergistic cell death for the combination therapy, suggesting cell cycle arrest 
may not be the determining factor for synergism, as long as significant levels of DNA damage 
are induced in the combination therapy. 
 Unlike the success story for cytarabine, we found no clear synergism for the platinum-
based anti-neoplastic drug cisplatin with AZD1775 in DLBCL. Cisplatin treatment has 
many genotoxic effects, which include induction of monoadducts, inter- and intra-strand 
crosslinks, and/or DNA protein crosslinks [16]. Although cisplatin is currently used in many 
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cancer types, resistance to cisplatin monotherapy is a major issue [17]. Many studies have 
shown that WEE1 inhibition works synergistically with cisplatin, and is even able to overcome 
cisplatin resistance [11,12,18]. These observations were attributed to the abrogation 
of the cisplatin-induced G2/M arrest and abolishment of the cisplatin-induced CDC2 
phosphorylation, through activation of the ATR-CHK1-WEE1 axis. Indeed, in SUDHL-10 
pCDC2 protein levels appeared to steadily increase after cisplatin treatment, however these 
effects did not correlate with a significant additional cell death in combination treatment, and 
were not observed in SC-1. Moreover, we observed no G2/M arrest upon cisplatin treatment 
in DLBCL cell lines, whereas this has been described in other cancers and was suggested 
as part of the synergism mechanism for AZD1775 and cisplatin [12,18]. In addition, it must 
be noted that overall the DLBCL cell lines were much less sensitive to cisplatin treatment 
(average IC50 13 µM) when compared to the reported (cisplatin-resistant) cell lines, and 
that much lower cisplatin treatment concentrations were used in the published combination 
experiments for head and neck cancer (1.5 µM) [12], breast cancer (10 µM) [11] and gastric 
cancer (2 µM) [18]. This raises the question when cells should be labeled as “insensitive” or 
“resistant”, as this may differ greatly from cancer to cancer. In the current study, we observed 
that treatment of cisplatin-sensitive DLBCL cell lines (IC50 ≤0.5 µM) synergized with WEE1 
inhibition, whereas treatment of cisplatin-insensitive cell lines (IC50 ≥10 µM cisplatin) did not, 
as a result of reduced WEE1 gene transcription. Based on the fact that DNA intercalation 
by cisplatin induces activation of the DNA damage response pathway, WEE1 would seem 
an obvious target to prevent DNA damage repair and induce catastrophic DNA damage. 
This is the case for cisplatin-sensitive cell lines, which indeed show an additive effect for 
cisplatin and AZD1775 combinational therapy. However, in cisplatin-insensitive cells we 
encounter a more sinister effect of cisplatin: a dramatic change in WEE1 protein and mRNA 
expression, most likely the result of this previously beneficial DNA intercalation preventing 
access of the transcriptional machinery. Several mechanisms have been described by which 
platinum-based compounds might inhibit gene transcription [19], of which stalling of RNA 
polymerase II [20] is often noted as a major contributor. Therefore, DNA intercalation by 
cisplatin treatment might be viewed as a double-edged sword: on the one hand it might lead 
to beneficial catastrophic DNA damage, whereas on the other hand it might dramatically 
alter expression of the protein targeted by the specific inhibitor. 
 Another often discussed factor in cancer therapy is the TP53 mutation status. Genotoxic 
agents such as cytarabine and cisplatin should work especially well in a TP53-mutated 
setting, as TP53-mutated cancers can no longer rely on the G1/S phase DNA damage repair 
checkpoint controlled by TP53, making them completely dependent on repair at the G2/M 
phase [21]. However, in our study cisplatin showed a lack of synergism in both TP53-mutated 
cell lines SUDHL-10 (c.994-1G>C) and U-2932 (c.527G>A), and in one of the two TP53 wild 
type cell lines, i.e. SC-1. Similarly, Osman et al. found no relation between TP53 status and 
synergism for AZD1775 and cisplatin [12]. Only for the TP53-mutated cell line SUDHL-2 
(TP53: c.701A>C add protein change as well) synergism was observed, which was also the 
most cisplatin-sensitive cell line. 
 In conclusion, in this study we analyzed at the most commonly used second line 
chemotherapeutic and DNA damage-inducing agents cytarabine and cisplatin in DLBCL, 
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and found synergistic results for cytarabine combined with AZD1775, but dose-dependent 
antagonistic effects for cisplatin combined with AZD1775. These latter results seem in 
conflict with earlier publications, but we show a concentration dependent reduction of WEE1 
protein activity and WEE1 gene transcription upon cisplatin treatment in cisplatin-insensitive 
cells. These results highlight the importance of thorough in vitro research for combination 
therapies, because seemingly rational treatment strategies might not be beneficial. 
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Supporting information
Supplemental Table 1. DLCBL cell lines and their TP53 status and IC50 values for cytarabine, cisplatin and 
AZD1775. The sensitivity of eight DLBCL cell lines was determined by treatment of cells with cytarabine for 96 hours, 
cisplatin for 72 hours and AZD1775 for 72 hours. Cell viability was established using propidium iodide staining and flow 
cytometry analysis. Plotted is the average of n=3 experiments.








OCI-LY3 ABC WT 0.6 1.5 357
U-2932 ABC MUT 0.4 35 623
SUDHL-2 ABC MUT 2 0.2 543
SUDHL-4 GCB MUT 1 5 1835
SUDHL-5 GCB WT 0.1 3 805
SUDHL-6 GCB MUT 0.2 8 1503
SUDHL-10 GCB MUT 0.2 5 608
SC-1 GCB WT 0.5 50 412
Supplemental Table 2. Synergism calculation for cytarabine or cisplatin with AZD1775 in DLBCL cell lines. 
Shown are the expected and observed effect of the AZD1775 with cytarabine or cisplatin combination treatment with 
their p-values. Values are calculated from 3 individual experiments. Significant antagonistic combinations are depicted in 
dark red and significant synergistic combinations in dark green. Near significant or trend antagonistic combinations are 
depicted in light red and insignificant combinations are depicted in light green as they represent the additive combination 
treatments.
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Supplemental Figure 1. Combination therapy of cytarabine or cisplatin with AZD1775 in cell lines U-2932 and 
SUDHL-2. Efficiency of AZD1775 combined with (A) cytarabine for 96 hours and (B) cisplatin for 72 hours. Data was 
normalized to the control and plotted as the mean ± S.D. of n=3. Statistical analysis was performed with paired T-test. * 
indicates p≤0.05, ** indicates p≤0.01 and *** indicates p≤0.001.
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Supplemental Figure 2. Cell cycle and γH2AX analysis of cytarabine and AZD1775 combination therapy. (A) 
Representative cell cycle analysis of cell lines SUDHL-10 and SC-1 treated with cytarabine and AZD1775 for 24 hours. 
(B) Representative γH2AX analysis of cell lines SUDHL-10 and SC-1 treated with cytarabine and AZD1775 for 24 hours.
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Supplemental Figure 3. Cell cycle and γH2AX analysis of cisplatin and AZD1775 combination therapy. (A) 
Representative cell cycle analysis of cell lines SUDHL-10 and SC-1 treated with cisplatin and AZD1775 for 24 hours. 
(B) Representative γH2AX analysis of cell lines SUDHL-10 and SC-1 treated with cisplatin and AZD1775 for 24 hours.
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Supplemental Figure 4. WEE1 protein and gene expression dosage effect of cytarabine treatment. (A) 
Representative western blot of WEE1, pCDC2 and γH2AX protein levels in SUDHL-10 and SC-1 treated with increasing 
concentration of cytarabine for 24 hours. (B) mRNA expression of WEE1 in SUDHL-10 and SC-1 treated with increasing 
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Abstract
The current treatment of R-CHOP for diffuse large B-cell lymphoma (DLBCL) cures only 
60% of patients, therefore novel therapeutic targets or treatment strategies are needed to 
improve therapy outcome. We recently showed that the WEE1 inhibitor AZD1775 resulted in 
DLBCL cell death as a result of increased DNA damage and premature mitotic entry. Here, 
we applied the popular paradigm of targeting multiple kinases in one pathway to improve the 
efficacy of AZD1775, by testing AZD1775 alongside CDK1 inhibitor RO3306. 
 We show that simultaneous treatment of cells with AZD1175 and RO3306 was synergistic 
in cell viability experiments in 50% of DLBCL cell lines, but induced strong antagonism in the 
other 50% of cases. In addition, combination of AZD1775 with CDK1/2 inhibitor roscovitine or 
CDK4/6 inhibitor palbociclib also resulted in strong anatogonism in DLBCL cell lines. Analysis 
of DNA damage marker yH2AX revealed antagonism was the results of reduced the levels 
of yH2AX, thereby rescuing cells from AZD1775-induced DNA damage. Protein analysis 
of the DNA damage response pathway revealed treatment with RO3306 phosphorylated 
a long isoform of checkpoint kinase 1 (CHK1) at 56 kDa in antagonistic cells, whereas 
synergetic cells showed phosphorylation of a shorter CHK1 isoform at 45 kDa, indicating 
CHK1 determines therapy outcome. 
 Taken together, our results indicate that the success of the AZD1775 and CDK1 inhibitor 
combination treatment in determined by expression of the different phospho-CHK1 isoforms. 
This could have important implications for patient treatment, and therefore further research 
should be performed to investigate the effects and involvement of the CHK1 isoforms on 
therapy outcome.
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Introduction
Genomic instability and activation of the DNA damage response are two hallmarks of diffuse 
large B-cell lymphoma (DLBCL) [1], the most common form of non-Hodgkin lymphoma. 
Despite increasing knowledge on the genetic profile of DLBCL, little advancement has 
been made in improving the current therapy regime, which consist of cyclophosphamide, 
vincristine, doxorubicin, prednisolone and the anti-CD20 antibody rituximab (R-CHOP). 
This current treatment cures roughly 60% of DLBCL patients, leaving many with relapse or 
refractory disease. 
 We recently discovered WEE1, a cell cycle regulator, as a novel target in DLBCL and 
demonstrated both single agent potential for WEE1 inhibitor AZD1775 [2] and synergism in 
combination with CHOP and radiation therapy (paper accepted for publication). To further 
enhance therapy response to AZD1775 and potentially reduce treatment dosage, we applied 
the paradigm of targeting multiple kinases in one pathway [3], by inhibiting both WEE1 and 
CDK1. During cell cycle progression, CDK1 forms a complex with cyclin A to stimulate S/
G2 phase transition and forms a complex with cyclin B to allow cell cycle progression during 
G2/M phase, making it a key cell cycle regulator. Activity of CDK1 is controlled by the kinase 
WEE1, which inhibits CDK1 kinase activity through phosphorylation, and the CDC25 family 
of phosphatases, which remove WEE1’s inhibiting phosphate group [4]. In addition to being 
involved is the same pathway, CDK1 was also independently one of our top 500 potential 
targets in DLBCL [2]. Pre-clinical research with CDK1 inhibitor RO3306 has shown to reduce 
proliferation and metastasis in neuroblastoma tumours [5] and enhance sensitivity to the 
multi-kinase inhibitor sorafenib in hepatocellular carcinoma [6]. Moreover, CDK1 inhibition 
has shown to be synthetic lethal with KRAS mutations in colorectal and pancreatic tumour 
cell models [7] and overcome apoptotic resistance in BRAF-mutant colorectal cancer when 
simultaneously treated with MEK/ERK inhibitors [8]. In addition, many CDK inhibitors such 
as seliciclib/roscovitine (CDK1/2 inhibitor) and palbociclib (CDK4/6 inhibitor) are currently 
being tested in clinical trials (NCT01333423; NCT02806648). Based on these data, CDK1 
inhibition with RO3306 seems like a suitable treatment to test in combination with AZD1775, 
since both inhibitors target kinases which are involved in the same pathway, which fits in the 
current paradigm of cancer treatment [3].
 Here, we showed that combination of AZD1775 and RO3306 induced either a 
synergistic or a antagonistic effect on cell viability, indicating DLBCL cells respond differently 
to treatment. Protein analysis of DNA damage response protein CHK1 revealed activation 
and phosphorylation at serine 345 of different isoforms CHK1 was the determining factor 
for therapy outcome. Based on these data we propose further in-depth in vivo research for 
CDK1/2 inhibitors as therapy in combination with DNA damage inducing agents to determine 
the implications for clinical application.
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Materials and methods
Cell lines and culture conditions
The DLBCL cell lines U-2932, SUDHL-2, SUDHL-4 and SC-1 were cultured in suspension in 
Roswell Park Memorial Institute medium 1640 (RPMI 1640; Lonza BioWhittaker, Walkersville, 
MD, USA) with 10% fetal bovine serum (FBS; HyClone Thermo Scientific, Waltham, MA, 
USA), 1% penicillin-streptomycin (PS; Lonza BioWhittaker) and 1% glutamine (Lonza 
BioWhittaker). The DLBCL cell lines OCILY3, SUDHL-5, SUDHL-6 and SUDHL-10 were 
cultured in suspension in RPMI 1640 with 20% FBS, 1% PS and 1% glutamine. All cell lines 
were cultured at 37°C with 5% CO2 in a humidified atmosphere. The identity of our cell lines 
was checked on a regular basis. Cell of origin (COO), BCL-2 and MYC status was based on 
data from ATCC and DSMZ.
Compounds
The WEE1 inhibitor AZD1775 (#S1525, Houston, TX, USA), the CDK1 inhibitor RO3306 
(#S7747), the CDK1/2 inhibitor roscovitine (#S1153) and the CDK4/6 inhibitor palbociclib 
(#S1579) were all acquired from Selleckchem. UV radiation was performed using UVP® CL-
1000® Ultraviolet Crosslinkers.
Flow cytometry – Cell viability
For cell viability analysis, 0.2 x 106 cells/mL were treated for the appropriate times, washed 
with 1% BSA/PBS and resuspended in propidium iodide solution (P4170, Sigma). Samples 
were processed on a BD FACSCalibur 2 and analysed with ModFit LT (Verity Software 
House). Experiments were performed three times.
Flow cytometry – cell cycle and γH2AX 
For cell cycle analysis, 0.2 x 106 cells/ml were treated for the indicated time points, washed 
with 1% BSA/PBS and resuspended in solution containing 0.1% sodium citrate (A0158348, 
Merck, Kenilworth, New Jersey, United States), 0.01% propidium iodide (P4170, Sigma-
Aldrich, St. Louis, Missouri, United States), 0.002% RNase A (R4875, Sigma-Aldrich) and 
0.3% Triton X100 (T9284, Sigma-Aldrich). Samples were processed on a BD FACSCalibur 2 
and analysed with ModFit LT (Verity Software House). Experiments were performed 3 times.
 For γH2AX analysis, 0.2 x 106 cells/ml were treated for the indicated time points and 
then stained with mouse anti-γH2AX-AlexaFluor-647 (clone 2F3, #613408, BioLegend) 
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and propidium iodide solution (P4170, Sigma) according to the protocol provided with the 
eBioscience™ Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher, #00-5523-00). 
Samples were processed on a MACSQuant and the data were analyzed using Kaluza 1.5 
analysis software (Beckman). Experiments were performed 3 times.
Western blot
Western blot was performed as previously described (2). Staining with primary antibodies for 
anti-WEE1 (1:200, sc-5285 (B11), Santa Cruz Biotechnology, Dallas TX, USA), anti-phospho-
CDC2 (Tyr15) (1:1000, #4539 (10A11), Cell Signaling Technology, Danvers, MA, USA), anti-
phospho-Histone H2AX (Ser139) (1:1000, clone JBW301, Merck Millipore, Temecula, CA, 
USA) anti-phospho-CHK1 (Ser345) (1:1000, #2348 (133D3), Cell Signaling Technology), 
anti-phospho-RPA32 (Ser33) (1:1000, Bethyl, #A300-246A), anti-PAPR1 (1:1000, #9542, Cell 
Signaling Technology) and GAPDH (1:10,000; NovusBio) was done overnight at 4°C. 
RT-qPCR
RNA was isolated from different DLBCL cell lines according to the protocol miRNeasy Mini 
Kit (Qiagen), followed by cDNA synthesis. 300 ng random primers hexamers and  10 mM 
dNTP-mix was added to 500 ng RNA. Samples were then incubated at 65°C for 5 min. After 
cooling on ice 5x first strand buffer, 10% v/v 0.1M dithiothreitol (DTT), 40 units/µl RNaseOUT 
and 200 units Superscript II was added to the samples. cDNA was synthesized using the 
following programme; 10 min at 25°C, 50 min at 42°C and 15 min at 70°C.
Table 1. Primers and probers for CHK1 RT-qPCR.
Gene Forward primer Reversed primer Probe



















Data were analyzed using Graphpad PRISM (version 5.0) software and tested for significant 
differences with a paired T-test. Correlation was analyzed using Spearman’s correlation. * 
indicates p≤0.05, ** indicates p≤0.01 and *** indicates p≤0.001.
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Results
DLBCL cell lines show either a synergistic or an antagonistic response to CDK1i and 
WEE1i combination therapy
Both WEE1 inhibition and CDK1 inhibition are currently being tested as (mono)therapy in 
several types of cancer. To evaluate the efficiency of a combination therapy, we treated 
eight DLBCL cell lines with WEE1 inhibitor AZD1775 and CDK1 inhibitor RO3306 for 72 
hours (Figure 1A). In half of our DLBCL cell line panel (SUDHL-10, SUDHL-5, SUDHL-6 and 
SUDHL-2), the combination of AZD1775 and RO3306 resulted in a synergistic reduction in 
cell viability (Supplemental table 1), where addition of AZD1775 enhanced cell death with on 
average 40%. However, in other cell lines (U-2932, SC-1, OCI-LY3 and SUDHL-4) the same 
combination of AZD1775 and RO3306 had no (additional) effect on cell viability or rescued 
the AZD1775-induced cell death, making the combination antagonistic (Supplemental table 
1). These outcomes were not related to a specific cell or origin (COO) or TP53 mutations 
status (Supplemental table 2). 
 Analysis of DNA damage marker yH2AX confirmed that in cell lines where the 
combination of AZD1775 and RO3306 showed synergism, the combination significantly 
Figure 1. Combination of RO3306 (CDK1i) with AZD1775 (WEE1i) in DLBCL cell lines. (A) Cell viability curves 
of eight DLBCL cell lines treated with CDK1 inhibitor RO3306 and WEE1 inhibitor AZD1775 for 72 hours. Data was 
normalized to the control and plotted as the mean ± S.D. of n=3 experiments. (B) Analysis of DNA damage marker 
yH2AX after treatment with RO3306 and AZD1775 for 24 hours (n=3).
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enhanced DNA damage levels with on average 20% (Figure 1B). In contrast, cell lines where 
the combination of AZD1775 and RO3306 showed antagonism, the same combination 
resulted in a strong rescue of DNA damage levels. To determine the factor(s) that could 
regulate either the synergistic of antagonistic outcome, we analyzed the cell viability data 
for RO3306 and AZD1775 and found that synergistic cell lines were twice as sensitive to 
RO3306 (mean IC50 6 µM; p=0.0366) compared to antagonistic cell lines (mean IC50 11 µM) 
(Supplemental figure 1A), while no differences were observed for AZD1775 (Supplemental 
figure 1B). In addition, cell cycle analysis showed treatment after CDK1 blocking with RO3306 
increased the percentage of G2/M phase cells as a result of cell cycle arrest induced by 
CDK1 inhibition, however no significant differences were observed between synergistic 
or antagonistic cell lines (Supplemental figure 2). Taken together, these results show that 
AZD1775 combined with R03306 can induce either a synergistic or and antagonistic effect 
on cell viability of DLBCL cell lines, which is likely caused by enhanced or reduced DNA 
damage levels, respectively.
 To evaluate whether other CDK inhibitors could have a similar dual effect like observed 
for RO3306, we looked at cell viability and DNA damage levels in cells treated with AZD1775 
combined with CDK1/2 inhibitor roscovitine or CDK4/6 inhibitor palbociclib. Since CDK1/2 
are involved in the regulation of the S/G2/M phase and CDK4/6 in regulation of the G1 phase, 
these data will help elucidate if the stage of cell cycle arrest plays a role in determining 
Figure 2. Combination of roscovitine (CDK1/2i) or palbociclib (CDK4/6i) with AZD1775 (WEE1i) in DLBCL. (A) 
Cell viability analysis of DLBCL cells treated with roscovitine combined with AZD1775 in cell lines SUDHL-10, SUDHL-6, 
SC-1 and U-2932 for 72 hours. Data was normalized to the control and plotted as the mean ± S.D. of n=3 experiments. 
(B) Analysis of DNA damage marker yH2AX after treatment with roscovitine and AZD1775 for 24 hours (n=3). (C) Cell 
viability analysis of cells treated with palbociclib combined with AZD1775 for 72 hours. (D) Analysis of DNA damage 
marker yH2AX after treatment with palbociclib combined with AZD1775 for 24 hours (n=3).
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therapy outcome when combined with AZD1775. Cell viability results in two representative 
“synergistic (S)” cell lines SUDHL-6 and SUHDL-10 showed only minor levels of enhanced 
cell death when roscovitine was combined with AZD1775, whereas significant antagonism 
with respect to cell viability was observed in the two representative “antagonistic” cell lines 
SC-1 and U-2932 (Figure 2A). In addition, DNA damage analysis revealed mild enhanced 
cell death in SUHDL-10 (S) and SUDHL-6 (S) at lower concentration of 0.5 µM AZD1775, 
whereas the combination of roscovitine with 1 µM AZD1775 resulted in reduced yH2AX 
levels, indicating antagonism (Figure 2B). In line with previous cell viability data for SC-1 and 
U-2932 (Figure 2A), combination of roscovitine with AZD1775 resulted in strong reduction of 
yH2AX levels (Figure 2B).  These results demonstrate that CDK1/2 inhibitor roscovitine has 
a very different effect when combined with AZD1775 compared to CDK1 inhibitor RO3306, 
which potentially induces strong synergism in 50% of the cells. In contrast, combination of 
AZD1775 with palbociclib showed antagonism in both cell viability (Figure 2C) and DNA 
damage analysis (Figure 2D) in all four cell lines. Together, these data show that CDK 
inhibitors are likely not suitable to combine with AZD1775, as they result in strong antagonism 
in DLBCL cell lines in most cases. 
DLBCL cell lines express different phospho-CHK1 isoforms upon CDK1 inhibition
Based on previous data, we wanted to further investigate how the combination of AZD1775 
and RO3306 can results in both synergistic and antagonistic on cell viability, and how RO3306 
differs from the other CDK1 inhibitors. To this end we first performed protein analysis of the 
DNA damage response pathway in “synergistic” cell line SUDHL-5 treated with AZD1775, 
RO3306, roscovitine, palbociclib and as positive control UV radiation (Figure 3).
Figure 3. Protein analysis of 
DNA damage response proteins. 
Analysis of DNA damage response 
proteins pCHK1, pCHK2, WEE1, 
pCDC2, yH2AX, pRPA, (cleaved) 
PARP and H3. 
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 Treatment of cells with WEE1 inhibitor AZD1775 induced reduction of WEE1 and its 
downstream target phospho-CDC2 (Tyr15). In addition, treatment induced activation of DNA 
damage-related proteins yH2AX, phospho-RPA and marker of apoptosis cleaved PARP. For 
CDK1 inhibitor RO3306, no changes were observed in the phosphorylation levels of CDC2, 
however treatment resulted in strong activation of yH2AX (double-stranded DNA breaks) 
and activation of cleaved PARP. In addition, treatment with RO3306 resulted in activation 
of phospho-CHK1, however at a much lower molecular weight of 45 kDa, instead of the 
conical 56 kDa, as observed after UV radiation. For CDK1/2 inhibitor roscovitine, treatment 
activated both yH2AX and cleaved PARP, but not phospho-CHK1. Similarly, CDK4/6 
inhibitor palbociclib induced both phospho-RPA and cleaved PARP in the absence of CHK1 
activation, unlike RO3306. Moreover, treatment with palbociclib significantly reduced protein 
levels of total CHK1, indicating less potential for CHK1 activation. These data demonstrate 
the different effects induced by different CDK1 inhibitors on the DNA damage response 
pathway, and how they potentially might alter the outcome of combination therapies with 
DDR inhibitors. 
 Based on previous data, we further tested the effect of AZD1775 combined with RO3306 
on the phosphorylation of CHK1 in two representative synergistic (SUDHL-10 and SUDHL-5) 
and two antagonistic (U-2932 and SC-1) DLBCL cell lines (Figure 4). Protein analysis showed 
activation of phospho-CHK1 in synergistic cell lines SUDHL-5 and SUDHL-10 was observed 
at a protein size of 45 kDa upon treatment with RO3306, whereas treatment with AZD1775 
induced no phospho-CHK1 activation in cell line SUDHL-5 and a weak band of phospho-
CHK1 at a protein size of 56 kDa in cell line SUDHL-10 (Figure 4A). In contrast, activation 
Figure 4. Western blot analysis of pCHK1 protein levels after treatment with CDK1i and WEE1i. (A) Protein 
analysis of phospho-CHK1 (Ser345), WEE1, phospho-CDC2 (Tyr15) and yH2AX after treatment with CDK1 inhibitor 
RO3306 and/or WEE1 inhibitor AZD1775 for 24 hours in synergistic cell lines SUDHL-10 and SUDHL-5. (B) Protein 
analysis of phospho-CHK1, WEE1, phospho-CDC2 and yH2AX after treatment with RO3306 and/or AZD1775 for 24 
hours in antagonistic cell lines U-2932 and SC-1.
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of phospho-CHK1 upon treatment with RO3306 was not observed in antagonistic cell lines 
SC-1 and U-2932, whereas treatment with AZD1775 induced strong activation of phospho-
CHK1 at a protein size of 56 kDa (Figure 4B). Protein levels of yH2AX showed a similar 
activation pattern as the phospho-CHK1 protein expression and previous flow cytometry 
data in both synergistic and antagonistic cells lines (Figure 1B), indicating phospho-CHK1 
was activated in response to DNA damage induction. 
 Taken together, these data indicate that cells that show synergism upon the AZD1775 
and RO3306 combination treatment activate a shorter, and perhaps less functional isoform of 
phospho-CHK1, resulting in inefficient DNA damage repair and enhanced cell death. At the 
same time, cells that show an antagonistic response to AZD1775 and RO3306 combination 
treatment activate a long isoform of phospho-CHK1 that likely is able to efficiently activate 
pathways for repair, thereby reducing DNA damage in the combination treatment.
Gene expression of CHK1 short is very low compared to CHK1 long in DLBCL cell 
lines
Figure 5. Gene expression of CHK1 and CHK1-S in DLBCL cell lines. (A) Gene expression of the CHK1 long and 
short isoform in DLBCL cell lines that showed synergism (left) or antagonism (right) for the combination of AZD1775 with 
RO3306. (B) Ratio of gene expression levels of CHK1 long to CHK1 short in DLBCL cell lines. (C) Gene expression of 
CHK1 long and short isoforms in cell lines SUDHL-10, SUDHL-5, SC-1 and U-2932 treated with AZD1775, RO3306 or 
combined for 24 hours.
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Based on our protein analysis, we established that the two CHK1 isoforms are actively 
phosphorylated on serine 345 in response to different treatments. However, analysis of total 
CHK1 protein showed little expression of the short CHK1 isoform. Therefore, we checked if 
the CHK1 gene expression levels were also altered by CDK1 inhibitor treatment. 
 Gene expression of the long CHK1 (CHK1) and short CHK1 (CHK1-S) isoforms in the 
DLBCL cell line panel showed expression of CHK1-S was significantly (~10-fold) lower 
compared to CHK1 (Figure 5A), which would explain the undetectable expression levels of 
the short CHK1 isoform in the western blot. Comparison of the different cell lines showed there 
were no differences between synergistic and antagonistic cell lines in the level of CHK1-S 
expression levels or the CHk1/CHK1-S ratio (Figure 5A-B). Treatment of cells with RO3306 
alone or in combination with AZD1775 induced an increase in gene expression levels of 
both CHK1 and CHK1-S, and was observed in both synergistic and antagonistic cells lines 
(Figure 5C and Supplemental figure 3). Based on these data, it seems phosphorylation of the 
different CHK1 isoforms, and not expression of the CHK1 isoforms, is the critical difference 
between synergistic or antagonistic outcome.
CDK1i treatment, but not WEE1i, HU, cytarabine or UV activate the phospho-CHK1 
short isoform
Next, we investigated whether other forms of DNA damage inducing compounds could 
also activate the short isoform of phospho-CHK1 in the representative cells lines SUDHL-10 
(synergism) and SC-1 (antagonism). Cells were treated for 6 or 24 hours with hydroxy urea 
(HU), a known inducers of replication stress [9], and the anti-metabolic agent cytarabine, 
known for its interference with DNA synthesis [10], alongside RO3306 and AZD1775 as 
positive and negative controls. Protein analysis revealed activation of the short phospho-
CHK1 isoform was only present in SUDHL-10 cells treated with RO3306 after 24 hours 
(Figure 6A). Activation of the long CHK1 isoform was observed after 6 hours of treatment 
with AZD1775, but was absent at 24 hours, despite the presence of yH2AX. Treatment 
with hydroxy urea and cytarabine activated the long phospho-CHK1 isoform but not the 
short isoform, and showed induction of yH2AX. Analysis of total CHK1 protein expression 
showed strong presence of the long CHK1 isoform, but expression of the CHK1 short isoform 
was only observed in cells treated with RO3306 for 24 hours. In cell line SC-1, treatment 
with RO3306 activated neither the short nor the long isoform of phospho-CHK1, whereas 
AZD1775, hydroxy urea and cytarabine all activated the long phospho-CHK1 isoform and 
induced expression yH2AX (Figure 6B). In all treatments, activation of (long) phospho-CHK1 
in SC-1 was more pronounced after 6 hours treatment compared to 24 hours treatment. 
Analysis of total CHK1 protein showed only expression of the long CHK1 isoform, which 
is in concordance with activation of only the long phospho-CHK1 isoform. Similar results 
were obtained when cell lines SUDHL-10 and SC-1 were treated with UV radiation, which 
also activated the long, but not the short phospho-CHK1 isoform (Supplemental figure 4). In 
addition, combination of UV with RO3306  showed a similar pattern as AZD1775 combined 
with RO3306, in which cell lines SUDHL-10 and SUDHL-5 showed synergism and cell lines 
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SC-1 and U-2932 showed antagonism for the combination (Supplemental figure 5). These 
results demonstrate a unique activation pattern of isoforms for phospho-CHK1, which is both 
treatment specific but also timing dependent.
Discussion
Many CDK inhibitors are currently being tested as possible anti-cancer therapeutics, 
including seliciclib/roscovitine (CDK1/2 inhibitor; NCT01333423), palbociclib (CDK4/6 
inhibitor; NCT02806648), voruciclib/P1446A-05 (CDK4i; NCT01841463) and AT7519M 
(CDK1/2/4/5/9i; NCT01652144). However, these therapies will most likely be used in 
combination with other (existing) therapies, warranting the need for proper combination 
studies. Here, we show the potential danger of combining CDK1 inhibitor RO3306 with DNA 
damage-inducing treatments, which can induce both synergistic and antagonistic effects 
(Figure 1). Our data showed that one of the determining factors of therapy outcome could be 
the phosphorylation of either a short or long isoform of the checkpoint kinase CHK1 (Figure 
4). CHK1 is activated by the DNA damage response kinase ATR, which mostly respond 
to single stranded DNA damage or replication stress [11]. Activation of CHK1 results in 
downstream inhibition of cell cycle progression, through inhibition of CDC25A and CDC25C, 
and subsequent activation of WEE1 [12]. At the same time, CHK1 is also able to prevent 
apoptosis, although the exact mechanism behind this phenomenon is still unknown [13]. 
Research has shown the existence of two different isoforms of CHK1, a (normal) long CHK1 
isoform of 56 kDa and a short n-terminally truncated CHK1 splice variant with a size of ~43 
kDa, which is missing part of its kinase domain [14-16]. This short CHK1 isoform was highly 
Figure 6. Western blot analysis of pCHK1 protein levels after treatment with chemotherapeutic compounds. 
(A)  Protein analysis of phospho-CHK1 (Ser345), WEE1, phospho-CDC2 (Tyr15) and yH2AX after treatment with 10 
µM CDK1 inhibitor RO3306, 1 µM WEE1 inhibitor AZD1775, 3 mM hydroxy urea (HU) or 1 µM cytarabine in cell line 
SUDHL-10. Samples were harvested after 6 and 24 hours. (B) Protein analysis of phospho-CHK1, WEE1, phospho-
CDC2 and yH2AX after treatment with 10 µM CDK1 inhibitor RO3306, 1 µM WEE1 inhibitor AZD1775, 3 mM hydroxy 
urea (HU) or 1 µM cytarabine in cell line SC-1. Samples were harvested after 6 and 24 hours.
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expressed in cancer tissue compared to control healthy tissue, and the presence of the 
short CHK1 isoform was strongly associated with disease progression in patient samples 
of ovarian cancer and prostate cancer [16]. Moreover, it has been suggested that through 
direct interaction of the short and long isoform, activity of the long isoform was diminished 
[16,17]. However, these experiments focused mainly on the presence or absence of the 
short and long CHK1 proteins itself, and did not further study the CHK1 phosphorylation 
sites. Here, we show for the first time that phosphorylation at site serine 345 of these isoforms 
is differently activated in response to therapeutic treatment, and that they may determine 
therapy outcome in DLBCL cell lines treated with CDK1 inhibitor RO3306 combined with 
DNA damage inducing drugs. This would pose a serious problem for patient treatment, and 
therefore further studies with in vivo or PDX models should be performed to further validate 
these outcomes before we can properly determine the clinical implications. In addition, the 
question remains 1) why the alternative isoform phosphorylation is active in specific cells 
but not in others, and 2) how specific treatment is able to activate this alternative isoform 
phosphorylation, since the short CHK1 isoform is likely less functional and therefore less 
beneficial for cellular survival.
 In addition, we showed combination of AZD1775 with CDK4/6 inhibitor palbociclib 
always induced strong antagonistic effects in DLBCL (Figure 2). These data are in line with 
research from Roberts et al., who showed co-administration of palbociclib with carboplatin, 
doxorubicin, etoposide, camptothecin or paclitaxel all resulted in reduced levels of yH2AX foci, 
indicating palbociclib reduced levels of DNA damage induced by these chemotherapeutic 
drugs [18]. Similar to CDK1/2 inhibitors, it appears the CDK4/6 inhibitor palbociclib can 
block effectivity of DNA damage-inducing agents, resulting is strong antagonism. However, 
where the effects of CDK1/2 inhibition are possibly dose-dependent, CDK4/6 inhibition seem 
to always induce strong antagonism. This indicates an important difference in perhaps the 
underlying mechanism behind this phenomenon or the importance of the different cell cycle 
stage at which these events are taking place. Further research would be needed to elucidate 
the differences and/or similarities between the different CDK proteins and how they are 
affected by inhibitor treatment. 
 In conclusion, based on the current evidence we propose a model for the possible 
outcomes when CDK1 inhibitor RO3306 is combined with DNA damage-inducing compounds 
(Figure 7A) and a model when two (or more) DNA damage-inducing compounds are combined 
(Figure 7B). In the first situation (Figure 7A), DNA damage induction combined with RO3306 
allows cells time for repair or survival by arresting cells at the G2/M phase. However, DNA 
damage repair and avoidance of apoptosis is only achieved if cells are able to activate the 
long isoform of CHK1, which contains the full-length kinase domain for activation of down-
stream targets. If through alternative activation the short CHK1 isoform is phosphorylated, 
cells are unable to induce repair and avoid apoptosis, resulting in (enhanced) cell death. 
If cells are treated with a combination of two (or more) DNA damage-inducing compounds 
(Figure 7B), cells experience a double hit of DNA damage, making it harder to cope with 
cellular stress and detain apoptosis. At the same time, cells are not automatically arrested to 
allow repair. Therefore, even though a full length and functional CHK1 protein is activated, 
cells are unable to cope with the extreme levels of damage and stress, resulting in cell death.
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Figure 7. Schematic overview of the CHK1 isoforms and their involvement in DNA damage repair and apoptosis. 
(A) In the situation when DNA damage inducing treatments are combined with CDK1 inhibitor RO3306 (left panel), the 
cell cycle arrest induced by Ro3306 has the potential to allow DNA damage repair, thereby avoiding apoptosis. However, 
proper repair can only be performed when cells activate the long phospho-CHK1 isoform, whereas activation of the short 
phospho-CHK1 isoform results in apoptosis. (B) In the situation when two (or more) DNA damage inducing treatments 
are combined (right panel), the extent of DNA damage is too severe to repair and therefore cells will undergo apoptosis, 
despite activation of the long CHK1 isoform.
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Supporting information
Supplemental Table 1. Combination index (CI) for RO3306 combined with AZD1775. The combination index (CI) 
was based on cell viability data for RO3306 combined with AZD1775 after 72 hours of incubation. CI was calculated 
using the Chou-Talalay method. Numbers in red are classified as antagonistic (CI>1), in white as additive (CI=1) or in 
green as synergistic (CI<1).
SUDHL-10 SUDHL-5
RO3306/AZD1775 100 nM 500 nM RO3306/AZD1775 100 nM 500 nM
2 µM 2,0 0,5 2 µM 39 1,2
4 µM 3,0 0,6 4 µM 1,2 0,8
6 µM 0,7 0,8 6 µM 0,8 0,9
8 µM 0,8 0,9 8 µM 1,0 1,1
10 µM 1,0 1,1 10 µM 1,1 1,3
SUDHL-6 SUDHL-2
RO3306/AZD1775 100 nM 500 nM RO3306/AZD1775 100 nM 500 nM
2 µM 1,2 1,3 2 µM 1,3 0,9
4 µM 1,0 1,1 4 µM 0,7 0,7
6 µM 0,7 1,1 6 µM 0,7 0,8
8 µM 0,8 1,2 8 µM 0,9 0,9
10 µM 0,9 1,3 10 µM 0,9 0,9
SC-1 U2932
RO3306/AZD1775 100 nM 500 nM RO3306/AZD1775 100 nM 500 nM
2 µM 2,7 1,1 2 µM 1,3 0,8
4 µM 0,8 1,2 4 µM 0,6 1,1
6 µM 0,9 1,5 6 µM 1,0 1,7
8 µM 1,2 1,7 8 µM 1,3 1,9
10 µM 1,4 2,0 10 µM 1,5 2,1
SUDHL-4 OCI-LY3
RO3306/AZD1775 100 nM 500 nM RO3306/AZD1775 100 nM 500 nM
2 µM 94 101 2 µM 1,1 1,2
4 µM 1,6 1,9 4 µM 1,0 1,5
6 µM 1,1 1,4 6 µM 1,1 1,9
8 µM 1,1 1,4 8 µM 1,4 2,1
10 µM 1,2 1,5 10 µM 1,7 3,7
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Supplemental Table 2. Overview of DLBCL cell lines characteristics. Overview of the eight DLBCL cell lines with 
their corresponding cell of origin (COO) classification, TP53 mutation status, IC50 value for RO3306 and AZD1775 and 
response to the AZD1775 and RO3306 combination treatment.
Cell line Subtype TP53 status RO3306 (µM) AZD1775 (nM) Combination response
SUDHL-10 GCB MUT 9,0 930 Synergism
SUHDL-5 GCB WT 3,8 558 Synergism
SUDHL-6 GCB MUT 6,0 462 Synergism
SUDHL-2 ABC MUT 4,7 520 Synergism
SC-1 GCB WT 14,4 778 Antagonism
U-2932 ABC MUT 9,1 710 Antagonism
OCI-LY3 ABC WT 9,2 225 Antagonism
SUDHL-4 GCB MUT 9,3 1140 Antagonism
Supplemental Figure 1. Comparison of IC50 values between synergistic and antagonistic DLBCL cell lines. 
(A) Comparison between IC50 values for RO3306 between cell lines which showed synergism for the RO3306 and 
AZD1775 combination (SUDHL-2, SUDHL-5, SUDHL-6 and SUDHL-10) and cell lines which showed antagonism for the 
RO3306 and AZD1775 combination (SC-1, U-2932, OCI-LY3 and SUDHL-4). (B) Comparison between IC50 values for 
AZD1175 between cell lines which showed synergism for the RO3306 and AZD1775 combination (SUDHL-2, SUDHL-5, 
SUDHL-6 and SUDHL-10) and cell lines which showed antagonism for the RO3306 and AZD1775 combination (SC-1, 
U-2932, OCI-LY3 and SUDHL-4).
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Supplemental Figure 2. Cell cycle analysis of DLBCL cell lines treated with CDK1i and WEE1i. Flow cytometry 
cell cycle analysis data of eight DLBCL cell lines treated for 24 hours with CDK1 inhibitor RO3306 and WEE1 inhibitor 
AZD1775. Plotted are the mean of n=3 experiments.
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Supplemental Figure 3. Gene expression ratio of CHK1-S and CHK1 in DLBCL cell lines. Gene expression ratio 
was calculated by dividing the short CHK1 isoform (CHK1-S) by the normal CHK1 isoform (CHK1). Plotted are the results 
for two synergistic cell lines (SUDHL-10 and SUHDL-5) and two antagonistic cell lines (SC-1 and U-2932). 
Supplemental Figure 4. Western blot analysis of pCHK1 protein levels after treatment with UV radiation. Protein 
analysis of phospho-CHK1 (Ser345), CHK1, WEE1, phospho-CDC2 (Tyr15), yH2AX, phospho-RPA (Ser33) and PARP 
after treatment with 20 J/m2 UV radiation in cell line SUDHL-10 and SC-1. Samples were harvested after 6 and 24 hours.
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Supplemental Figure 5. Combination of CDK1i with UV radiation in DLBCL cell lines. Cell viability curves of four 
DLBCL cell lines treated with CDK1 inhibitor RO3306 and UV radiation for 72 hours. Data was normalized to the control 
and plotted as the mean.
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Abstract
Genomically unstable cancers are dependent on specific cell cycle checkpoints to maintain 
viability and prevent apoptosis. The cell cycle checkpoint protein WEE1 is highly expressed 
in genomically unstable cancers, including diffuse large B-cell lymphoma (DLBCL). Although 
WEE1 inhibition effectively induces apoptosis in cancer cells, the effect of WEE1 inhibition 
on anti-apoptotic dependency is not well understood. We show that inhibition of WEE1 
by AZD1775 induces DNA damage and pre-mitotic entry in DLBCL, thereby enhancing 
dependency on BCL-2 and/or MCL-1. Combining AZD1775 with anti-apoptotic inhibitors such 
as venetoclax (BCL-2i) or S63845 (MCL-1i) enhanced sensitivity in a cell-specific manner. In 
addition, we demonstrate that both G2/M cell cycle arrest and DNA damage induction put 
a similar stress on DLBCL cells, thereby enhancing anti-apoptotic dependency. Therefore, 
genotoxic or cell cycle disrupting agents combined with specific anti-apoptotic inhibitors 
may be very effective in genomic unstable cancers such as DLBCL and therefore warrants 
further clinical evaluation.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is a genomically unstable cancer with multiple low-
frequency mutations, somatic copy number alterations, and chromosomal translocations [1]. 
To survive in such a genetically hazardous setting, DLBCL cells rely on cell cycle checkpoints, 
DNA repair, and anti-apoptotic proteins [2,3]. We have recently demonstrated that the cell 
cycle regulator WEE1 is highly expressed in DLBCL and is a relevant target for therapy 
[4]. WEE1 acts through phosphorylation of cyclin-dependent kinase 1 (CDK1/CDC2), which 
blocks the cell cycle at G2/M to allow time for DNA damage surveillance [5]. Under normal 
circumstances, factors such as cell cycle disruption and DNA damage result in induction 
of (intrinsic) apoptosis [6–10]. Indeed, blocking of WEE1 activity with AZD1775 results in 
apoptosis in solid cancers [11], lymphoma [4], and leukaemia [12,13]. In order to survive 
intrinsic apoptosis, DLBCL and many other cancers induce upregulation of various anti-
apoptotic proteins, leading to apoptosis resistance, resulting in a cellular reliance on anti-
apoptotic proteins commonly termed ‘anti-apoptotic dependency’ [14,15]. Since AZD1775 is 
very effectively able to induce intrinsic apoptosis, we aimed to investigate whether AZD1775 
could alter the anti-apoptotic dependency and enhance the sensitivity of DLBCL cells to anti-
apoptotic inhibitors (a.k.a., BH3 mimetic drugs).
 The intrinsic apoptotic pathway is regulated by a complex interaction of pro- and anti-
apoptotic proteins at the surface of mitochondria. Cells undergo apoptosis when this protein 
complex is balanced towards pro-apoptotic proteins (e.g., BIM (pro-apoptotic effector), 
BAD, NOXA, PUMA, BMF, HRK (pro-apoptotic sensitizers)). On the other hand, when 
apoptotic dependency shifts towards anti-apoptotic proteins (e.g., BCL-2, BCL-XL, BCL-W, 
and MCL-1) cells can avoid apoptosis [16]. Many studies in both cell lines and primary 
patients’ samples have demonstrated the (clinical) potential of BH3 profiling, a technique 
that can identify a selective dependency on individual pro- or anti-apoptotic proteins in this 
complex network [17]. With this method, cells are exposed to BH3 peptides which enter 
the mitochondria and interact with anti-apoptotic proteins, resulting in a mitochondrial outer 
membrane permeabilization (MOMP) which can be measured using the JC-1 dye or as 
cytochrome-c release. Dynamic BH3 profiling (dBH3) is an ex vivo, clinically applicable 
variant of BH3 profiling which measures early changes in the apoptotic signalling cascade 
at the mitochondrial level, whether induced in cancer cells by treatment with classical 
chemotherapy or by specific anti-cancer agents [18–20].
 In the present study we showed that WEE1 inhibitor AZD1775 induces cell death through 
apoptosis. In addition, we showed that AZD1775 significantly enhanced the dependency on 
anti-apoptotic proteins and enhanced sensitivity to BH3 mimetic drugs in DLBCL cells in a 
cell-specific manner. Similar changes in the anti-apoptotic dependency were induced by 
DNA damage and cell cycle arrest independently. Based on these results, we predict that 
AZD1775 and other similar drugs are very suitable to combine with BH3 mimetic drugs for 
the treatment of cancer.
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Materials and Methods
Cell Lines and Culture Conditions
The DLBCL cell lines U-2932 (ABC), SUDHL-2 (ABC), SUDHL-4 (GCB), and SC-1 (GCB) 
were cultured in suspension in Roswell Park Memorial Institute medium 1640 (RPMI 1640; 
Lonza BioWhittaker, Walkersville, MD, USA) with 10% fetal bovine serum (FBS; HyClone 
Thermo Scientific, Waltham, MA, USA), 1% Penicillin-Streptomycin (PS; Lonza BioWhittaker) 
and 1% glutamine (Lonza BioWhittaker). The DLBCL cell lines OCILY3 (ABC), SUDHL-5 
(GCB), SUDHL-6 (GCB), and SUDHL-10 (GCB) were cultured in suspension in RPMI 1640 
with 20% FBS, 1% PS and 1% glutamine. All cell lines were cultured at 37 °C with 5% CO2 in 
a humidified atmosphere. The identity of our cell lines was checked on a regular basis. Cell 
line characteristics are given in Table S1.
Patient Material and METC Statement
Patient material was acquired in accordance with international regulations and professional 
guidelines (the Declaration of Helsinki and the International Conference on Harmonization 
Guidelines for Good Clinical Practice). Material used in this project was obtained from 
anonymous rest material. The medical ethics review board waives the need for approval 
if rest material is used, under the law in the Netherlands and waives the need for informed 
consent when patient anonymity is assured. 
BH3 Profiling—Plate-Based Assay
Cells were incubated at 0.5 × 106 cells/mL for 18 h with AZD1775 (WEE1 inhibitor, 
Selleckchem No.S1525, Houston, TX, USA) (Figure S8), palbociclib (CDK4/6 inhibitor, 
Selleckchem No.S1116), RO3306 (CDK1 inhibitor, Selleckchem No.S7747), roscovitine 
(CDK2 inhibitor, Selleckchem No. S1153), nocodazole (M1404, Sigma Aldrich, St. Louis, MO, 
USA), or ultraviolet (UV) radiation (IBL 637, CisBioInternational, Gif-sur-Yvette, France). After 
incubation, cells were washed with mannitol experimental buffer (MEB) (150 mM D-mannitol 
(M9647, Sigma Aldrich,), 10 mM HEPES (H3375, Sigma Aldrich), 50 mM KCl (1.04936, 
Merck, Darmstadt, Germany), 20 nM EGTA (E4378, Sigma Aldrich), 20 nM EDTA (11280, 
Serva Electrophoresis, Heidelberg, Germany), 0.1% BSA (11930, Serva Electrophoresis), 5 
mM succinate (1.00682, Merck) in dH2O, pH 7.5) and resuspended at 3.2 × 106 cells/mL 
in MEB. A cell suspension was mixed 1:1 with 4 µM JC-1 permeabilization/staining solution 
((ENZ-52304, Enzo Life Sciences, Farmingdale, NY, USA), 0.004% digitonin (1500 643, 
Boehringer Mannheim, Mannheim, Germany), 20 mM β-mercaptoethanol (8.05740, Merck) 
and 40 µg/mL oligomycin (O4876, Sigma Aldrich) prepared in MEB) and incubated at room 
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temperature in the dark for 10 min. BIM, PUMA, BAD, NOXA, MS1, HRK, BMF, and PUMA2A 
(JPT Peptide Technologies, Berlin, Germany) were prepared in MEB in a black flat-bottom 
non-treated polystyrene 96-well plate (3915 Costar, Corning Incorporated, Kennebunk, ME, 
USA). Peptide sequences used for the assay were identical to those described in Ryan and 
Letai [18]. Plates were either used directly or sealed (Silverseal sealer ref 676090, Greiner-
Bio-One, Frickenhausen, Germany), frozen at −80 °C and thawed for 1 h at room temperature 
before use. Cells in permeabilization/staining solution were added to the plate 1:1 at a final 
volume of 100 uL and shaken for 15 s, followed by measurement of fluorescence (excitation 
545 nm, emission 590 nm) every 5 min for 2 h at 30 °C (Varioskan). All experiments were 
performed in triplicates or quadruplicate. The area under the curve (AUC) was calculated as 
a percentage of mitochondrial outer membrane permeabilization (MOMP) and normalized 
to PUMA2A (negative control) and FCCP (positive control) with the formula: 1 − ((AUC 
sample – AUC FCCP) ÷ (AUC PUMA2A– AUC FCCP)) × 100%. The dynamic BH3 profile 
(ΔMOMP) was calculated by subtracting the percentage treated MOMP from percentage 
untreated MOMP. Based on the specific interacting partners of the BH3 peptides [18], the 
cell specific anti-apoptotic dependency of cells can be established. BH3 profiling with a 
mean ΔMOMP ≥ 20% were classified as biologically relevant, even if they were not always 
statically significant. ΔMOMP changes for the BIM peptide indicates cells have become 
more primed for apoptosis or closer to their apoptotic threshold. Similarly, ΔMOMP changes 
for NOXA, HRK, or BAD indicate cells have become more dependent on MCL-1, BCL-XL, or 
BCL-2/XL/W, respectively. Together, these data can predict on which anti-apoptotic protein 
cells are dependent, and how this changes upon inhibitor treatment.
BH3 Profiling—Flow Cytometry-Based Assay
Peripheral blood mononuclear cells were isolated from a DLBCL patient, washed with 10% 
FBS RPMI, incubated at 1.0 × 106 cells/mL for 18 h with 1 µM AZD1775 (WEE1 inhibitor, 
Selleckchem) in RPMI medium supplemented with 10% fetal bovine serum, 1% Penicillin-
Streptomycin, and 1% glutamine. After incubation, cells were washed with 1% BSA (11930, 
Serva) in PBS and incubated with CD19-APC antibody (IQP-106A, IQ Products, Groningen, 
The Netherlands) for 30 min at 4 °C. After staining, cells were washed with and suspended 
in MEB at 3–5 × 106 cells/mL. Cells were incubated with peptides in 0.001% digitonin 
at 25°C for 60 min. The reaction was stopped by addition of 2% formaldehyde (104005, 
Merck) in PBS and cells were fixed in 2% formaldehyde for 20 min at room temperature. 
Cells were washed in 1% BSA in PBS and stained overnight for intracellular cytochrome-c 
in PBS containing 1% BSA in PBS, 0.2% Tween 20 (P7949 Sigma Aldrich) and 1:400 Alexa 
Fluor 488 anti-cytochrome-c antibody (612308, BioLegend 9727 Pacific Heights Blvd. San 
Diego, CA 92121, USA) at 4 °C. Before analysis, cells were washed with 1% BSA in PBS and 
flow cytometry analysis was performed on a FACSCalibur (BD Biosciences, 1 Becton Drive, 
Franklin Lakes, NJ 07417-1880, USA). Data were normalized to PUMA2A (negative control) 
and alamethicin (positive control). The dynamic BH3 profile (ΔMOMP) was calculated by 
subtracting the percentage treated MOMP from percentage untreated MOMP.
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Flow Cytometry-Based Apoptosis Assay
Cells were incubated at 0.1 × 106 cells/mL with AZD1775 (WEE1 inhibitor, Selleckchem) with 
or without QVD-Oph (pan-caspase inhibitor, Selleckchem, No. S7311) for 18, 24 or 72 h. After 
incubation, cells were washed with 1% BSA in PBS and stained with Annexin V-FITC (IQP-
120F, IQ products, Groningen, The Netherlands) for 20 min on ice. Cells were washed with 
1% BSA in PBS and stained with propidium iodide (Sigma Aldrich) to assess early apoptosis 
(Annexin V positive/propidium iodide negative) and late apoptosis (Annexin V positive/
propidium iodide positive). Apoptosis was measured by flow cytometry (FACSCalibur, BD 
Biosciences). Data were analysed in Winlist 3D (Verity Software house, Topsham, ME, USA).
Flow Cytometry—Cell Cycle, γH2AX, and pH3 with DNA Content
For cell cycle analysis, 0.2 × 106 cells/mL were treated for the indicated time points, washed 
with 1% BSA/PBS and resuspended in solution containing 0.1% sodium citrate (A0158348, 
Merck, Kenilworth, New Jersey, USA), 0.01% propidium iodide (P4170, Sigma Aldrich), 
0.002% RNase A (R4875, Sigma Aldrich), and 0.3% Triton X100 (T9284, Sigma Aldrich). 
Samples were processed on a BD FACSCalibur 2 and analysed with ModFit LT (Verity 
Software House, Topsham, ME , USA).
For γH2AX analysis, 0.2 × 106 cells/ml were treated for the indicated time points and then 
stained with mouse anti-γH2AX-AlexaFluor-647 (clone 2F3, #613408, BioLegend) and 
propidium iodide solution (P4170, Sigma Aldrich) according to the protocol provided with the 
eBioscience™ Foxp3/Transcription Factor Staining Buffer Set (ThermoFisher, #00-5523-00, 
Waltham, MA, USA). Samples were processed on a MACSQuant and the data were analyzed 
using Kaluza 1.5 analysis software (Beckman, Brea, CA, USA).
Flow Cytometry-Based Viability Assay
Cells were incubated at 0.1 × 106 cells/mL with AZD1775 (WEE1 inhibitor, Selleckchem) 
for 18 h. After washing with 1% BSA in PBS, cells were incubated with venetoclax/ABT-
199 (BCL-2-selective inhibitor, Selleckchem), S63845 (MCL-1 inhibitor, Selleckchem), or 
navitoclax/ABT-263 (BCL-XL/BCL-2/BCL-W inhibitor Selleckchem) for 48 h at 37 °C. After 
incubation, cells were washed with 1% BSA in PBS and stained with propidium iodide (Sigma 
Aldrich) to assess cell viability by flow cytometry (FACSCalibur, BD Biosciences). Data were 
analysed in Winlist 3D (Verity Software House, Topsham ME, USA).
Statistical Analysis
A one-sample T-test was used to assess the significance of the dynamic BH3 profiling results 
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(n=3 independent repeats). Comparison of IC50 values between untreated and AZD1775-
treated samples was done using a two-tailed paired T-test. Correlation analysis was carried 
out using Pearson’s correlation test. * indicates p≤0.05, ** indicates p≤0.01, and *** indicates 
p≤0.001. 
Results
AZD1775 Induces Apoptosis and Enhances Anti-Apoptotic Dependency in DLBCL
DLBCL is a genomic unstable and heterogeneous cancer that shows a variety of molecular 
phenotypes. We previously demonstrated high expression of WEE1 in DLBCL cells compared 
to normal B-cells [4] and found this difference is significantly higher in DLBCL compared 
to other cancers (Supplemental figure 1). These data suggest that genomically unstable 
tumours such as DLBCL might be particularly sensitive to WEE1 inhibition. Thereto, we 
selected a panel of DLBCL cell lines with different genetic aberrations (Table S1). Treatment 
of DLBCL cell lines with WEE1 inhibitor AZD71775 induced a rapid decline in cell viability, 
with IC50 values ranging from 0.4 to 1.8 µM (Figure 1A and Supplemental table 1).
 Cell death was induced by apoptosis, as measured by flow cytometry for annexin V/
PI staining (Figure 1B). Apoptosis induced by AZD1775 could be observed in both a 
time and dose-dependent manner and could be rescued by pan-caspase inhibitor QVD 
(Supplemental figure 2). Next, we used dynamic BH3 profiling (Figure 1C and Supplemental 
table 2), which measures the changes in anti-apoptotic dependency upon treatment with 
AZD1775. As a result of AZD1775 treatment, cell lines OCI-LY3, SUHDL-6, SUDHL-10, 
and SC-1 had increased mitochondrial response to the pro-apoptotic peptide BIM at 27% 
(p=0.0058), 10% (ns), 14% (p=0.0480), and 8% (ns), respectively, indicating cells were more 
primed to undergo apoptosis. BH3 profiling with a mean ΔMOMP ≥ 20% was classified as 
biologically relevant, even if they were not statically significant, as they often lead to significant 
enhanced sensitivity to BH3 mimetic drugs, indicating biological relevance. In addition, the 
changes induced by AZD1775 treatment could be induced in a dose-dependent manner 
(Supplemental figure 3A) and were significantly correlated to the percentage of apoptotic 
cells (Supplemental figure 3B-C). 
 To investigate whether AZD1775-treated cells try to resist apoptosis, we next studied the 
dynamics of anti-apoptotic proteins MCL-1, BCL-XL, and BXL-2 in response to WEE1 inhibition 
as measured by mitochondrial response for NOXA, HRK, and BAD, respectively (Figure 
1C). A significantly increased mitochondrial response to NOXA was observed in SUDHL-5 
(12%, p=0.0256) and in SUDHL-10 (13%, p=0.0393), indicating increased dependency on 
MCL-1 upon AZD1775 treatment. For cell lines OCI-LY3 and SC-1, a significantly increased 
response was observed for HRK (21%; p=0.0866 and 27%; p=0.0223, respectively), 
demonstrating WEE1 inhibition increased dependency on BCL-XL. Most cell lines showed 
an increased mitochondrial response to BAD upon AZD1775 treatment, which reached 43% 
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in OCI-LY3 (p=0.0195), 20% in U-2932 (ns), 23% in SUDHL-4 (p=0.0317), 11% in SUDHL-6 
(p=0.0223), and 30% in SC-1 (p=0.0540). These results suggest that AZD1775 treatment 
leads to an increased dependency on BCL-2/BCL-XL/BCL-W. Only in cell line SUDHL-2, 
AZD1775 treatment did not induce changes in the anti-apoptotic dependency (Figure 1C), 
despite being relatively sensitive to AZD1775 treatment (Figure 1A). These results suggest 
that perhaps other apoptosis pathways, such as the extrinsic pathway, might be involved 
in the induction of apoptosis in SUDHL-2. Dynamic changes induced by AZD1775 in the 
different DLBCL cell lines showed no significant differences dependent on the GCB or 
ABC-subtype of DLBCL cell lines nor the TP53 status (Supplemental table 1). In conclusion, 
AZD1775 induces cell death through apoptosis, which enhanced the dependency on anti-
apoptotic proteins.
Figure 1. Apoptosis induced by AZD1775 in diffuse large B-cell lymphoma (DLBCL). (A) Cell viability analysis was 
measured with propidium iodide flow cytometry in DLBCL cell lines treated with AZD1775 for 72 h. Data were plotted 
as the mean ± S.D. (n=3). (B) Representative flow cytometry of apoptosis (Annexin V/Propidium iodide) induced by 
treatment of AZD1775 for 18h in representative cell lines SUDHL-10 and SC-1. (C) Mitochondrial response of DLBCL cell 
lines treated with AZD1775 for 18h, plotted as the delta mitochondrial outer membrane permeabilization (ΔMOMP%). 
ΔMOMP% was calculated by subtracting the percentage treated MOMP from percentage untreated MOMP. Cell line 
SUDHL-10 was treated with 0.25 µM AZD1775, cell lines OCI-LY3, U-2932, SUDHL-2, and SUDHL-5 were treated with 
0.5 µM AZD1775 and cell lines SUDHL-4, SUDHL-6, and SC-1 were treated with 1 µM AZD1775. Data were plotted as 
the mean ± S.D. (n=3). Statistical analysis was performed using a one-sample T-test as compared to untreated control 
cells (* p≤0.05).
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DNA Damage and Premature Mitotic Entry Induced by AZD1775 Enhance Anti-
Apoptotic Dependency
WEE1 inhibition by AZD1775 induces both premature mitotic entry [21,22] and DNA damage 
[23] in various types of cancer cells. To confirm that AZD1775 has a similar effect on DLBCL 
cells, we analysed cell cycle distribution and γH2AX expression as a marker for DNA damage 
in the representative MCL-1 dependent cell line SUDHL-10 and the BCL-2 dependent cell 
line SC-1 (Figure 2A). AZD1775 treatment resulted in a dose-dependent increase in the 
percentage of G2/M cells, indicating premature mitotic entry and/or prolonged mitotic arrest 
and a dose-dependent increase of DNA damage (γH2AX positive cells) in both SUDHL-10 
and SC-1 (Figure 2A).
Figure 2. Cellular effect of AZD1775 treatment in DLBCL. (A) Representative examples of flow cytometry cell cycle 
and γH2AX analysis of AZD1775 in SUDHL-10 and SC-1 treated for 18h. (B) Correlation of the mitochondrial response 
(ΔMOMP%) for 10 µM NOXA in SUDHL-10 or 0.1 µM BAD in SC-1 versus the percentage of G1 phase cells treated with 
AZD1775. (C) Correlation of the mitochondrial response (ΔMOMP%) for 10 µM NOXA in SUDHL-10 or 0.1 µM BAD in 
SC-1 versus the percentage of S/G2/M phase cells treated with AZD1775. (D) Correlation of the mitochondrial response 
(ΔMOMP%) of 10 µM NOXA in SUDHL-10 or 0.1 µM BAD in SC-1 versus the percentage of γH2AX cells treated with 
AZD1775. Cells were treated with 0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, or 1.0 µM AZD1775 for 18 h. (E) Representative 
examples of cell cycle flow cytometry and γH2AX analysis in SC-1 treated with 1 µM AZD1775, 50 ng/mL nocodazole, 
and 20 J/m2 UV radiation. (F) Dynamic BH3 profile for 0.3 µM BIM, 10 µM NOXA, 10 µM HRK, and 0.1 µM BAD of SC-1 
cells treated with AZD1775, nocodazole, and (ultra violet) UV radiation. Data were plotted as the mean ± S.D. (n=3). 
Statistical analysis was performed using a one-sample T-test as compared to untreated control cells (* p≤0.05).
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 In addition, dynamic BH3 profiling showed a dose-dependent correlation between 
mitochondrial response to BAD in SC-1 cells treated with AZD1775 and the decrease in 
the percentage of G1 phase cells (R=−0.8544, p=0.0069) (Figure 2B), an increase in the 
percentage of S/G2/M phase cells (R=0.8646, p=0.0056) (Figure 2C), and an increase in 
γH2AX levels (R=0.8383, p=0.0093) (Figure 2D). Similar correlation for response to NOXA 
and G-1 phase cells (R=−0.7817, p=0.0219), percentage of S/G2/M phase cells (R=0.9036, 
p=0.0021), and γH2AX (R=0.8822, p=0.0037) were observed in SUDHL-10. These results 
indicate a potential relation between G2/M cell cycle arrest and increased DNA damage that 
could affect the anti-apoptotic dependency in DLBCL cells.
 Next, we investigated if cell cycle distribution and/or DNA damage could induce 
changes in anti-apoptotic dependency, by exploring the ability of nocodazole to induce cell 
cycle arrest and of ultraviolet radiation (UV) to induce γH2AX (Figure 2E-F and Supplemental 
figure 4) in SC-1 cells. Nocodazole treatment induced an increase in the percentage of cells 
in the G2/M phase and a moderate (6%) increase in γH2AX-positive cells. UV exposure had 
a limited effect on the cell cycle distribution, but induced γH2AX in about 60% of the cells 
(Figure 2E and Supplemental figure 4). Dynamic BH3 profiling revealed that both nocodazole 
and UV exposure induced a significant increase in the mitochondrial response to BIM, of 
24% (p=0.0249) and 45% (p=0.0224), respectively (Figure 2F). Similarly, response levels to 
BAD significantly increased, at 39% (p=0.0027) and 46% (p=0.0307), respectively.
 To further test the hypothesis that WEE1 inhibition induces changes in anti-apoptotic 
dependency as a result of cell cycle changes and DNA damage, we tested the combination 
of AZD1775 together with the CDK1 inhibitor RO3306, CDK4/6 inhibitor palbociclib, and 
CDK1/2 inhibitor roscovitine (Figure 3 and Supplemental figure 4), which has previously 
been shown to rescue AZD1775-induced DNA damage [24,25].
 Treatment of SC-1 cells with the (single agent) roscovitine had little effects on either 
apoptosis levels, the cell cycle, or levels of DNA damage (Figure 3A,B). However, when 
combined with AZD1775, roscovitine significantly reduced DNA damage levels (from 75% 
to 7%, p=0.0024) and largely prevented alterations in cell cycle distribution (Figure 3A,B). 
Treatment with roscovitine alone or in combination with AZD1775 did not lead to an altered 
dynamic BH3 profile, demonstrating that a full rescue of both cell cycle distribution and DNA 
damage prevents anti-apoptotic changes induced by AZD1775 (Figure 3B). In addition, 
we tested CDK1 inhibitor RO3306 (Figure 3A,B and Supplemental figure 5), which rescues 
only AZD1775-induced DNA damage, and CDK4/6 inhibitor palbociclib (Figure 3A,B and 
Supplemental figure 5 and 6), which rescues only AZD1775-induced cell cycle arrest. 
Neither partial rescue of DNA damage (Supplemental figure 4) nor cell cycle distribution 
(Figure 3A) were sufficient to prevent anti-apoptotic changes induced by AZD1775. Based 
on these results, we conclude that both DNA damage and cell cycle disruption induced 
independently changes in the mitochondria and enhanced anti-apoptotic dependency.
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AZD1775 Increases Sensitivity to BCL-2 and MCL-1 Inhibitors in DLBCL
Now that we have established that DNA damage and cell cycle disruption by AZD1775 
(Figure 2) is sufficient to induce intrinsic apoptosis (Supplemental figures 1–3) and 
enhance dependency on anti-apoptotic proteins to prevent apoptosis, we next studied the 
combination of AZD1775 with anti-apoptotic inhibitors. We used SC-1 as a cell line with 
enhanced dependency on BCL-2/BCL-XL/BCL-W, and SUDHL-10 and SUDHL-5 as cell lines 
with enhanced dependency on MCL-1 as predicted by BH3 profiling (Figure 1C). Combined 
treatment of AZD1775 and venetoclax caused a 10-fold decrease in cell viability in SC-1 
(Figure 4A).
 A significant decline in viability from 82% to 26% (p<0.0001) was observed when 0.01 
µM venetoclax was combined with 1 µM AZD1775, resulting in an IC50 decrease from 
0.04 µM in AZD1775-untreated cells to 0.003 µM in AZD1775-treated cells for venetoclax 
(p=0.0039, Figure 4B). In the MCL-1 dependent cell lines SUDHL-10 and SUDHL-5, as 
expected, co-treatment with AZD1775 did not enhance sensitivity to venetoclax. In these cell 
Figure 3. Rescue of AZD1775-induced cellular effects by CDK inhibitors RO3306, palbociclib and roscovitine. 
(A) Representative examples of apoptotic cells, cell cycle, and γH2AX flow cytometry analysis of SC-1 treated with 10 
µM RO3306, 1 µM palbociclib, 15 µM roscovitine, and 1 µM AZD1775 after 18 h of incubation. (B) Dynamic BH3 profile 
for 0.3 µM BIM, 10 µM NOXA, 10 µM HRK, and 0.1 µM BAD of SC-1 cells treated with RO3306, palbociclib, roscovitine, 
and AZD1775 after 18 h of incubation. Delta mitochondrial outer membrane permeabilization (ΔMOMP%) was calculated 
by subtracting the percentage treated MOMP from percentage untreated MOMP. Data were plotted as the mean ± S.D. 
(n=3). Statistical analysis was performed using a one-sample T-test as compared to untreated control cells (* p≤0.05).
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lines, AZD1775 induced enhanced dependency on MCL-1, suggesting cells would become 
more sensitive to MCL-1 inhibitor S63845. 
 Combined treatment of 1 µM AZD1775 and S63845 indeed caused a dose-dependent 
decrease in cell viability in the cell line SUDHL-5 (from 61% to 31% (p=0.0024) at 50 nM 
Figure 4. Combination of AZD1775 and BH3 mimetic drugs in DLBCL cell lines. (A) Cell viability flow cytometry 
data for the cell lines SC-1, SUDHL-5, and SUDHL-10 pre-treated with 1 µM AZD1775 and incubated with increasing 
concentrations of venetoclax. Data were normalized to the control and plotted as the mean ± S.D. (n=4). (B) Venetoclax 
IC50 values as calculated from cell viability curves. Data were plotted as the mean ± S.D. (n=4). (C) Cell viability flow 
cytometry data for SC-1, SUDHL-5, and SUDHL-10 pre-treated with 1 µM AZD1775 and incubated with increasing 
concentrations of S63845. Data were normalized to the control and plotted as the mean ± S.D. (n=4). (D) S63845 IC50 
values as calculated from cell viability curves. Data plotted as the mean ± S.D. (n=4). Statistical analysis was performed 
using a two-tailed paired T-test (* p≤0.05) (** p≤0.01).
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S63845) and in cell line and SUDHL-10 (from 83% to 40% (p=0.0003) at 50 nM S63845) 
(Figure 4C). These changes resulted in a 7-fold decrease in IC50 values for S63845 in 
SUDHL-10 (from 544 to 77 nM, p=0.0658) and a 2-fold decrease in IC50 values for S63845 in 
SUDHL-5 (from 61 to 35 nM, p=0.0028) (Figure 4D). No effect on cell viability was observed 
when AZD1775 was combined with S63845 in SC-1 (Figure 1C). These results confirm that the 
changes observed in dynamic BH3 profiling upon AZD1775 treatment enhance dependency 
on anti-apoptotic proteins, a dependency that can be effectively exploited through targeting 
with the appropriate BH3 mimetic.
AZD1775 Alters the Anti-Apoptotic Dependency of Patient-Derived DLBCL Cells
Finally, we studied anti-apoptotic dependency and the dynamic BH3 profile following 
AZD1175 treatment of lymphoma cells from a DLBCL patient (Supplemental figure 7). 
Efficient apoptotic priming was observed (Figure 5A), and dynamic BH3 profiling (Figure 
5B) showed an increase in the mitochondrial response to BAD (56% at 0.1 µM BAD) but not 
to HRK after AZD1775 treatment, suggesting an increased sensitivity to BCL-2 or BCL-W 
inhibitors, but not to BCL-XL inhibitors.
 These findings were validated by ex vivo treatment of lymphoma cells with AZD1775 at 
increasing concentrations of venetoclax (BCL-2i) or navitoclax (BCl-2i, BCl-Xli, and BCL-Wi). 
Venetoclax did not alter cell viability (Figure 5C), but navitoclax induced a 2-fold decrease 
Figure 5. Dynamic BH3 profile and validation experiments in a DLBCL patient treated with AZD1775. (A) Static 
BH3 profile and (B) dynamic BH3 profile of DLBCL patient cells treated with 0.5 µM AZD1775 for 18 h. Alamethicin and 
PUMA2A were used as positive and negative controls, respectively. Delta mitochondrial outer membrane permeabilization 
(ΔMOMP%) was calculated by subtracting the percentage treated MOMP from percentage untreated MOMP. (C) Cell 
viability flow cytometry data for DLBCL patient cells pre-treated with AZD1775 for 18 h and incubated with increasing 
concentrations of venetoclax and (D) navitoclax for 24 h. Data were normalized to the control.
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in cell viability (Figure 5D), together with a decrease in IC50 from 0.015 µM for navitoclax 
alone to 0.0067 µM for navitoclax combined with AZD1775, indicating a dependency on 
BCL-W. We were unable to study the effect of BCL-W inhibition, as specific BCL-W inhibitors 
are not currently available. Taken together, these data emphasize the potential of AZD1775 
combined with BH3 mimetics in the treatment of DLBCL patients and underscore the clinical 
utility of BH3 profiling.
Discussion
In genomically unstable cancers such as DLBCL, WEE1 is highly expressed and a relevant 
target for therapy. Since the WEE1 inhibitor AZD1775 is indeed effective in inducing 
apoptosis we investigated if it could alter anti-apoptotic dependency and increase sensitivity 
to BH3 mimetic drugs in DLBCL cell lines and patient material. Our findings demonstrate 
that [1] AZD1775 induces cell death through apoptosis; [2] AZD1775-mediated inhibition 
of WEE1 alters the anti-apoptotic dependency in DLBCL; [3] combination of AZD1775 with 
cell-specific anti-apoptotic inhibitors (such as venetoclax) leads to enhanced potency; [4] 
both DNA damage and G2/M arrest induced by WEE1 inhibition independently enhances 
dependency on anti-apoptotic proteins. Based on these results, we propose a model in which 
cell cycle disruption (such as premature mitotic entry or G2/M arrest) and DNA damage can 
induce changes in the mitochondrial response, resulting in an altered dependency on anti-
apoptotic proteins in DLBCL cells (Figure 6).
 In normal B-cell development, dependency on anti-apoptotic proteins changes during 
B-cell maturation. Naïve B-cells are dependent on BCL-2, GC B-cells shift to dependency 
on MCL-1, memory B-cells are once more dependent on BCL-2, while plasma cells depend 
Figure 6. Proposed mechanism for the relation between inhibition of cell cycle regulator WEE1 and the resistance 
of apoptosis. As a result of WEE1 inhibition cells are able to prematurely enter mitosis, without proper repair of genomic 
aberrations or mutations. This elimination of the checkpoint at the transition from the G2-phase into the M-phase leads to 
continuous cell cycling and results in high levels of DNA damage that activate apoptosis pathways. To prevent apoptosis, 
cancerous cells become increasingly dependent on anti-apoptotic proteins such as BCL-2, MCL-1, BCL-XL, and BCL-W, 
which ensure survival under high levels of genomic stress.
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on BCL-XL [26]. The t(14;18) IGH-BCL-2 translocation, found in ~20% of DLBCL patients, 
is a hallmark of follicular lymphoma and is more commonly found in the germinal centre 
derived-DLBCL subtype [14,27]. BCL-W has a potentially important role in B-cell survival, as 
overexpression of the BCL-W gene is associated with a worse prognosis in specific DLBCL 
cases [28]. Using baseline BH3 profiles and sensitivity to BH3 mimetic drugs, we showed 
that DLBCL cell lines are dependent on multiple anti-apoptotic proteins. These associations 
showed no direct relationship to the cell of origin, thus highlighting the heterogeneity of 
DLBCL.
 To date, the primary application of dynamic BH3 profiling has been measurement 
of responses to chemotherapy [17]. Here, we were able to accurately predict changes 
in anti-apoptotic dependency profiles as a result of WEE1 inhibition by AZD1775. These 
dependencies changed both quantitatively and qualitatively. For example, dynamic BH3 
profiling highlighted interesting shifts in dependency, such as the shift to dependency 
on BCL-XL after AZD1775 treatment of the previously BCL-XL independent SC1 cell line. 
This shows that tumour cells can shift their dependency from one anti-apoptotic protein 
to another. Unfortunately, current multiple anti-apoptotic protein inhibitors, including those 
targeting BCL-XL such as navitoclax, are poorly tolerated and have significant side effects 
[29]. Inhibition of BCL-XL also shortens platelet lifespan [30], hampering use of these agents. 
Nevertheless, as tumour cells appear able to use and adapt their dependency to multiple anti-
apoptotic proteins, there is clearly a need for new, tolerated multi-target inhibitors in order to 
prevent resistance and relapse in DLBCL patients. Our results demonstrate the broad range 
of effects of AZD1775 on cellular states, including the ability to influence apoptotic pathways, 
clearly highlighting potential therapeutic targets. It can be argued that analyses of protein 
levels by western blot or immunohistochemistry, perhaps including RNA expression levels, 
are suboptimal approaches when determining the anti-apoptotic dependency of tumour 
cells. By contrast, static BH3 profiling of cell lines or primary patient samples has proven 
itself as a fast and reliable tool to establish the functionality of and dependency on anti-
apoptotic proteins.
 Treatment of solid cancers [11] and leukaemia [12,13] with inhibitors of the cell cycle 
regulator WEE1 has proven successful in early clinical trials, as WEE1 inhibitors result in 
cell cycle disruption [21,22], induction of DNA damage [23,31] and eventually, induction of 
apoptosis. Our data highlighted a novel effect of WEE1 inhibition, an altered dependency on 
anti-apoptotic proteins. Rescue experiments preventing either DNA damage and/or G2/M 
cell cycle arrest after WEE1 inhibition showed that both events are able to induce changes 
in anti-apoptotic dependency, either individually or in combination. Mitochondrial fission at 
mitosis is known to be tightly regulated by the CDK1-cyclinB complex, which phosphorylates 
the GTPase Drp1 and thus induces mitochondrial fragmentation to promote mitochondrial 
fission [32,33]. Loss of Drp1 results in dysfunctional mitochondrial fission, persistent 
mitochondrial hyperfusion, delayed G2/M cell cycle progression, replication stress, DNA 
damage, ATM activation, and genomic instability [34]. Since WEE1 is the main regulator of 
the CDK1-cyclinB complex, loss of WEE1 will induce premature mitochondrial fragmentation, 
destabilizing the connection between cell cycle division and mitochondrial homeostasis. 
Similarly, activation of the DNA damage response protein ATM in response to double-
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stranded DNA breaks results in phosphorylation of the BH3 activator protein BID, initiating 
DNA damage-induced apoptosis [35]. Here, we show a novel direct link between the cell 
cycle, DNA damage and mitochondrial apoptosis, in which either premature mitotic entry or 
DNA damage induced by WEE1 inhibition alters anti-apoptotic dependency. Although this 
mechanism was not tested in other cancer types, based on the fundamental role of WEE1 in 
cell cycle regulation we expect a similar association and response in other cell types. With 
the current development of BH3 mimetics, WEE1 inhibition would be an excellent candidate 
for dose reduction combination therapy in treatment-naïve patients, or could be applied as a 
BH3 mimetic sensitizer in WEE1 inhibitor-resistant tumours.
 In conclusion, we demonstrated for the first time that WEE1 inhibition in DLBCL can 
lead to further sensitization to anti-apoptotic inhibitors, revealing a novel mechanism and 
as yet unexplored application for WEE1 inhibition. Using cell cycle and DNA damage 
rescue experiments, we unraveled the mechanism underlying changes in anti-apoptotic 
dependency, highlighting mechanisms that may have applications in the treatment of other 
cancers. These findings suggest important applications for WEE1 as a novel therapeutic 
treatment approach, but also suggest broader possibilities for genotoxic drugs, cell cycle 
deregulators, or DNA damage response inhibitors in combination with BH3 mimetic drugs. 
Finally, we showed that combining WEE1 inhibition with dynamic BH3 profiling represents 
an educated approach to guided therapy, and may lead to novel strategies in optimized/
personalized treatment selection in DLBCL patients.
Conclusions
In conclusion, we demonstrate that treatment of cells with WEE1 inhibitor AZD1775 can 
enhance the dependency on anti-apoptotic proteins and enhanced sensitivity to BH3 
mimetic drugs. In addition, we showed that DNA damage and cell cycle arrest independently 
induce similar changes in the anti-apoptotic dependency. Therefore, we predict that other 
DNA damage-inducing of cell cycle arresting agents will synergize with BH3 mimetic drugs.
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Supporting information
Supplemental Table 1. Characteristics of DLBCL cell lines. Characteristics of the DLBCL cell lines and their cell of 
origin (COO), IC50 value for AZD1775, TP53 mutation status and cytogenetic profile (DSMZ/ATCC).








Cytogenetics (DSZM or ATCC)
OCI-LY3 ABC 0.68 WT x Human flat-moded hypertriploid karyotype; 
72-77<3n>XXYY, +1, +9, -10, +13, +14, -17, 





t(14;19), dup(20)(q11q13)x2; sdl with der(6)
t(6;12)(p21;q21), der(7)t(5;7)(?p15;p24) etc; 
resembles published karyotypes; carries cryptic 
t(14;19) with rearrangement of IGH and SPIB, 
and t(4;18) with copy number amplification of 
the BCL2 region.
U-2932 ABC 1.02 MUT c.527G>A Human polyclonal hypodiploid karyotype 







(q13); sdl with del(2)(q11), t(4;15)(q22;q14), 
add(7)(q21), del(13)(?q21), der(13)add(13)
(p11)add(13)(q32); extensive genomic 
amplification of BCL2 region; resembles 
published karyotype.
SUDHL-2 ABC 0.42 MUT c.701A>C Most of these cells were hyperdiploid, with 
a sharp modal number of 51 chromosomes; 
occasional cells in the hypertetraploid range 
were also seen. A minute marker chromosome 
was consistently observed, and increased 
numbers of chromosomes were seen in the A, 
B, C, and F groups.
SUDHL-4 GCB 0.99 MUT c.817C>T Human hyperdiploid karyotype with 4% 
polyploidy - 50(47-51)<2n>XY/XXY, -3, +7, +8, 




t(14;18)(q32.3;q21.1) - carries t(14;18) effecting 
BCL2(MBR)-IGH fusion - matches published 
karyotype.
SUDHL-5 GCB 0.81 WT x Human hyperdiploid karyotype with 1.5% 
polyploidy - 47(41-48)<2n>XX, +12, del(6)
(q13), del(12)(q13) - sideline with del(6)x2 - 
matches published karyotype.
SUDHL-6 GCB 1.42 MUT c.701A>G Human hyperdiploid karyotype with 2% 
polyploidy - 47(42-48)<2n>X, -Y, +6, +7, 




- sideline with dic(8;9)(q24;p13), ider(8)(q10)
t(8;9(q24;p13) - matches published karyotype - 
carries t(14;18) effecting IGH-BCL2 fusion.
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Supplemental Table 1 continued.








Cytogenetics (DSZM or ATCC)
SUDHL-10 GCB 0.79 MUT c . 9 9 4 -
1G>C





- carries concurrent rearrangements of IGH 
with MYC and BCL2 - resembles published 
karyotype.
SC-1 GCB 0.83 WT x Human hyperdiploid karyotype with 4% 
polyploidy - 47(43-48)<2n>XY, +7, -17, +mar, 
add(3)(q27), t(8;14;18)(q24;q32;q21), add(14)
(q32) - carries 3-way t(8,14,18) effecting 
genomic co-amplification of BCL2 and MYC - 
resembles published karyotype.
Supplemental Table 2. BH3 treatment schedule for DLBCL cell lines. Schematic overview of the treatment schedule 
applied to the DLBCL cell lines in order to establish the effect of AZD1775 on anti-apoptotic dependency via dynamic 
BH3 profiling.
Cell line AZD1775 
(µM)
BIM (µM) NOXA 
(µM)
HRK (µM) BAD (µM)
OCI-LY3 0.5 0.1 10 10 0.1
U-2932 0.5 0.1 10 10 0.1
SUDHL-2 0.5 0.1 10 10 10
SUDHL-4 1 0.1 10 10 0.1
SUDHL-5 0.5 0,1 10 10 10
SUDHL-6 1 0.03 10 10 1
SUDHL-10 0.25 0.1 10 10 10
SC-1 1 0.3 10 10 0.1
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Supplemental Figure 1. Gene expression levels of WEE1 in multiple cancer types. Plotted is the factor of tumor 
tissue / representative normal tissue gene expression for WEE1 across multiple types of cancers. Cancers included 
are adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), 
cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangio carcinoma (CHOL), colon 
adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBCL), esophageal carcinoma (ESCA), glioblastoma 
multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear 
cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (AML), brain lower grade 
Glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma 
(LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), 
pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), 
sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors 
(TGCT), thyroid carcinoma (THCA), Thymoma (THYM), uterine corpus endometrial Carcinoma (UCEC), uterine 
carcinosarcoma (UCS) and uveal melanoma (UVM). Data was acquired from the online available GEPIA database 
(gepia.cancer-pku.cn).
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Supplemental Figure 2. Time and dose-dependent induction of apoptosis by AZD1775 in DLBCL. Flow cytometry 
analysis of early apoptosis (Annexin V positive/Propidium iodide negative) and late apoptosis (Annexin V positive/
Propidium iodide positive) in cell lines SUDHL-10, SC-1 and U-2932 treated with AZD1775 ± 20 µM caspase inhibitor 
QVD for 18, 24 or 48 h. Plotted is the mean of n=3.
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Supplemental Figure 3. Dose-response effect of AZD1775 on mitochondrial outer membrane permeabilization. 
(A) Dynamic BH3 profile of cell lines SUDHL-10 and SC-1 cell line treated with an increasing concentration of AZD1775 
for 18 h. Delta mitochondrial outer membrane permeabilization (ΔMOMP%) for 10 µM NOXA for cell line SUDHL-10 and 
0.1 µM BAD for cell line SC-1 was calculated by subtracting the percentage treated MOMP from percentage untreated 
MOMP. Data were plotted as the mean ± S.D. (n=3). Statistical analysis was performed using a one-sample T-test 
as compared to untreated control cells (*p≤0.05). (B) Flow cytometry analysis of early apoptosis (Annexin V positive/
Propidium iodide negative) and late apoptosis (Annexin V positive/Propidium iodide positive) in cell lines SUDHL-10 and 
SC-1 treated with AZD1775 ± 20 µM caspase inhibitor QVD for 18 h. Plotted is the mean of n=3. (C) Correlation of the 
ΔMOMP% for 10 µM NOXA in SUDHL-10 and 0.1 µM BAD in cell line SC-1 and the percentage of early apoptotic cells 
(Annexin V positive/Propidium iodide negative) after 18 h of AZD1775 treatment.
Supplemental Figure 4. DNA damage induced by AZD1775, nocodazole or UV treatment. Percentage of yH2AX 
positive cells after treatment of cell line SC-1 with 1 µM AZD1775, 50ng/mL nocodazole or 20 J/m2 after 18 hours of 
incubation. Data were plotted as the mean ± S.D. (n=3). Statistical analysis was performed using a two-tailed paired 
T-test comparing treatment to control (*p≤0.05) (**p≤0.01).
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Supplemental Figure 5. DNA damage induced by AZD1775 alone or combined with CDK inhibitors. Percentage of 
yH2AX positive cells after treatment of cell line SC-1 with 10 µM RO3306, 1 µM palbociclib, 15 µM roscovitine and 1 µM 
AZD1775 after 18 h of incubation. Data were plotted as the mean ± S.D. (n=3). Statistical analysis was performed using 
a two-tailed paired T-test comparing treatment to control (*p≤0.05) (**p≤0.01).
Supplemental Figure 6. Correlation of dynamic BAD BH3 profile and γH2AX after Palbociclib and AZD1775. (A) 
Correlation of the (ΔMOMP%) for 0.1 µM BAD versus the percentage of γH2AX cells in cell line SC-1 cells treated with 
AZD1775 and palbociclib for 18 h.
Supplemental Figure 7. DLBCL patient characteristics. (A) Flow cytometry analysis of bone marrow aspirate. (B) 
Smear of bone marrow aspirate and (C) enlarged image of bone marrow aspirate smear. Depicted DLBCL patient 
sample contains 60% CD10+/CD19+/CD45+ monoclonal lymphoid B-cells.
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Abstract
Expression of the anti-apoptotic B-cell lymphoma 2 (BCL-2) protein in patients with diffuse 
large B-cell lymphoma (DLBCL) strongly correlates with resistance to standard therapy 
with cyclophosphamide, vincristine, doxorubicin, prednisolone, and rituximab (R-CHOP). 
Although studies focus mainly on the contribution of BCL-2, here we also investigate 
the contribution of other anti-apoptotic proteins to CHOP-therapy resistance in DLBCL. 
Functional dynamic BCL-2 homology (BH)3 profiling was applied to DLBCL cell lines upon 
CHOP treatment or single CHOP compounds. Cell-specific anti-apoptotic dependencies 
were validated with corresponding BH3-mimetics. We found high expression of anti-
apoptotic BCL-2, MCL-1, and BCL-XL in DLBCL cell lines and patients. CHOP treatment 
resulted in both enhanced and altered anti-apoptotic dependency. Enhanced sensitivity to 
different BH3-mimetics after CHOP treatment was confirmed in specific cell lines, indicating 
heterogeneity of CHOP-induced resistance in DLBCL. Analysis of single CHOP compounds 
demonstrated that similar changes could also be induced by doxorubicin or vincristine, 
providing evidence for clinical combination therapies of doxorubicin or vincristine with BH3-
mimetics in DLBCL. In conclusion, we show for the first time that CHOP treatment induces 
increased anti-apoptotic dependency on MCL-1 and BCL-XL, and not just BCL-2. These 
results provide new perspectives for the treatment of CHOP-resistant DLBCL and underline 
the potential of BH3 profiling in predicting therapy outcomes.
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Introduction
The B-cell lymphoma 2 (BCL-2) family of proteins is a group of pro- and anti-apoptotic 
proteins with key roles in the regulation of intrinsic apoptosis. Proteins of the BCL-2 family 
share a general structure of one or more BCL-2 homology (BH) domains, of which expression 
of the BH3 domain is a universally shared feature. Expression of this BH3 domain is essential 
for protein-protein interactions, thereby allowing dimerization of pro-apoptotic sensitizer 
proteins (e.g., BAD, NOXA and HRK) with anti-apoptotic proteins (e.g., BLC-2, BCL-XL, 
MCL-1 and BCL-W). This interaction leaves the pro-apoptotic activator proteins (e.g., BID 
and BIM) free to interact with the effector proteins (e.g., BAX and BAK) to induce pore 
formation and cytochrome c release from the mitochondria, thus promoting apoptosis [1]. 
Dysregulated expression of several important anti-apoptotic proteins, such as BCL-2, plays 
a crucial role in carcinogenesis and anti-cancer therapy resistance [2]. The specific anti-
apoptotic dependency in a particular cancer cell is often unknown, and cancer cells may 
adapt their anti-apoptotic dependencies when exposed to particular apoptosis-inducing 
therapies (e.g., chemotherapy) to further facilitate therapy resistance [3].
 In diffuse large B-cell lymphoma (DLBCL), overexpression of the anti-apoptotic protein 
BCL-2 is correlated with adverse survival in patients treated with standard rituximab, 
cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) [4]. In DLBCL 
patients, BCL-2 is commonly overexpressed due to either a t(14;18) chromosomal translocation 
or to BCL-2 amplification or transcriptional upregulation. The t(14;18) translocation is more 
common, at 20%–30% of cases, in the germinal center (GCB) molecular subtype, whereas 
BCL-2 amplification is found in 8%–30% of the activated B-cell (ABC) subtype [5,6].
 Inhibition of the anti-apoptotic activity of BCL-2 has been suggested as a promising 
strategy for treatment [7], however, a single-agent phase I study of the specific BCL-2 inhibitor 
venetoclax in relapsed or refractory DLBCL reported limited efficacy [8]. On the other hand, 
promising results, including an overall response of 87.5% and a complete response (CR) 
of 79.2%, were reported in a phase I trial of venetoclax combined with R-CHOP as first-line 
treatment in non-Hodgkin lymphomas, including DLBCL [9]. However, other studies have 
reported that apoptotic resistance in DLBCL can be acquired through proteins other than 
BCL-2 [10]. Analysis of primary DLBCL patient samples treated with BH3 mimetic drugs 
(BCL-2 inhibitor and MCL-1 inhibitor) showed that patients could be subdivided into BCL-
2-sensitive or MCL-1-sensitive subgroups [10]. However, the effect of standard (prolonged) 
CHOP treatment itself on DLBCL-specific pro- and anti-apoptotic signaling is currently 
unknown. To this end, we studied the effect of CHOP therapy on anti-apoptotic dependency 
in DLBCL using functional dynamic BH3 profiling [11]. By employing functional dynamic 
BH3 profiling, we compared the profiles of eight DLBCL cell lines before and after CHOP 
treatment and thus determined the change in dependency on anti-apoptotic proteins. Our 
results showed that CHOP resistance is not exclusively mediated through BCL-2, but by 
multiple other anti-apoptotic proteins. These results highlight the heterogeneity of anti-
apoptotic dependency in DLBCL, which likely depends on other anti-apoptotic proteins in 
154 | Chapter 7
addition to BCL-2. These results could have implications for clinical trials evaluating efficacy 
of BH3 mimetics.
Materials and Methods
Cell Lines and Culture Conditions
The DLBCL cell lines U-2932, SUDHL-2, SUDHL-4, and SC-1 were cultured in suspension in 
Roswell Park Memorial Institute medium 1640 (RPMI 1640; Lonza BioWhittaker, Walkersville, 
MD, USA) with 10% fetal bovine serum (FBS; HyClone Thermo Scientific, Waltham, MA, 
USA), 1% penicillin-streptomycin (PS; Lonza BioWhittaker) and 1% glutamine (Lonza 
BioWhittaker). The DLBCL cell lines OCILY3, SUDHL-5, SUDHL-6, and SUDHL-10 were 
cultured in suspension in RPMI 1640 with 20% FBS, 1% PS, and 1% glutamine. All cell lines 
were cultured at 37 °C with 5% CO2 in a humidified atmosphere. Cell lines were obtained 
from ATCC and DSMZ. The identity of our cell lines was checked on a regular basis. Cell of 
origin (COO), BCL-2, and MYC status was based on data from ATCC and DSMZ.
Patient Material
Patient material was used from 55 DLBCL patients with primary DLBCL, including most 
subtypes. Material was acquired in accordance with international regulations and professional 
guidelines (the Declaration of Helsinki and the International Conference on Harmonization 
Guidelines for Good Clinical Practice). Material used in this project (RR#201800551, 1 
November 2018) was obtained from anonymous rest material. The medical ethics review 
board (Central Ethics Review Board non-WMO studies, University Medical Center Groningen 
(UMCG)) waives the need for approval if rest material is used, under the law in the Netherlands 
and waives the need for informed consent when patient anonymity is assured.
Immunohistochemistry (IHC)
IHC was performed with antibodies against BCL-2 (M0887, Dako, Glostrup, Denmark), BCL-
XL (SC7195, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and MCL-1(A3534, Dako, 
Glostrup, Denmark) on paraffin-embedded tissue sections after antigen retrieval (pH 6, pH 
9, and pH 6, respectively). Staining was visualized using HRP-labeled secondary antibodies 
(Dako) and 3,3’-diaminobenzidine (Sigma–Aldrich, St Louis, MO, USA). Appropriate positive 
and negative controls were performed for each staining. The cases were stained and scored 
on a tissue micro-array (TMA). In the TMA, each case was represented by three tissue cores.
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Compounds
The BCL-2 inhibitor venetoclax (#S8048, Houston, TX, USA), the BCL-2/BCL-XL/BCL-W 
inhibitor navitoclax (#S1001), and the MCL-1 inhibitor S63845 (#S8383) were all acquired 
from Selleckchem. CHOP chemotherapy consisted of cyclophosphamide (University 
Medical Center Groningen (UMCG) pharmacy, Groningen, the Netherlands), doxorubicin 
(#S1208, Selleckchem, Houston, TX, USA), vincristine (UMCG pharmacy, Groningen, the 
Netherlands), and prednisolone (#S1737, Selleckchem), in a composition set at the clinical 
ratio of 83/5.5/0.16/11.1, respectively [12].
BH3 Profiling-Plate-Based Assay
BH3 profiling is a method to functionally characterize the interplay between anti- and pro-
apoptotic proteins for a particular cell line by employing a panel of pro-apoptotic BH3 domain 
peptides to measure specific anti-apoptotic protein reactions. Upon treatment with these 
peptides, the mitochondrial outer membrane response can be measured by cytochrome c 
release from the mitochondria using flow cytometry or as the altered mitochondrial membrane 
potential by measuring fluorescence emission of the JC-1 dye in a plate-based assay [3]. The 
BIM peptide is a pro-apoptotic activator protein that reacts with multiple anti-apoptotic BH-3 
proteins and can be used to establish whether cells are able to undergo intrinsic apoptosis 
[11]. To determine the specific anti-apoptotic dependency of a DLBCL cell line, we looked 
at the mitochondrial response of cells to the pro-apoptotic sensitizers BAD, HRK, NOXA, 
or MS1. Cells dependent on anti-apoptotic BCL-2 will release cytochrome c in response 
to the BAD peptide, which interacts with BCL-2, BCL-XL, and BCL-W, but not HRK (which 
interacts only with BCL-XL). If cells are dependent on BCL-XL, cytochrome c release will be 
observed in response to both BAD and HRK peptides. Cells dependent on anti-apoptotic 
MCL-1 will show a response to NOXA and MS1.In order to establish the effect of CHOP with 
BH3, profiling cells were incubated at a density of 1.0 × 106 cells/mL for 18 h with CHOP. 
After incubation, cells were washed in mannitol experimental buffer (150 mM D-mannitol 
(M9647 Sigma–Aldrich, 3050 Spruce St., St. Louis, MO, USA), 10 mM HEPES (H3375 
Sigma–Aldrich), 50 mM KCl (1.04936 Merck KGaA, Darmstadt, Germany), 20 nM EGTA 
(E4378 Sigma–Aldirch), 20 nM EDTA (11280, Serva Electrophoresis GmbH, Carl-Benz-Str. 
7, Heidelberg, Germany), 0,1% bovine serum albumin (BSA) (11930 Serva Electrophoresis 
GmbH), 5 mM succinate (1.00682 Merck KGaA) dissolved in dH2O, pH 7.5 (MEB)) and 
resuspended at 3.2 × 106 cells/mL in MEB. The cell suspension was mixed 1:1 with 4 µM 
JC-1 permeabilization/staining solution (ENZ-52304, Enzo Life Sciences, 10 Executive Blvd., 
Farmingdale, NY 11735, USA), 0.004% digitonin (1500 643, Boehringer Mannheim GmbH, 
Mannheim, Germany), 20 mM β-mercaptoethanol (8.05740 Merck KGaA), and 40 µg/mL 
oligomycin (O4876, Sigma–Aldrich) prepared in MEB) and incubated at room temperature 
for 10 min in the dark. BIM, PUMA, BAD, NOXA, HRK, BMF, and PUMA2A (JPT Peptide 
Technologies GmbH, Volmerstrasse, Berlin, Germany) were prepared in MEB in a black flat-
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bottom non-treated polystyrene 96-well plate (3915 Costar, Corning Incorporated, 2 Alfred 
Road, Kennebunk, ME, USA). Peptide sequences used for the assay were identical to those 
described by Ryan and Letai ([13]). Plates were either used directly or sealed (Silverseal 
sealer, ref 676090, Greiner-Bio-One GmbH, Mayback Str., Frickenhausen, Germany), frozen 
at −80 °C and thawed for one hour at room temperature before use. Cells in permeabilization/
staining solution were added to the plate 1:1 at a final volume of 100 µL and shaken for 15 s, 
followed by measurement of fluorescence (excitation 545 nm, emission 590 nm) every 5 min 
for 2 h at 30 °C (Varioskan). All experiments were performed in triplicate or quadruplicate. 
Area under the curve (AUC) was calculated as the percentage mitochondrial outer membrane 
permeabilization (MOMP) and normalized to PUMA2A (negative control) and FCCP (positive 
control) with the formula: 
 1 − ((AUC sample − AUC FCCP) ÷ (AUC PUMA2A − AUC FCCP)) × 100%      (1)
 The dynamic BH3 profile (ΔMOMP) was calculated by subtracting the percentage treated 
MOMP from the percentage untreated MOMP. BH3 profiling with a mean ΔMOMP ≥ 20% 
were classified as biologically relevant, even if they were not always statically significant, as 
they often lead to significant enhanced sensitivity to BH3 mimetic drugs, indicating biological 
relevance.
Flow Cytometry—Cell Viability for IC50
For cell viability analysis, 0.2 × 106 cells/mL were treated for the appropriate times, washed 
with 1% BSA/PBS and resuspended in propidium iodide solution (P4170, Sigma). Samples 
were processed on a BD FACSCalibur 2 and analyzed with ModFit LT (Verity Software House, 
version 4.1.7, Topsham, ME , USA). Experiments were performed three times.
Resazurin—Metabolic Viability for Combination Therapies
After treatment of 0.4 × 106 cells/mL, 1/20th of the total volume of resazurin (AlamarBlue, 
Thermo Fisher Scientific, Waltham, MA, USA) was incubated for nine hours prior to read-out 
(Varioskan, excitation 560 nm, emission 590 nm). Experiments were performed 3 times.
Western Blot
Western blot was performed as previously described ([14]). Primary antibodies used were 
anti-BIM (1:1000, #2933 (C34C5) Cell Signaling Technology, Danvers, MA, USA), anti-
MCL-1 (1:1000, #5453 (D35A5) Cell Signaling Technology), anti-BCL-2 (1:1000, ab32124 
(E17), Abcam, Cambridge, United Kingdom), and anti-BCL-XL (1:1000, #2764 (54H6) Cell 
Signaling Technology).
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Statistical Analysis 
Data were analyzed using Graphpad PRISM (version 5.0, GraphPad Software, San Diego, 
CA, USA) software and tested for significant differences with a paired T-test. Correlation 
was analyzed using Spearman’s correlation. Combination index (CI) was calculated using 
the Chou-Talalay method and CompuSyn software (ComboSyn Inc, NJ, USA). * indicates 
p≤0.05, ** indicates p≤0.01, and *** indicates p≤0.001.
Results
DLBCL Cells are Dependent on BCL-2 or MCL-1, but Not BCL-XL
BCL-2 protein overexpression is an important predictive and prognostic marker in DLBCL 
patients [4]. We first validated the importance of different anti-apoptotic BCL-2 family protein 
expression in our representative DLBCL cell line panel with different genetic backgrounds 
(5 GCB and 3 ABC) and correlated anti-apoptotic protein expression to their functional anti-
apoptotic dependency as determined by BH3 profiling (Figures 1, S1, and S2).
 All DLBCL cell lines showed protein expression of apoptotic activator BIM, indicating 
that cells are capable of undergoing apoptosis (Figure 1B). Variable protein expression of 
anti-apoptotic proteins MCL-1, BCL-XL, and BCL-2 was observed in the DLBCL cell lines, 
indicating that cells employed different and/or multiple anti-apoptotic proteins to protect from 
apoptosis. In most cases, cells with acquired translocation or amplification of the BCL-2 
protein showed high expression of BCL-2, with the exception of cell line SUDHL-10, which 
showed high expression of MCL-1 instead (Figure 1A–B). Next, we performed BH3 profiling 
to determine the intrinsic functional dependency of cells on specific anti-apoptotic proteins 
(Figures 1C and Supplemental figure 1). BH3 profiling revealed that all cells showed a strong 
response to the BIM peptide (min 71%; max 95%), which confirms previous results for BIM 
protein expression (Figure 1B). In addition, cell lines with high BCL-2 protein expression 
showed a mitochondrial response to the BAD peptide (min 30%; max 93%), indicating 
functional dependency on BCL-2. Cell lines SUDHL-5 and SUDHL-10, which were not 
dependent on BCL-2, instead showed high response to the NOXA/MS1 peptides (min 17%; 
max 68%), indicating functional MCL-1 dependency, which matches with relatively high 
MCL-1 protein expression (Figure 1B). Together, these data demonstrate that DLBCL cells 
were either exclusively dependent on BCL-2 or MCL-1, but not on BCL-XL or multiple anti-
apoptotic proteins simultaneously, despite expression of multiple anti-apoptotic proteins.
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DLBCL Patients Show Simultaneous Expression of BCL-2, BCL-XL, and MCL-1
To validate that, like the DLBCL cell lines, DLBCL patients also show simultaneous expression 
of BCL-2, BCL-XL, and MCL-1, we performed immunohistochemistry staining on 55 DLBCL 
patient tissues (Table 1 and Figure 2).
 Staining for the anti-apoptotic proteins revealed 34/55 patients (62%) stained positive 
for BCL-2, 55/55 (100%) stained positive for BCL-XL, and 52/55 (95%) stained positive for 
MCL-1. In addition, one case (2%) was positive for only one anti-apoptotic protein (BCL-XL), 
22 cases (40%) were positive for two out of three anti-apoptotic proteins, and 32 cases (58%) 
were positive for all three anti-apoptotic proteins. Of the BCL-2 negative cases, 21/21 (100%) 
were positive for BCL-XL and 20/21 (95%) were positive for MCL-1 (Table 1 and Figure 2A–
C). A similar trend was observed in the BCL-2 positive cases, of which 33/34 (97%) stained 
positive for BCL-XL and 32/34 (94%) were positive for MCL-1 (Table 1 and Figure 2D–F). 
Together, these data demonstrate that there are high levels and simultaneous expression of 
the multiple anti-apoptotic proteins, which strongly mirror our findings in the DLBCL cell lines.
Figure 1. Expression and dependency on anti-apoptotic proteins in diffuse large B-cell lymphoma (DLBCL) cell lines. 
Overview of eight DLBCL cell lines with their (A) cell of origin (COO) classification, and translocation (TRANS) or 
amplification (AMP) status for B-cell lymphoma 2 (BCL-2) or MYC. (B) Protein expression of anti-apoptotic proteins 
encoded by BIM, MCL-1, BCL-XL and BCL-2. (C) BCL-2 homology (BH)3 profile peptide response as measured by 
mitochondrial outer membrane permeabilization (MOMP) (n=3). Values marked in red were below 10% MOMP 
and therefore classified as unresponsive, whereas values marked in green were above 10% MOMP and classified 
as responsive. (D) The half maximal inhibitory concentration (IC50) values for venetoclax (BCL-2i; 48 h), navitoclax 
(BCL-2/XL/Wi; 48 h), S63845 (MCL-1i; 48 h) and cyclophosphamide, vincristine, doxorubicin, prednisolone (CHOP) 
chemotherapy (72 h) (n=3). IC50 values below 1 µM (for venetoclax, navitoclax, or S63845) or below 5 µg/mL (for CHOP) 
were deemed sensitive and marked in red, whereas values above 1 µM (for venetoclax, navitoclax, or S63845) or above 
5 µg/mL (for CHOP) were deemed insensitive and therefore marked in green.
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Table 1. Immunohistochemistry of BCL-2, BCL-XL and MCL-1 in DLBCL patients (n = 55).
DLBCL cases BCL-2 Negative (n = 21) BCL-2 Positive (n = 34)
BCL-XL negative 0/21 (0%) 1/34 (3%)
BCL-XL positive 21/21 (100%) 33/34 (97%)
MCL-1 negative 1/21 (5%) 2/34 (6%)
MCL-1 positive 20/21 (95%) 32/34 (94%)
BCL-2 Expression Predicts Sensitivity to Venetoclax and CHOP
Next, we correlated the intrinsic functional anti-apoptotic dependency of our cells to the 
sensitivity for anti-apoptotic inhibitors venetoclax (BCL-2i), S63845 (MCL-1i), navitoclax 
(BCL-2/BCL-XL/BCL-Wi), and CHOP chemotherapy (Figure 3).
 We found a negative correlation between venetoclax IC50 and the BAD response 
(R=−0.810; p=0.022) (Figure 3A), but not for navitoclax and BAD response (R=−0.575; 
p=0.143) (Figure 3B), indicating that a high BAD response is predictive of a low venetoclax 
IC50 and thus high sensitivity to BCL-2 inhibition. This discrepancy between venetoclax and 
navitoclax is likely caused by the individual potency of the inhibitors, as venetoclax has 
a very high sensitivity for BCL-2 (Ki <0.01 nM) compared to navitoclax (Ki ≤ 0.5 nM for 
BCL-XL and Ki ≤ 1 nM for BCL-2). On the other hand, cell lines with low or absent BCL-2 
protein expression (SUDHL-2, SUDHL-5, and SUDHL-10) had a significantly higher IC50 for 
Figure 2. Immunohistochemistry staining for BCL-2, MCL-1, and BCL-XL in DLBCL. (A) Representative example 
of a BCL-2 negative DLBCL patient with positive staining for MCL-1 (B) and BCL-XL (C). (D) Representative example of 
a BCL-2 positive DLBCL patient with positive staining for MCL-1 (E) and BCL-XL (F). All images were captured at 200× 
magnification.
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venetoclax (median IC50 11 µM) compared to cell lines with high BCL-2 protein expression 
(OCI-LY3, U-2932, SUDHL-4, SUDHL-6, and SC-1; median IC50 for venetoclax of 0.17 µM; 
p=0.0004) (Figures 1D and Supplemental figure S3A). In addition, functional BH3 profiling for 
NOXA (R=−0.903; p=0.005) and MS1 (R=−0.756; p=0.041) showed a strong correlation with 
sensitivity to S63845 (Figure 3C–D), whereas no correlation could be established between 
the S63845 sensitivity and MCL-1 protein expression (Supplemental figure 3C). 
Figure 3. Correlation between BH3 response to BAD, NOXA, and MS1 peptides and sensitivity to anti-apoptotic 
inhibitors venetoclax (BCL-2i), navitoclax (BCL-2/XL/Wi), S63845 (MCL-1i), and CHOP chemotherapy in DLBCL 
cell lines. (A) Correlation between venetoclax IC50 versus BAD peptide response (%MOMP). (B) Correlation between 
navitoclax IC50 versus BAD peptide response (%MOMP). (C) Correlation between CHOP IC50 versus BAD peptide 
response (%MOMP). (D) Correlation between S63845 IC50 versus NOXA peptide response (%MOMP). (E) Correlation 
between S63845 IC50 versus MS1 peptide response (%MOMP). (F) Correlation between CHOP IC50 versus NOXA 
peptide response (%MOMP). Data were plotted as the mean of n = 3. Correlation was analyzed using Spearman’s 
correlation. Cell lines without a ‘double hit’ (MYC/BCL2) status are represented by open symbols () and cell lines with 
a ‘double hit’ status by closed symbols (). Cell lines with the highest BCL-2 protein expression (U-2932 and SC-1) are 
represented by an asterisk ().
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 These results demonstrate that, for venetoclax, both BCL-2 protein expression and 
functional BH3 profiling can predict sensitivity, whereas only functional BH3 profiling can 
predict sensitivity to S63845. Following these results, we correlated anti-apoptotic protein 
expression and the functional BH3 profiles to CHOP chemotherapy sensitivity and found 
that absence of BCL-2 protein expression was associated with low CHOP IC50 (median 
IC50 0.44 µg/mL) (Figures 1D and Supplemental figure 3D), while high BCL-2 protein 
expression was associated with high CHOP IC50 values (median 5 µg/mL). These results 
are similar to findings in DLBCL patients, in which BCL-2 overexpression (with or without 
MYC rearrangement) are associated with poor survival in patients treated with R-CHOP (4). 
This correlation trend was also observed for the functional BCL-2 BH3 profile and CHOP 
response, in which a high BAD response showed a trend towards high CHOP IC50 values 
(R=0.595; p=0.1323) (Figure 3E). No correlation was observed with CHOP sensitivity and 
MCL-1 protein expression (Supplemental figure 3E) or the functional NOXA BH3 profile 
(Figure 3F). Taken together, these results show that in untreated/treatment naïve cells, 
both high BCL-2 expression and functional BH3 profiling for BAD can predict sensitivity to 
venetoclax and CHOP. However, in the situation that cells show no expression of BCL-2, 
functional BH3 profiling should be applied to determine sensitivity to specific anti-apoptotic 
inhibitors.
CHOP Chemotherapy Alters Dependency on Anti-Apoptotic Proteins
Based on previous experiments, we have established that DLBCL cells can express multiple 
anti-apoptotic proteins simultaneously, but usually show functional dependency on either 
BCL-2 or MCL-1. However, it remains unclear if standard CHOP treatment has the ability 
to alter or shift this dependency on anti-apoptotic proteins. To test this hypothesis, we 
employed dynamic BH3 profiling, which compares the BH3 profiles of treated and untreated 
cells and plots the differences in response to each BH3 peptide, revealing the altered anti-
apoptotic dependencies after specific treatments. Dynamic BH3 profiling of CHOP-treated 
DLBCL cell lines revealed an enhanced mitochondrial response to the BIM peptide (OCI-
LY3, SUDHL-5, SUDHL-6, SUDHL-10, and SC-1), indicating that cells had become more 
primed for apoptosis (Figure S4).
 In addition, five of the eight cell lines (OCI-LY3, U-2932, SUDHL-2, SUDHL-4, SUDHL-6, 
and SC-1) showed a mitochondrial response to the BAD peptide (Figure 4A), which could 
indicate that cells had become more dependent on BCL-2 after CHOP treatment. Apart from 
responses to BAD, three cell lines showed a strong response to the HRK peptide (SUDHL-2, 
OCI-LY3, and SUDHL-4) (Figure 4B), which could indicate enhanced dependency on BCL-
XL, and two cell lines (SUDHL-5 and SUDHL-10) showed a response to the NOXA peptide 
(Figure 4C), which could indicate enhanced dependency on MCL-1 after CHOP treatment. 
Combined, these data suggest that CHOP treatment altered the BCL-2 dependency of cell 
lines OCI-LY3 and SUDHL-4 towards BCL-XL dependency, and made the anti-apoptotic 
independent cell line SUDHL-2 dependent on BCL-XL (Figure 4D). In the other cell lines, 
the cell specific anti-apoptotic dependency remained the same, however, it was further 
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enhanced. None of these CHOP-induced changes were related to a specific cell of origin 
(COO) or BCL2/MYC status, suggesting that changes are COO and BCL-2/MYC independent. 
Taken together, these data demonstrate that CHOP chemotherapy not only enhances the 
anti-apoptotic dependency, it can also alter the anti-apoptotic dependency, demonstrating 
that upfront expression levels of anti-apoptotic proteins are insufficient to predict successful 
combination with anti-apoptotic inhibitors.
CHOP Chemotherapy Enhances Sensitivity to Anti-Apoptotic Inhibitors
To validate that CHOP treatment enhances or alters the cell specific dependency on anti-
apoptotic proteins, we tested the combination of CHOP chemotherapy with venetoclax (BCL-
2i), navitoclax (BCL-2/BCL-XL/BCL-Wi), or S63845 (MCL-1i) in the cell lines SC-1 (enhanced 
BCL-2 dependency), SUDHL-4 (altered BCL-2 à BCL-XL dependency), and SUDHL-10 
(enhanced MCL-1 dependency).
 Treatment with CHOP induced a dose-dependent enhanced sensitivity to venetoclax 
in cell lines SC-1 and SUDHL-4 (Supplemental figure 5), resulting in a decrease in IC50 
Figure 4. Dynamic BH3 profiles of DLBCL cell lines treated with CHOP chemotherapy. (A) Dynamic BH3 profiles 
for the DLBCL cell lines OCI-LY3 (1 µg/mL), U-2932 (10 µg/mL), SUDHL-2 (1 µg/mL), SUDHL-4 (10 µg/mL), SUDHL-5 
(0.1 µg/mL), SUDHL-6 (1 µg/mL), SUDHL-10 (10 µg/mL), and SC-1 (10 µg/mL) after treatment with CHOP for 18 h for 
BAD, HRK (B) and NOXA (C). Delta mitochondrial outer membrane permeabilization (ΔMOMP%) was calculated by 
subtracting the percentage treated MOMP from percentage untreated MOMP. Data were plotted as the mean ± S.D. 
(n=3). Statistical analysis was performed with a one-sample T-test (* p≤0.05) (** p≤0.01). (D) Schematic overview of the 
anti-apoptotic dependency in DLBCL cell lines before and after CHOP treatment. White = no specific dependency (N.A.), 
blue = BLC-2 dependency, red = BCL-XL dependency, and green = MCL-1 dependency.
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values for venetoclax (Figure 5A) and overall strong synergism for the combination of CHOP 
with venetoclax (Figure 5B). A similar effect was observed when CHOP was combined with 
navitoclax, which also induced a decrease in IC50 values (Figure 5C) and overall strong 
synergism (Figure 5D) in cell lines SC-1 and SUDHL-4. These changes were not observed 
in cell line SUDHL-10, as predicted by dynamic BH3 profiling. Instead, SUDHL-10 showed a 
strong decrease in IC50 values for S63845 (Figure 5E) and overall strong synergism for the 
combination of CHOP with S63845 (Figure 5F). Together, these data demonstrate that CHOP 
chemotherapy can significantly enhance the effectivity of anti-apoptotic inhibitors in DLBCL.
 In addition to testing the synergy for CHOP together with anti-apoptotic inhibitors, we 
also investigated whether CHOP treatment would alter the expression levels of anti-apoptotic 
proteins BCL-2, MCL-1, or BCL-XL (Figure 6).
 Despite the increased sensitivity to venetoclax and the changes observed in the 
dynamic BH3 profiles for the cell lines SC-1 and SUDHL-4, no changes were observed in 
BCL-2 protein levels after CHOP treatment. Similarly, no changes were observed in MCL-1 
Figure 5. Effect of CHOP and BH3 mimetic combination treatments on viability in DLBCL cell lines. (A) IC50 values 
for venetoclax and CHOP combination therapy calculated from metabolic activity data in the cell lines SC-1, SUDHL-4, 
and SUDHL-10. Cells were treated for 72 h and data were normalized to control. Data were plotted as the mean ± S.D. 
(n=3). (B) Synergism was determined by calculating the combination index (CI) from metabolic activity data for the 
venetoclax and CHOP combination therapy. Synergism was calculated with the Chou–Talalay method using CompuSyn. 
Synergistic combinations are depicted in green (CI<1.0), additive combinations are depicted in white (CI=1.0), and 
antagonistic combinations are depicted in red (CI>1.0). (C) IC50 values for navitoclax and CHOP combination therapy 
calculated from metabolic activity data in SC-1, SUDHL-4, and SUDHL-10. Cells were treated for 72 h and data were 
normalized to control. Data were plotted as the mean ± S.D. (n=3). (D) Synergism calculations from metabolic activity 
data for the navitoclax and CHOP combination therapy (n=3). (E) IC50 values for S63845 and CHOP combination 
therapy calculated from metabolic activity data in cell lines SC-1, SUDHL-4, and SUDHL-10. Cells were treated for 72 
h and data were normalized to control. Data were plotted as the mean ± S.D. (n=3). (F) Synergism calculations from 
metabolic activity data for the S63845 and CHOP combination therapy (n=3).
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protein expression after CHOP treatment in SUDHL-10, despite the strong dynamic BH3 
response and enhanced sensitivity for MCL-1 inhibitor S63845. However, protein expression 
of BCL-XL was increased after CHOP treatment in both SC-1 and SUDHL-4, but not in 
SUDHL-10. These findings are in line with the observed HRK response in the BH3 profile 
found in SUDHL-4, although an increased HRK response was not observed in SC-1. These 
results suggest that while CHOP treatment can change expression levels of anti-apoptotic 
proteins, these changes may not accurately reflect the dependency of cells on these anti-
apoptotic proteins.
 In conclusion, we were able to validate that CHOP treatment enhances the dependency 
on anti-apoptotic proteins, without necessarily altering the expression levels of the anti-
apoptotic proteins. Importantly, high levels of synergism could be achieved for CHOP with 
anti-apoptotic inhibitors. Therefore, performing functional assays such as dynamic BH3 
profiling is essential to establish how anti-apoptotic dependency may have changed as a 
result of chemotherapeutic pressure.
Vincristine and Doxorubicin Change Dependency on Anti-Apoptotic Proteins
In previous experiments we demonstrated that CHOP chemotherapy can greatly alter or 
enhance the dependency on anti-apoptotic proteins, resulting in synergism with anti-
apoptotic inhibitors. However, since CHOP chemotherapy is composed of cyclophosphamide 
(C), doxorubicin (H), vincristine (O) or prednisolone (P), it remains unclear which of 
these compounds is responsible for the induced effects. We therefore tested each 
individual compound at the representative dosage of 10 µg/mL CHOP in a clinical ratio of 
83/5.5/0.16/11.1, respectively [12] in the representative cell line SC-1 (Figure 7).
 Dynamic BH3 profiling of cells treated with vincristine or doxorubicin showed a similar 
response to the BIM (Figure 7A) and BAD (Figure 7B) peptide when compared to the full 
CHOP regimen, albeit somewhat lower. The combined effects for vincristine and doxorubicin 
on BIM (BIM Δ38% + Δ4% = Δ52%) were similar compared to the effects induced by CHOP 
(BIM Δ54%), which was also observed for BAD (BAD Δ49% + Δ23% = Δ72% vs. Δ63% by 
CHOP). No changes were induced by cyclophosphamide or prednisolone. So, although the 
greatest effect on anti-apoptotic dependency is achieved with complete CHOP, the bulk of 
the effect can likely be attributed to the actions of vincristine and doxorubicin, indicating that 
Figure 6. Western blot of anti-apoptotic proteins after CHOP treatment in DLBCL cell lines. Western blot of anti-
apoptotic proteins BCL-2, MCL-1, BCL-XL, and loading control GAPDH in the DLBCL cell lines SC-1, SUDHL-10 and 
SUDHL-4 treated with 10 µg/mL CHOP for 24 h.
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vincristine and doxorubicin are suitable chemotherapeutics in combination with BH3 mimetic 
drugs.
Discussion
While the relationship between BCL-2 expression and CHOP therapy resistance is well 
established [15,16], it has remained unclear how CHOP treatment affects anti-apoptotic 
proteins in DLBCL. Using functional BH3 profiling, we showed for the first time that CHOP 
treatment enhances dependency on anti-apoptotic proteins, making cells more sensitive to 
BH3 mimetic drugs, most likely through vincristine and/or doxorubicin. We also confirmed 
that CHOP treatment increases the sensitivity of DLBCL cells to BH3 mimetics, highlighting 
the potential for clinical applications. Furthermore, our findings highlighted the heterogeneity 
of anti-apoptotic dependency in DLBCL, in that CHOP treatment resulted in enhanced 
dependency, not only on BCL-2, but also on MCL-1 and BCL-XL. Since we found similar 
heterogeneity of anti-apoptotic expression in DLBCL patients, it seems plausible that in 
patients a similar enhanced or altered pattern on anti-apoptotic proteins might occur. A recent 
study by Smith et al. confirms this heterogeneity in DLBCL, as they demonstrated in a similar 
fashion how DLBCL cell lines show specific dependency on either BCL-2, BCL-XL, or MCL-1 
for survival [17]. None of the observed changes were related to a specific COO in our DLBCL 
cell line panel, indicating that initial inhibitor sensitivity or CHOP-induced anti-apoptotic 
changes might not be related to the differentiation stadium at which DLBCL might occur. 
In addition, we observed anti-apoptotic changes after CHOP treatment in both ‘double-hit’ 
(double MYC/BCL-2 translocation) and non-hit cell lines. It has been recently suggested that 
BCL-2, but not MCL-1, inhibition is effective in double-hit DLBCL [18]. However, as we have 
shown that double-hit status does not always match protein expression (e.g., SUDHL-10 
Figure 7. Dynamic BH3 profiles of SC-1 treated with individual CHOP compounds. Dynamic BH3 profile of (A) BIM and 
(B) BAD in the SC-1 cell line treated for 18 h with 10 µg/mL CHOP, 31.7 µM cyclophosphamide, 18 nM vincristine, 1 µM 
doxorubicin or 3.18 µM prednisolone. Delta mitochondrial outer membrane permeabilization (ΔMOMP%) was calculated 
by subtracting the percentage treated MOMP from the percentage untreated MOMP. Data were plotted as the mean ± 
S.D. (n=3). Statistical analysis was performed using a one-sample T-test (* p≤ 0.05) (** p≤ 0.01).
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lacks BCL-2 expression), this could result in ineffective treatment. In fact, we saw an effective 
response to MCL-1 inhibitor treatment in the BCL-2/MYC double-hit SUDHL-10 cell line, both 
prior to CHOP treatment and after CHOP treatment, whereas no response was observed to 
BCL-2 inhibition. Although our data are broadly in line with recently published clinical trial 
data for venetoclax in NHL [8], we found a potential impact for MCL-1 dependency after 
CHOP treatment, which might indicate that a significant number of patients would derive 
greater benefit from a MCL-1 inhibitor than from venetoclax treatment.
 Robust immunohistological chemical staining for BCL-2 expression and the prognosis of 
R-CHOP treated patients are both well established. However, as this is not the case for MCL-
1 and other BCL-2 family members, it is still impossible to predict the prognosis of R-CHOP-
treated patients based on the expression of anti-apoptotic proteins. Alternatively, dynamic 
BH3 profiling would be a very useful tool to predict an anti-apoptotic response to CHOP 
chemotherapy when applied to treatment-naïve fresh DLBCL patient samples. However, in 
routine clinical practice, dynamic BH3 profiling of DLBCL samples is challenging, as tissue 
samples are scarce and dividing cells are required in order to observe possible effects of 
chemotherapy (e.g., CHOP) on the subsequent BH3 response in vitro. Ex vivo culture of 
DLBCL is not possible without stimulation, and stimulation of cells (e.g., CD40 ligand) might 
skew and alter the BH3 response to chemotherapy. Further research and optimization of 
BH3 profiling is therefore warranted. In addition, in vivo experiments with either a patient-
derived xenograft (PDX) model or a spontaneous DLBCL mouse model should preferably be 
performed to predict and validate the clinical applications of combining CHOP chemotherapy 
with a broad range of BH3 mimetic drugs.
 Besides identifying MCL-1 and BCL-XL as novel contributors to CHOP-induced 
resistance, our data also show the therapeutic potential of vincristine and doxorubicin 
in combination with BH3 mimetics. In the current setting, the 10 µg/mL CHOP treatment 
contained single compound concentrations of 31.7 µM cyclophosphamide, 18 nM vincristine, 
1 µM doxorubicin, and 3.18 µM prednisolone, which are all within the range of clinical 
maximal plasma levels in patients (128 µM cyclophosphamide, 7 nM vincristine, 6.73 µM 
doxorubicin, and 0.145 µM prednisolone) [19]. At the moment, clinical trials are underway 
regarding liposomal vincristine and venetoclax in relapsed or refractory T-cell or B-cell 
NHL (NCT03504644/clinicaltrials.gov). Based on our data, we predict that both vincristine 
and doxorubicin will induce changes in anti-apoptotic dependency, although whether 
changes will always favor BCL-2 rather than MCL-1 or BCL-XL will remain unclear without 
functional dBH3 profiling. In addition, additional experiments with higher concentrations 
of cyclophosphamide might induce similar anti-apoptotic changes, which warrants further 
investigation for cyclophosphamide with BH3 mimetic drugs.
 In conclusion, we demonstrated the potential of BH3 profiling as a predictor of anti-
apoptotic dependencies in DLBCL. Moreover, we showed that CHOP treatment induces 
increased anti-apoptotic dependency, not only on BCL-2, but also on MCL-1 and BCL-XL. 
As a result, patient-specific BH3 mimetic treatment might well lead to synergistic lethality 
and reduce unnecessary treatment. Although BCL-2 remains one of the primary actors in 
anti-apoptotic resistance, our results indicate that caution is advisable and that other BH3 
mimetics should not be neglected as they might well influence or alter therapy outcomes.
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Supporting information
Supplemental Figure 1. Static BH3 profiles of DLBCL cell lines. Static BH3 profiles of DLBCL cell lines, expressed 
as the percentage mitochondrial outer membrane permeabilization (MOMP%) upon treatment with BH3 peptides (n=3). 
FCCP and PUMA2A were used as positive and negative controls, respectively.
Supplemental Figure 2. Dose-response curves of DLBCL cell lines treated with BH3 mimetics. (A) Dose-response 
curve of eight DLBCL cell lines treated with the BCL-2 inhibitor venetoclax for 48 hours (n=3). (B) Dose-response curve 
of eight DLBCL cell lines treated with the MCL-1 inhibitor S63845 for 48 hours (n=3). (C) Dose-response curve of eight 
DLBCL cell lines treated with the BCL-2/BCL-XL/BCL-W inhibitor navitoclax for 48 hours (n=3). (D) Dose-response 
curve of eight DLBCL cell lines treated with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and 
prednisolone) for 72 hours (n=3).
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Supplemental Figure 3. Relation between BCL-2 and MCL-1 protein expression and sensitivity to BH3 mimetics 
and CHOP chemotherapy in DLBCL cell lines. (A) Venetoclax IC50 plotted based on the absence or presence of 
BCL-2 protein expression for DLBCL cell lines. (B) Navitoclax IC50 plotted based on the absence or presence of BCL-2 
protein expression for DLBCL cell lines. (C) S63845 IC50 plotted based on the absence or presence of MCl-1 protein 
expression for DLBCL cell lines. (D) CHOP IC50 plotted based on the absence or presence of BCL-2 protein expression 
for DLBCL cell lines. (E) CHOP IC50 plotted based on the absence or presence of MCl-1 protein expression for DLBCL 
cell lines. Statistical analysis was performed with two-tailed paired T-test (*p≤0.05) (**p≤0.01). Cell lines without a ‘double 
hit’ (MYC/BCL2) status are represented by open symbols () and cell lines with a ‘double hit’ status by closed symbols 
(). Cell lines with the highest BCL-2 protein expression are represented by an asterisk ().
Supplemental Figure 4. Dynamic BH3 profiles of DLBCL cell lines treated with CHOP chemotherapy. (A) Dynamic 
BH3 profiles for the DLBCL cell lines OCI-LY3 (1 µg/mL), U-2932 (10 µg/mL), SUDHL-2 (1 µg/mL), SUDHL-4 (10 µg/mL), 
SUDHL-5 (0.1 µg/mL), SUDHL-6 (1 µg/mL), SUDHL-10 (10 µg/mL) and SC-1 (10 µg/mL) after treatment with CHOP for 
18 hours for BIM. Delta mitochondrial outer membrane permeabilization (ΔMOMP%) was calculated by subtracting the 
percentage treated MOMP from percentage untreated MOMP. Data were plotted as the mean ± S.D. (n=3). Statistical 
analysis was performed with a one-sample T-test (*p≤0.05) (**p≤0.01).
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Supplemental Figure 5. Combined effect of CHOP and BH3 mimetics. (A) Metabolic activity of the DLBCL cell lines 
SC-1, SUDHL-4 and SUDHL-10 treated with CHOP and venetoclax (BCL-2i) for 72 hours, measured with resazurin. (B) 
Metabolic activity of the SC-1, SUDHL-4 and SUDHL-10 cell lines treated with CHOP and navitoclax (BCL-2/XL/Wi) for 
72 hours, measured with resazurin. (C) Metabolic activity of SC-1, SUDHL-4 and SUDHL-10 treated with CHOP and 
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Summary
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous disease. Current 
treatment consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone, 
together with the monoclonal anti-CD20 antibody rituximab (R-CHOP), cures roughly 60% of 
patients. Unfortunately, this means that many patients will experience relapse or refractory 
disease and require additional therapy. In this thesis, we aimed to find novel targets to 
improve current patient treatment and gain more insight into disease development. 
 In Chapter 2, we performed a guilt-by-association analysis for genes co-expressed with 
CD20, which is both a driver for DLBCL and a target for DLBCL therapy. Further selection 
based on the presence of clinical compounds resulted in many potential novel targets for 
treatment. These targets were involved in various different pathways, including the cell cycle 
regulator protein and the DNA damage protein PARP1. Immunohistochemistry and western 
blot revealed high expression of WEE1 and PARP in both DLBCL patients and DLBCL cell 
lines. Moreover, targeting with the clinically available drugs AZD1775 targeting WEE1 and 
olaparib targeting PARP1 were effective in DLBCL cell lines, indicating their potential for 
treatment of DLBCL patients. These targets were chosen from the top-500 drugable target 
list, leaving many targets unexplored. Based on the good results for WEE1 and PARP1, 
we further explored suitability of other targets involved in similar or different pathways 
as targets for therapy. At the moment clinical trials are already underway for targeting of 
CDK1 with seliciclib (NCT00999401) in solid tumors and targeting of HDAC1 with vorinostat 
(NCT00667615) or panobinostat (NCT00967044) in non-Hodgkin lymphoma, which were 
all part of our top-500 list. In addition, further research into combination of multiple (top-
500) targets could be explored to increase therapy efficiency. Simultaneous inhibition of 
WEE1 and PARP1 was beneficial for treatment outcome in ovarian cancer, breast cancer [1], 
gastric cancer [2] and in acute leukemia [3] patients and enhanced sensitivity to radiation 
therapy in non-small cell lung cancer (NSCLC) [4] and pancreatic cancer [5]. 
 Based on the promising results for treatment with the WEE1 inhibitor AZD1775 as 
monotherapy and in combination with rituximab in DLBCL cell lines, we next decided to 
investigate the potential enhanced efficiency of combining AZD1775 with standard CHOP 
chemotherapy and radiation therapy (RT) in Chapter 3. In line with our expectations, 
combination therapy for WEE1 inhibition alongside CHOP or RT effectively reduced cell 
viability. Further experiments showed that combination therapy resulted in activation of 
the DNA damage response, induced premature mitotic entry and increased DNA damage 
levels, resulting in a strong synergistic effect. Following-up on these data, we decided to 
investigate the potential for WEE1 in combination with second line therapeutic compounds 
cytarabine and cisplatin in Chapter 4. Similar to our findings for the combination of CHOP 
and RT, we found that cytarabine strongly reduced cell viability in DLBCL cell lines when 
combined with AZD1775. To our surprise, the combination of AZD1775 with cisplatin was 
only effective in one out of four tested DLBCL cell lines, indicating antagonistic effects for this 
combination. This antagonistic effect was supported by the observation that WEE1 protein 
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levels were strongly reduced. The reduced expression could be attributed to a reduction of 
histone marks for active transcription upon cisplatin treatment. Together, these data suggest 
that cisplatin prevents transcription of the WEE1 gene, thereby resulting in reduced WEE1 
protein levels. This makes cisplatin an unsuitable partner for combination with WEE1 inhibitor 
AZD1775. These data highlight the importance of thorough studies for testing combination 
treatments, as DLBCL cells might respond differently to a combination treatment shown to be 
otherwise successful in gastric cancer [6], breast cancer [7] and medulloblastoma [8]. 
 In Chapter 5, we tested a yet unexplored combination therapy for AZD1775 together 
with CDK1/2 inhibitors RO3306 (CDK1i), roscovitine/seliciclib (CDK1/2i) and palbociclib 
(CDK4/6i). Since both WEE1 inhibitors and CDK inhibitors are currently being tested in 
clinical trials for solid tumors and hematological malignancies as monotherapies, we aimed 
to investigate the potential effect of a combination therapy. Surprisingly, we found that the 
combination with CDK1 or CDK1/2 inhibitors resulted in either synergism or antagonism 
in DLBCL cell lines, indicating distinct differences between individual cell lines. Further 
investigation revealed that these effects were caused by phosphorylation of different 
checkpoint kinase 1 (CHK1) isoforms, with synergism in cell lines that show activation of the 
short CHK1 isoform and antagonism in cell lines with the long/normal CHK1 isoform being 
activated. In other studies, promising results were obtained for the combination of SNS-032 
(CDK2/CDK7/CDK9 inhibitor) combined with cytarabine in AML [9] and AZD5438 (CDK1/2/9i) 
in combination with radiation therapy in non-small cell lung cancer (NSCLC) [10]. Our results 
pose a difficult challenge and warning for CDK1/2 inhibitor combination therapies: although 
therapy can be extremely effective in certain cell types, additional studies will be needed 
to predict effectiveness of therapy outcome and prevent potential harmful effects in part of 
the patients. Ideally, knock-in experiments should be performed to prove that presence of 
the short CHK1 isoform indeed results in synergism in therapy-resistant cell lines. It then 
remains to explain why in some cells the short CHK1 isoform is expressed and activated 
upon combined WEE1 and CDK1/2 treatment, and whether this is also observed in DLBCL 
patients. 
 A more uniform picture was observed for the combination of WEE1 with the CDK4/6 
inhibitor palbociclib, which induced antagonism in all DLBCL cell lines. In this situation, 
dosage and timing of the combination therapy were shown to be of the utmost importance 
in establishing the best possible outcome. Dean et al. showed that the combination of 
doxorubicin and palbociclib gave better results when breast cancer cells were treated 
sequentially, rather than concurrently, which resulted in antagonism [11]. In contrast, 
combination of CDK4/6 inhibitor ribociclib with cisplatin in ovarian cancer was synergistic 
[12], indicating possible differences between cell types and/or specific inhibitors. Since 
palbociclib was shown to be antagonistic with many different chemotherapeutics [13], 
we propose to avoid combining palbociclib with DNA damage inducing therapies. In this 
scenario more beneficial results might be acquired when CDK4/6 inhibitors are combined 
with PI3 kinase inhibitors, AKT inhibitors or mTOR inhibitors [14].
 Besides focusing on (improving) the existing therapy options for DLBCL, we also 
investigated the potential new combinations with BH3 mimetics drugs for the treatment of 
DLBCL, by employing BH3 profiling. In Chapter 6 we used BH3 profiling to determine the 
176 | Chapter 8
effect of AZD1775 treatment on anti-apoptotic dependency and found that WEE1 inhibition 
enhanced sensitivity to multiple anti-apoptotic inhibitors. Interestingly, we showed that 
induction of DNA damage and/or G2/M cell cycle arrest induced similar changes, suggesting 
potential efficiency of combining BH3 mimetics with other compounds inducing similar 
effects. A similar approach was used to investigate the effect of CHOP chemotherapy on 
anti-apoptotic dependency in Chapter 7. Even though it is commonly assumed that anti-
apoptotic features/characteristics in DLBCL is acquired through the anti-apoptotic protein 
BCL-2, we found that cells treated with CHOP therapy became more dependent on the 
anti-apoptotic BCL-2, MCL-1 and BCL-XL proteins. These data indicate that although 
BCL-2 is important, other anti-apoptotic proteins such as MCL-1 and BCL-XL should not 
be overlooked when anticipating therapy resistance or planning targeted therapeutic 
strategies. The results for WEE1 inhibition and CHOP treatment make it likely that many 
other DNA damage inducing compounds will induce similar changes in the anti-apoptotic 
dependency as well. Previous studies showed that cisplatin-resistant lung cancer, cervical 
cancer and mesothelioma cell lines had enhanced levels of MCL-1, and in a limited number 
of cell lines BCL-2 [15]. In multiple myeloma cells, treatment with doxorubicin, etoposide and 
hydrogen peroxide caused upregulation of BCL-2 expression [16]. However, most studies 
performed have focused on the effect of anti-apoptotic proteins on therapy response, and 
neglected the opposite relation, i.e. how treatment might affect anti-apoptotic dependency. 
For example, we learned early on that exogenous overexpression of BCL-2 and BCL-XL 
protects lymphoid cells against vincristine, vinblastine, gamma-irradiation, etoposide and 
cisplatin treatment [17]. However, it remains unknown how (long-term) treatments with these 
compounds affect BCL-2 and BCL-XL expression levels or dependencies in specific normal 
and/or cancer cell types. This demonstrates the need to investigate the (long-term) effect 
of new and existing treatment on anti-apoptotic dependency in cancer, and how treatment 
should be adapted based on the status of these anti-apoptotic proteins. A particularly useful 
tool in this preclinical research and patient tracking would be the application of dynamic BH3 
profiling, as we previously showed that protein expression alone is not always representative 
of the anti-apoptotic dependency. Grundy et al. screened multiple anti-leukemic drugs with 
dynamic BH3 profiling in a myelo-monocytic leukemia cell line and showed that 9 out of 11 
compounds enhanced sensitivity to the BCL-2 inhibitor venetoclax, and 2 out of 11 enhanced 
sensitivity to the MCL-1 inhibitor A1210477 [18]. Moreover, they showed that BCL-2 inhibitors 
themselves enhanced sensitivity to MCL-1 inhibition, indicating a shift in anti-apoptotic 
dependency. This highlights the power of (dynamic) BH3 profiling for multi-drug screenings, 
combination strategy planning and potentially long-term follow-up of patient to asses therapy 
relapses.  
Discussion
In this thesis our initial aim was to find novel highly expressed and druggable targets to 
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improve treatment outcome in DLBCL patients. This resulted in the “discovery” of WEE1 
and the experimental support showing the efficiency of WEE1 targeting by various in vitro 
experiments either alone or in combination with other commonly used drugs. Although we 
have shown that WEE1 is an excellent target for the treatment of DLBCL, one question that 
remains to be unanswered is: what causes the very high expression of WEE1 in in DLBCL, 
especially compared to other cancers such as breast cancer and lung cancer? A unique 
feature of DLBCL compared to other cancers is the extremely high expression levels of DNA 
damage response genes (Figure 1). Although genomic instability is a hallmark of all cancers, 
gene expression data across multiple cancers shows a unique pattern with high expression 
for various DNA damage response genes in DLBCL. This specific signature is also present in 
thymomas, a cancer derived from the epithelial cells of the thymus, a primary lymphoid organ. 
The relative uncommon thymomas are strongly linked to auto-immune diseases such as 
myasthenia gravis [19,20]. This overlapping signature might indicate a similar immunological 
component in DLBCL. However, this pattern of high expression of DNA damage response 
genes is not observed in acute myeloid leukemia (Figure 1; AML). These studies further point 
towards the unique DNA damage signature of DLBCL.   
Figure 1. Gene expression of WEE1 and DNA damage response proteins in multiple cancer types. Plotted is the 
factor of tumor / normal tissue gene expression for WEE1 and DNA damage response (DDR) proteins RAD51, PARP1, 
BRCA1, BRCA2, ATR, ATM, CHK1 and CHK2 in several different cancer types. Gene expression of alpha-fetoprotein 
(AFP), a plasma protein produced by the yolk sac and the liver during fetal development, is plotted as a negative 
control. Cancers included are adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive 
carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangio carcinoma 
(CHOL), colon adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBCL), esophageal carcinoma (ESCA), 
glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney 
renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (AML), brain 
lower grade Glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell 
carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma 
(PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma 
(READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell 
tumors (TGCT), thyroid carcinoma (THCA), Thymoma (THYM), uterine corpus endometrial Carcinoma (UCEC), uterine 
carcinosarcoma (UCS) and uveal melanoma (UVM). Data was acquired from the online available GEPIA database 
(gepia.cancer-pku.cn).
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 Further reflection on the origin of DLBCL suggests a strong link between the germinal 
center reaction and the DNA damage response, creating a background for DLBCL that stands 
out from other cancers. DLBCL is a cancer derived as a result of malignant transformation of 
B-cells, which either occurs during the germinal center reaction (GCB-DLBCL) or directly after 
the germinal center reaction (non-GCB/ABC-DLBCL). In a normal germinal center reaction, 
expression of activation-induced cytidine deaminase (AID) is of crucial importance to induce 
somatic hyper mutation (SMH) and class switch recombination (CSR) in B-cells [21]. During 
these processes, DNA damage response (DDR) and repair pathways are activated to ensure 
proper cellular integrity. This explains the high expression of DDR and DDR-related proteins 
in germinal center B-cells compared to pre- or post-germinal center B-cells (Figure 2). 
 Despite activation of proper DDR pathways, the SHM and CSR processes create a 
landscape of genomic instability, that may lead to malignant transformation. A crucial role 
of AID in malignant transformation was supported by the reduced number of malignant 
transformations in AID-/- mouse models [22] and by the increased number of AID-mediated 
genomic translocations upon activation of AID in mouse models [23]. Various studies showed 
that AID is specifically important in the transformation of germinal center-derived lymphomas, 
and not in pre-germinal center malignancies [22,24,25]. Within the DLBCL patient population, 
AID expression is higher in the ABC-subtype compared to the GCB-subtype [24,26], which 
arises from the plasma blast stage of B-cell development representing a more differentiated 
B-cell. It is therefore not surprising that in DLBCL in patients AID expression is strongly 
Figure 2. Array gene expression data of DDR proteins during normal B-cell development. B-cells from tonsils (n=3) 
were collected and sorted for naïve, germinal center and memory B-cell populations using from cytometry. Data was 
normalized to the internal control HRP gene.
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associated with worse prognosis [27]. In addition, research has shown a close relation 
between DDR proteins and SHM and CSR processes, such as yH2AX [28], 53BP1 [29] and 
ATM [30,31]. Moreover, it was shown that inhibition of CHK1 [32] and CHK2 [33] affected 
AID activity, and as a result SHM and CSR. These studies highlighted the unique landscape 
of the germinal center, were DDR proteins are often employed in non-canonical activities, 
independent of their roles in DNA repair [34].
 Based on the above-discussed data, we hypothesized that the high expression of WEE1 
in DLBCL is likely caused by the AID-dependent induction of DNA lesions, activation of the 
DDR proteins and a block in cell cycle progression to allow repair. Moreover, the high WEE1 
expression may not solely be the result of (extreme) cellular proliferation, but likely also the 
result of high DDR activation. To study the link between WEE1 and proliferation, we analyzed 
the relation between the proliferation marker Ki67 and WEE1 in DLBCL patients (unpublished 
data). No correlation was seen in DLBCL, indicating that WEE1 is not controlled by cellular 
proliferation in DLBCL (Figure 3A-F). Moreover, correlation analysis between AID and WEE1, 
or AID with other DDR related proteins also showed no direct correlation (data not shown). 
Based on these data, it seems difficult to directly correlate AID activity and DDR activation in 
patients, despite the many mouse models linking AID and DLBCL [22,23]. Instead, it seems 
more likely that AID activity is part of a (potentially lengthy) process in which multiple events 
of aberrant translocations and faulty DNA damage repair are together contributing to the 
malignant transformation of B-cells over a period of time, something which is difficult to track 
in patient samples. 
Figure 3. Expression of WEE1 and Ki67 in DLBCL patients. (A) Gene expression data of WEE1 in DLBCL 
patient subtypes. (B) Gene expression data of Ki67 in DLBCL patient subtypes. (C) Correlation of WEE1 and Ki67 
gene expression in DLBCL patients. D) Immunohistochemistry of WEE1 protein expression in DLBCL subtypes. (E) 
Immunohistochemistry of Ki67 protein expression in DLBCL subtypes. (F) Correlation of IHC data for WEE1 and Ki67 
protein expression in DLBCL patients.
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 An important notion to take into consideration is the possibility that DDR pathways might 
be actively suppressed in the germinal center, as suggested by Ranuncolo et al. [35]. They 
showed that in order to withstand DNA damage caused by AID, both ATR and CHK1 are 
actively suppressed by the master transcription factor BCL-6, which is expressed in both 
normal human centroblasts and DLBCL cell lines [36,37]. Phan et al. showed that BCL-6 
actively suppresses TP53 [38] and P21 [39] in Burkitt lymphoma cell lines. This of course 
functions as a double-edged sword: on the one hand it might prevent TP53-dependent 
apoptosis and allow cellular proliferation, but at the same time it might also prevent crucial 
processing and repair of DNA breaks. Similar functions for BCL-6 were also observed in 
multiple myeloma, where induction of BCL-6 repressed formation of yH2AX, activated ATM 
but not ATR, and induced expression of AID [40]. Therefore, an intricate system is at play 
in the germinal center reaction, in which timing of specific pathways and balance between 
repair and apoptosis determines the outcome of germinal center B-cells. This balance 
becomes clear by another study of Phan et al., where they showed degradation of the BCL-
6 protein upon DNA damage induction with several chemotherapeutic compounds and 
radiation [41]. Therefore, it remains difficult to establish exactly how expression of WEE1 is 
regulated in DLBCL, whether this occurs early or in later stages of the disease and whether 
this is the cause or the consequence of transformation of germinal center B cells.
Future perspectives
Implication of WEE1 inhibitor treatment for DLBCL patients
Based on our research and the many publications on WEE1 inhibitor treatment in 
combination with other chemotherapeutic drugs and inhibitors [42], it is generally accepted 
that the treatment of cancer with WEE1 inhibitors has been a largely successful enterprise. In 
addition, a high number of clinical trials to test WEE1 inhibition combined with multiple drugs 
in patients are ongoing, such as fludarabine (NCT02791919) or cytarabine (NCT02791919) 
in AML, cisplatin in head and neck cancer (NCT02196168), paclitaxel and gemcitabine 
(NCT02194829) in pancreatic cancer and with carboplatin (NCT01164995) in ovarian 
cancer. Therefore, we predict that many different types of cancers will benefit from WEE1 
inhibition therapy, either as monotherapy or combined with other chemotherapeutics. For 
DLBCL, combination of AZD1775 with the currently applied R-CHOP treatment, which cures 
roughly 60% of patients, would most likely improve therapy outcome. However, additional 
in vivo experiments with PDX mouse models need to be done to provide the definitive proof 
that the combination of AZD1775 with R-CHOP will enhance survival in first line treatment. 
A similar strategy will be needed for AZD1775 combined with cytarabine, although much 
more promising clinical evidence for this combination is already available for other tumors, 
additional clinical trials in DLBCL will provide the necessary efficiency to show the efficiency 
of this combination treatment. 
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 However, despite promising results for cisplatin and AZD1775 treatment in other cancers 
[6-8,43-45], platinum-based agents might work antagonistic with AZD1775 in DLBCL, 
because of the cisplatin-induced repression of WEE1. Further research with other platinum-
based agents such as the clinically approved carboplatin, oxaliplatin and nedaplatin, or 
with compounds that are currently being tested in clinical trials, such as triplatin tetranitrate/
BBR3464 (NCT00014547), picoplatin (NCT00465725) or satraplatin (NCT00265655), are 
required to establish whether the antagonistic effects of cisplatin are specific for this drug 
or will be observed with all platinum-based agents. In addition, further research into the 
cisplatin-induced gene repression of WEE1 in DLBCL could elucidate whether these effects 
are dose-dependent, as suggested by our data. Based on these findings a maximum 
cisplatin dose could be established for the combined treatment at which WEE1 inhibition 
does not occur, but tumor cells still experiencing the detrimental effects of DNA crosslinking. 
Future research for CDK1/2 inhibitors and CHK1 isoforms
In contrast to the success story of WEE1 inhibitors in cancer therapy, much more research is 
going to be needed to investigate the possible implications of the different CHK1 isoforms in 
cancer treatment. Our data gave a first indication that activation of these different isoforms 
by phosphorylation could be the determining factor for therapy outcome in DLBCL. The short 
isoform, which is usually less abundant lacks the kinase domain. In addition, Pablo et al. 
demonstrated that this short CHK1 isoform was strongly associated with cancer and disease 
progression in ovarian and testicular cancer [46]. They suggested that its “role” in cancer is 
to inhibit the activity of the normal CHK1 isoform during an unperturbed cell cycle in order 
to promote S-to-G2/M phase transition. In a situation of DNA damage, phosphorylation of 
CHK1 could disrupt the interaction between the normal and short CHK1 isoforms, leaving 
the normal CHK1 free to facilitate cell cycle arrest and DNA damage repair. This would 
create an ideal situation for cancer cells, in which normal cell cycle progression is maximally 
stimulated, while in case of DNA damage repair can still be facilitated. However, we observed 
a clear flaw in this theory: cells which actively phosphorylated the short CHK1 instead of 
the long CHk1 isoform were less efficiently able to cope with DNA damage, resulting in 
increased levels of cell death. This slightly compromises the theory that under stress the 
normal CHK1 isoform will always resume its function, as we never observed simultaneous 
phosphorylation of the two CHK1 isoforms. However, our data do match with their in vivo 
data, in which xenograft mice expressing only the short CHK1 isoform had significantly less 
tumor outgrowth compared with mice expressing the normal CHK1 isoform or the CHK1 
kinase-dead mutant [46]. Therefore, we hypothesize that although activation of the short 
CHK1 isoform might be beneficial for unperturbed cell cycle progression, activation of the 
short CHK1 isoform during cellular stress weakens DNA repair and sensitizes cells to DNA 
damage inducing treatment. To validate our hypothesis, additional experiments with CDK1 
-/- cells could eliminate the possibility of off-target effects of the CDK1/2 inhibitors RO3306 
and roscovitine. This would establish a direct link between CDK1/2 inhibition and the CHK1 
isoforms, which could be further analyzed with knock-in or knock-out experiments of the 
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short or normal CHK1 isoforms. Cells actively expressing the short CHK1 isoform could be 
genetically modified to only express the normal CHK1 isoform to clarify whether this could 
rescue the cells from fatal DNA damage. Similarly, genetic modification of cells expressing 
the normal CHK1 isoform, to cells expressing the short CHK1 isoform will reveal whether 
this sensitizes previously resistant cells to the combination of CDK1/2 inhibitors and DNA 
damage inducing agents. With these data, we could make a firm, previously undiscovered 
connection between the cell cycle regulators CDK1/2 and the checkpoint kinase CHK1 in 
DLBCL. 
 At the moment, it remains unclear why CDK1/2 inhibition results in activation of the 
different CHK1 isoforms. It is well known that CHK1 is activated upon DNA damage by 
phosphorylation of Ser317 and Ser345 by the kinase ATR, resulting in downstream activation 
of WEE1 and inhibition of the CDC25 phosphatases, in order to block CDK activity and 
prevent cell cycle progression [47]. Our data suggests a possible feedback loop from CDK1 
and CDK2 back to the upstream activation of CHK1, thereby affecting the cellular response 
to cell cycle arrest. Something similar was proposed by Enomoto et al., who showed that 
CHK1 was phosphorylated at Ser286 and Ser301 by CDK1 during prophase in order to 
promote CHK1 translocation to the cytoplasm and stimulate mitotic entry [48]. Similarly, 
Bacevic et al. showed CDK2 stimulated activation of the ATR/CHK1 pathway upon treatment 
with hydroxyurea and was required for an efficient DNA replication checkpoint response 
[49]. In our experiments, inhibition of CDK1/2 seemed to affect activation of CHK1, perhaps 
through absence of an inhibitory signal from CDK1/2 or as a result of an omitted cytoplasmic 
translocation of CHK1 as suggested by Enomoto et al. [48]. At the same time, it might well be 
that currently unknown proteins are involved in the activation of the different CHK1 isoforms. 
Novel interaction partners of CHK1 might be discovered through co-immunoprecipitation, 
mass spectrometry or protein microarrays. In addition, our data showed that only CDK1/2 
inhibition, but not CDK4/6 inhibition, affected phosphorylation of the CHK1 isoforms. This 
is quite surprising, since one would expect that when the G2/M phase CDK1 and CDK2 
are able to influence CHK1 activity, a similar feedback loop would be in place for the G1/S 
phase CDK4 and CDK6. In general, it seems the mechanism of CDK4/6 at the G1/S phase of 
the cell cycle are less well understood compared to their counterparts CDK1/2 at the G2/M 
phase. For example, we know in great detail the regulating factors for CDK1 and CDK2, 
which involve: 1) association with their specific cyclins, 2) phosphorylation on Thr160 by 
CDK activating kinase (CAK), 3) inhibitory phosphorylation by WEE1 on Tyr15 and Thrr14 
by Myt1 and finally 4) dephosphorylation of Thr14/Tyr15 by the CDC25 phosphatases. Like 
CDK1/2, CDK4/6 are activated by CAK through phosphorylation on Thr172 and Thr177, 
respectively, and cellular stress induces phosphorylation of Tyr17 in CDK4 [50] and Tyr24 
in CDK6. However, CDK4 and CDK6 are not inhibited by WEE1 [51], but by Scr kinases [52] 
and their activity is regulated by their assembly with their respective cyclins. These data 
indicate that CDK4/6 act very different from CDK1/2, and might therefore not be associated 
with the activation of the different CHK1 isoforms. 
 At the same time, it remains unclear why activation of the ineffective short CHK1 isoform 
occurs in certain DLBCL cells, which are biologically capable of efficiently activating the 
normal CHK1 isoform, whilst it does not occur in other DLBCL cells. Deep analysis of the 
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differences between so-called “synergistic” and “antagonistic” cell lines could potentially 
elucidate the differences between these cell lines. One striking observation is the difference 
in expression of the anti-apoptotic protein BCL-2 between these cell lines. Our protein 
expression data (Chapter 6 and 7) showed that, with the exception of cell line SUDHL-6, 
synergistic cell lines lack strong expression of BCL-2, whereas all antagonistic cell lines 
show strong expression of BCL-2. Several studies have demonstrated a close relation 
between anti-apoptotic proteins and CDK1/2, where CDK1 is able to phosphorylate BCL-2 
[53] and BCL-XL [54] and CDK2 can phosphorylate MCL-1 [55]. The lack of BCL-2 might 
be an important factor in survival, creating a predisposition in which cells are more sensitive 
to DNA damage-inducing treatment when combined with CDK1/2 inhibitors. In addition, 
analysis of other hematological and solid cancers would be required in order to establish 
whether this phenomenon is unique for DLBCL, or applicable to other cancer types as well. 
Together, these data will give us new insights in the treatment of cancer with CDK inhibitors 
and might expose novel fundamental processes of the cancer biology.
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Targeting WEE1 in diffuse large B-cell lymphoma: 
mediator in DNA damage and apoptosis
Diffuus grootcellig B-cell lymfoom (Diffuse large B-cell lymphoma (DLBCL)) is een agressieve 
vorm van lymfklierkanker die behoort tot de groep van non-Hodgkin lymfomen. De ziekte 
ontstaat als gevolg van schadelijke mutaties in de cellen van het humorale immuunsysteem, 
de B-cellen. Tijdens de normale ontwikkeling van de B-cell ondergaat de B-cell meerdere 
fases van mutaties en proliferatie in de lymfeklier, om uiteindelijk te differentiëren tot een 
plasma cell of een B-geheugencel. Echter door foute mutaties in onder andere anti-apoptose 
eiwitten (bijv. BCL-2) of DNA-schade herstel eiwitten (bijv. TP53) ontsporen deze B-cellen tot 
DLBCL. Door middel van moleculair onderzoek kan DLBCL verder geclassificeerd worden 
op basis van het stadium van ontwikkeling in ‘germinal centre B-cell like’ (GCB), wat ontstaat 
vroeg in de B-cell ontwikkeling, en ‘activated B-cell like’ (non-GCB), wat ontstaat later in 
de B-cell ontwikkeling. Ondanks deze verschillen worden patiënten met DLBCL momenteel 
behandelt met dezelfde combinatie van verschillende chemotherapeutica (cyclofosfamide, 
doxorubicine en vincristine) samen met het monoklonale antilichaam rituximab. Rituximab is 
ontworpen om een interactie aan de gaan met het CD20 molecuul dat tot expressie komt op 
alle B-cellen, maar extreem hoog tot expressie komt op DLBCL B-cellen. Ondanks dat de 
huidige therapie genezing geeft voor ongeveer 60% van de patiënten, zijn er veel patiënten 
die niet reageren op de behandeling of patiënten waarbij de ziekte na verloop van tijd 
terugkomt.
 Om de behandeling voor DLBCL-patiënten te verbeteren, hebben we in Hoofdstuk 2 
een analyse uitgevoerd om nieuwe eiwitten te vinden waarvoor een gerichte therapie kan 
worden toegepast. In deze analyse hebben we gekeken welke eiwitten samen met het CD20 
molecuul hoog tot expressie kwamen in DLBCL-patiënten, o.a. omdat CD20 belangrijk is voor 
de behandeling met rituximab. In deze analyse vonden we hoge co-expressie van meerdere 
DNA-schade herstel eiwitten met CD20 in de DLBCL-patiënten, waaronder de eiwit kinase 
WEE1. De kinase WEE1 is belangrijk voor de regulatie van de celcyclus, en bepaalt wanneer 
de cell cyclus kan worden vervolgd of moet worden gestopt wanneer er sprake is van 
ernstige DNA-schade. Behandeling van DLBCL-cellijnen met de specifieke WEE1 remmer 
AZD1775 zorgde voor een sterke inductie van celdood, en werkte ook goed in combinatie met 
rituximab. Op basis van deze goede resultaten hebben we vervolgens in Hoofdstuk 3 verder 
onderzocht of de specifieke WEE1 remmer goed zou werken in combinatie met bestraling 
en de chemotherapeutica cyclofosfamide, doxorubicine en vincristine (CHOP) die gebruikt 
worden in de huidige DLBCL-behandeling. Uit deze experimenten bleek dat de combinatie 
van AZD1775 met bestraling of CHOP zorgde voor veel extra DNA-schade en verstoring van 
de cell cyclus, waardoor er sterke synergie optreedt voor de combinatie behandelingen. 
Vervolgens hebben we in Hoofdstuk 4 gekeken of de WEE1 remmer ook synergie zou 
vertonen met cytarabine en cisplatine, twee chemotherapeutica die worden gebruikt bij de 
tweedelijns behandeling van DLBCL patienten. Uit deze experimenten bleek dat AZD1775 
sterke synergie vertoonde samen met cytarabine, maar niet met cisplatine, hoewel dit laatste 
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wel in de literatuur beschreven was. Eiwit analyse toonde aan dat behandeling van DLBCL-
cellijnen met cisplatine zorgde voor een verminderde expressie van het WEE1 eiwit, waardoor 
de specifieke WEE1 remmer minder effectief was, een fenomeen wat nog niet eerder in de 
literatuur beschreven was. Op basis van deze gegevens verwachten we dat WEE1 remming 
goede resultaten zal opleveren in de kliniek als DLBCL-patiënten worden behandeld met 
AZD1775 in combinatie bestraling, CHOP of cytarabine. 
 Naast het versterken van de huidige behandelingen, hebben we in Hoofdstuk 5 
onderzocht of de therapie voor DLBCL verbeterd zou kunnen worden door het simultaan 
remmen van de CDK1 kinase en de WEE1 kinase, eiwitten die beiden hoog tot expressie 
komen met CD20 (hoofdstuk 2). Voor deze strategie hebben we gekeken naar de remming 
van WEE1 in combinatie met de CDK1 kinase. Zowel WEE1 als CDK1 kwamen sterk tot 
expressie in de DLBCL-patiënten genexpressie data, en zijn beiden betrokken bij de 
regulatie van de celcyclus, waarbij WEE1 de activiteit bepaald van CDK1. Deze combinatie 
therapie bleek goed te werken in 50% van de DLBCL-cellijnen, waarbij we synergie en extra 
DNA-schade konden aantonen. Daarnaast was er ook een groep die niet goed reageerde op 
de behandeling en waarbij we sterke antagonisme vaststelden in de combinatie. Deze data 
benadrukken o.a. de grote onderlinge verschillen tussen DLBCL-cellijnen, en wellicht ook 
DLBCL-patiënten. Om te achterhalen waarom DLBCL-cellijnen zo verschillend reageerden 
op de behandeling hebben we vervolgens gekeken naar de expressie van verschillende 
DNA-schade eiwitten. Hieruit bleek dat dit verschil wellicht verklaard zou kunnen worden 
door verschil in expressie van een korte dan wel lange isovorm van het CHK1 eiwit. De korte 
vorm kwam tot expressie in synergistische cellijnen en de lange vorm in antagonistische 
cellijnen. Verder onderzoek zal moeten aantonen of deze isovormen inderdaad verklaren 
waarom de combinatie behandeling van WEE1 en CDK1 remmers kan leiden tot zowel 
synergisme als antagonisme in DLBCL. 
 In het tweede deel van dit promotieonderzoek hebben we onderzocht hoe DLBCL-
cellen het proces van geprogrammeerde celdood, apoptose, proberen te voorkomen met 
behulp van de anti-apoptose eiwitten BCL-2, MCL-1 en BCL-XL. Het is algemeen bekend 
dat mutaties en/of over-expressie van BCL-2 vaak voorkomt in DLBCL-patiënten. Er lopen 
daarom meerdere klinische trials met de specifieke BCL-2 remmer venetoclax om te 
onderzoeken of dit middel werkt als mogelijk nieuwe behandeling voor DLBCL-patiënten. 
Omdat we in eerdere hoofdstukken hebben aangetoond dat WEE1 remming een goede 
behandeling strategie kan zijn voor DLBCL-patiënten, wilden we daarom onderzoeken of 
WEE1 remming ook goed zou combineren met anti-apoptotische remmers zoals venetoclax. 
In Hoofdstuk 6 hebben we daarom onderzocht wat het effect van behandeling met de 
specifieke WEE1 remmer zou zijn op de anti-apoptotische eiwitten BCL-2, MCL-1 en BCL-
XL. Uit deze experimenten bleek dat remming van de WEE1 kinase zorgde dat de cellen 
meer afhankelijk werden van de anti-apoptose eiwitten, terwijl de eiwit expressie nauwelijks 
veranderd. Deze afhankelijkheid was verschillend per cellijn, wat aan geeft hoe verschillend 
en heterogeen DLBCL-cellen zijn. Als gevolg van deze verhoogde afhankelijkheid waren 
de cellen hierdoor gevoeliger voor specifieke remmers van BCL-2, MCL-1 en BCL-XL, wat 
mogelijkheden biedt voor therapie. Daarnaast konden we aantonen dat onafhankelijk zowel 
DNA-schade als verstoring van de celcyclus, beiden effecten van de WEE1 remmer, zorgden 
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voor gelijkwaardige veranderingen in de anti-apoptose afhankelijkheid. Als laatste hebben 
we in Hoofdstuk 7 gekeken naar de effecten van de chemotherapeutica cyclofosfamide, 
doxorubicine en vincristine op de anti-apoptose afhankelijkheid in DLBCL. Omdat BCL-2 
vaak verhoogd to expressie komt in DLBCL, ligt de focus voor behandeling voornamelijk op 
de BCL-2 remmer venetoclax, en word er niet of nauwelijks gekeken naar de andere anti-
apoptose eiwitten. Daarnaast er is weinig bekend wat mogelijk het effect is van (langdurige) 
CHOP-behandeling op deze anti-apoptose eiwitten. Met behulp van DLBCL-patiënten 
materiaal konden we aantonen dat naast BCL-2, ook MCL-1 en BCL-XL vaak verhoogd 
tot expressie komen in DLBCL-patiënten. Ook zorgde behandeling met cyclofosfamide, 
doxorubicine en vincristine in DLBCL-cellijnen ervoor dat deze afhankelijkheid werd versterkt 
of werd veranderd. Hiermee konden we aantonen dat hoewel BCL-2 belangrijk is in DLBCL, 
andere anti-apoptose eiwitten ook bijdragen aan het voorkomen van apoptose in DLBCL en 
daarom ook gebruikt kunnen worden voor gerichte therapie in DLBCL-patiënten. 
 Met dit promotieonderzoek hebben we een eerste stap gedaan om nieuwe mogelijkheden 
te vinden om de behandeling van DLBCL-patiënten te verbeteren, en daarmee de ziekte beter 
te leren behandelen. Met behulp van deze resultaten hebben we aangetoond dat remming 
van WEE1 in combinatie met de huidige therapie, en mogelijk toekomstige therapieën, 
leidt tot gunstige resultaten en waarschijnlijk een goede strategie zou kunnen zijn voor de 
behandeling van DLBCL-patiënten. Ondanks dat we goede resultaten hebben behaald met 
de remming van WEE1, zijn er nog steeds veel andere eiwitten die nog verder onderzocht 
zouden kunnen worden. Hoewel deze eiwitten wellicht geschikt zijn voor behandeling met 
specifieke remmers als monotherapie, grondig onderzoek zal nodig zijn om te bepalen of dit 
zal leiden tot gunstige resultaten in combinatie met andere behandelingen. 
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